

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPplus patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPplus accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPplus enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPplus updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPplus enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded
NEWS 28 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 29 MAR 30 INPADOCDB will replace INPADOC on STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*JICST-EPLUS - JICST-EPlus File on Sci. & Tech. in Japan.1985-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3
DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e tamoxifen/cn

E1	1	TAMOTSU V/CN
E2	1	TAMOX-PUREN/CN
E3	1 -->	TAMOXIFEN/CN
E4	2	TAMOXIFEN ALCOHOL/CN
E5	1	TAMOXIFEN AZIRIDINE/CN
E6	1	TAMOXIFEN CITRATE/CN
E7	1	TAMOXIFEN HYDROCHLORIDE/CN
E8	1	TAMOXIFEN METHIODIDE/CN
E9	1	TAMOXIFEN N-OXIDE/CN
E10	1	TAMOXIFENOL/CN
E11	1	TAMP/CN
E12	1	TAMPACRYL/CN

=> s e3

L1 1 TAMOXIFEN/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 10540-29-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)

CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
(8CI)

OTHER NAMES:

CN (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine

CN ICI 47699

CN Mammaton

CN **Tamoxifen**

CN trans-Tamoxifen

CN Z-Tamoxifen

FS STEREOSEARCH

MF C26 H29 N O


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,
CHEMLIST, CIN, CSCHM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH,
IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*,
SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Best Available Copy

Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7522 REFERENCES IN FILE CA (1907 TO DATE)
176 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7539 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e raloxifene/cn

E1	1	RALOX LC/CN
E2	1	RALOX-A/CN
E3	1 -->	RALOXIFENE/CN
E4	1	RALOXIFENE HYDROCHLORIDE/CN
E5	1	RALOXAM/CN
E6	3	RALSTONITE/CN
E7	1	RALSTONITE (ALF2(OH))/CN
E8	1	RALSTONITE (ALF2(OH).1/2H2O)/CN
E9	1	RALTAT 10/CN
E10	1	RALTITREXED/CN
E11	1	RALUBEN/CN
E12	1	RALUFON CAS-OH/CN

=> s e3

L2 1 RALOXIFENE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 84449-90-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl] - (CA INDEX NAME)

OTHER NAMES:

CN Keoxifene

CN LY 139481

CN **Raloxifene**

CN [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-(2-(1-piperidinyl)ethoxy)phenyl]methanone


MF C28 H27 N O4 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1636 REFERENCES IN FILE CA (1907 TO DATE)
 35 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1643 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e toremifene/cn

E1 1 TORELOR/CN
 E2 1 TOREM/CN
 E3 1 --> TOREMIFENE/CN
 E4 1 TOREMIFENE CITRATE/CN
 E5 1 TOREMIFENE N-OXIDE/CN
 E6 1 TORENDRIKITE/CN
 E7 1 TORENTAL/CN
 E8 1 TOREPALLOY GW/CN
 E9 1 TOREPALLOY HW/CN
 E10 1 TOREPALLOY UN/CN
 E11 1 TOREPALLOY UW/CN
 E12 1 TOREPALLOY UW 1A/CN

=> s e3

L3 1 TOREMIFENE/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 89778-26-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-

CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)

OTHER NAMES:

CN Acapodene

CN Farestone

CN GTx 006

CN **Toremifene**

CN Z-Toremifene

FS STEREOSEARCH

DR 98644-21-4

MF C26 H28 Cl N O


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Double bond geometry as shown.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

661 REFERENCES IN FILE CA (1907 TO DATE)

16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
666 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e triphenylethylene/cn
E1      1      TRIPHENYLETHOXYMETHYLENEPHOSPHORANE/CN
E2      1      TRIPHENYLETHOXYLSILANE/CN
E3      1 --> TRIPHENYLETHYLENE/CN
E4      1      TRIPHENYLETHYLENE ANION RADICAL/CN
E5      1      TRIPHENYLETHYLENE BROMIDE/CN
E6      1      TRIPHENYLETHYLENE DIANION DILITHIUM SALT/CN
E7      1      TRIPHENYLETHYLENE GLYCOL/CN
E8      1      TRIPHENYLETHYLENE OZONIDE/CN
E9      1      TRIPHENYLETHYLPHOSPHONIUM BROMIDE/CN
E10     1      TRIPHENYLETHYLPHOSPHONIUM CHLORIDE/CN
E11     1      TRIPHENYLETHYLPHOSPHONIUM DIHYDROGEN PHOSPHATE/CN
E12     1      TRIPHENYLETHYLPHOSPHONIUM IODIDE/CN
```

```
=> s e3
L4      1 TRIPHENYLETHYLENE/CN
```

```
=> d
```

```
L4      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN      58-72-0  REGISTRY
ED      Entered STN:  16 Nov 1984
CN      Benzene, 1,1',1''-(1-ethenyl-2-ylidene)tris-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN      Ethylene, triphenyl- (6CI, 8CI)
OTHER NAMES:
CN      1,1,2-Triphenylethene
CN      1,1,2-Triphenylethylene
CN      Benzilidenediphenylmethane
CN      NSC 17535
CN      Triphenylethene
CN      Triphenylethylene
MF      C20 H16
CI      COM
LC      STN Files:  ADISNEWS, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT,
                  CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, IFICDB, IFIPAT,
                  IFIUDB, MEDLINE, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
                  (*File contains numerically searchable property data)
Other Sources:  EINECS**, NDSL**, TSCA**
                  (**Enter CHEMLIST File for up-to-date regulatory information)
```

Ph₂C=CH-Ph

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
623 REFERENCES IN FILE CA (1907 TO DATE)
51 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
624 REFERENCES IN FILE CAPLUS (1907 TO DATE)
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
```

```
=> file medline
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          28.95      29.16
```

FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007

FILE LAST UPDATED: 30 Mar 2007 (20070330/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s (antiestrogen or selective estrogen receptor modul? or serm)
      2839 ANTIESTROGEN
      232939 SELECTIVE
      80730 ESTROGEN
      566461 RECEPTOR
      279820 MODUL?
      2359 SELECTIVE ESTROGEN RECEPTOR MODUL?
            (SELECTIVE (W) ESTROGEN (W) RECEPTOR (W) MODUL?)
      532 SERM
L5      5161 (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)

=> d his

      (FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007)

      FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007
            E TAMOXIFEN/CN
L1      1 S E3
            E RALOXIFENE/CN
L2      1 S E3
            E TOREMIFENE/CN
L3      1 S E3
            E TRIPHENYLETHYLENE/CN
L4      1 S E3

      FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007
L5      5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)

=> s l1 or l2 or l3 or l4
      11703 L1
      1448 L2
      394 L3
      31 L4
L6      12869 L1 OR L2 OR L3 OR L4

=> s (tamoxifen or raloxifene or toremifene or triphenylethylene)
      15057 TAMOXIFEN
      1934 RALOXIFENE
      493 TOREMIFENE
      265 TRIPHENYLETHYLENE
L7      16501 (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE)

=> s (hot flash?)
      25185 HOT
      14661 FLASH?
L8      1538 (HOT FLASH?)
            (HOT (W) FLASH?)

=> d his

      (FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007)

      FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007
            E TAMOXIFEN/CN
L1      1 S E3
            E RALOXIFENE/CN
L2      1 S E3
            E TOREMIFENE/CN
L3      1 S E3
            E TRIPHENYLETHYLENE/CN
L4      1 S E3

      FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007
L5      5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
L6      12869 S L1 OR L2 OR L3 OR L4
L7      16501 S (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE)
L8      1538 S (HOT FLASH?)
```

=> s 15 and 18
L9 93 L5 AND L8

=> s 16 or 17
L10 16501 L6 OR L7

=> s 18 and 110
L11 182 L8 AND L10

=> d 19 1-93

L9 ANSWER 1 OF 93 MEDLINE on STN

Full Text

AN 2007013928 MEDLINE
DN PubMed ID: 17211091
TI Therapeutic agents for disorders of bone and calcium metabolism:
Bazedoxifene.
AU Chaki Osamu
CS Yokohama City University Medical Center, Section of Gynecology.
SO Clinical calcium, (2007 Jan) Vol. 17, No. 1, pp. 30-5. Ref: 8
Journal code: 9433326. ISSN: 0917-5857.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Japanese
FS Priority Journals
EM 200703
ED Entered STN: 10 Jan 2007
Last Updated on STN: 24 Mar 2007
Entered Medline: 23 Mar 2007

L9 ANSWER 2 OF 93 MEDLINE on STN

Full Text

AN 2006547551 MEDLINE
DN PubMed ID: 16972744
TI [Oncologic indications and contra-indications for hormones use in
menopause].
Indicaciones y contraindicaciones oncologicas del uso de hormonas en la
menopausia.
AU Sarria Jose Antonio
CS Universidad Nacional de Cordoba.
SO Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), (2005)
Vol. 62, No. 2 Suppl 1, pp. 59-66.
Journal code: 8303003. ISSN: 0014-6722.
CY Argentina
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Spanish
FS Priority Journals
EM 200703
ED Entered STN: 16 Sep 2006
Last Updated on STN: 9 Mar 2007
Entered Medline: 8 Mar 2007

L9 ANSWER 3 OF 93 MEDLINE on STN

Full Text

AN 2006492805 MEDLINE
DN PubMed ID: 16916481
TI A Canadian observational study of the optimal method of transition from
postmenopausal hormone therapy to raloxifene.
AU Lorraine Joanne; Lee Bobbie
CS Eli Lilly Canada, Toronto ON.
SO Journal of obstetrics and gynaecology Canada : JOGC = Journal
d'obstetrique et gynecologie du Canada : JOGC, (2006 Jul) Vol. 28, No. 7,
pp. 583-94.
Journal code: 101126664. ISSN: 1701-2163.
CY Canada
DT Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)

LA English
FS Priority Journals
EM 200609
ED Entered STN: 19 Aug 2006
Last Updated on STN: 19 Sep 2006
Entered Medline: 18 Sep 2006

L9 ANSWER 4 OF 93 MEDLINE on STN

Full Text

AN 2006293766 MEDLINE
DN PubMed ID: 16722623
TI Novel chromene-derived **selective estrogen receptor modulators**
useful for alleviating hot flushes and vaginal dryness.
AU Jain Nareshkumar; Kanojia Ramesh M; Xu Jiayi; Jian-Zhong Guo; Pacia
Emmanuel; Lai Muh-Tsann; Du Fuyong; Musto Amy; Allan George; Hahn DoWon;
Lundeen Scott; Sui Zhihua
CS Johnson & Johnson Pharmaceutical Research & Development LLC, 1000 Route
202, Raritan, New Jersey 08869, USA.
SO Journal of medicinal chemistry, (2006 Jun 1) Vol. 49, No. 11, pp. 3056-9.
Journal code: 9716531. ISSN: 0022-2623.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200607
ED Entered STN: 26 May 2006
Last Updated on STN: 13 Jul 2006
Entered Medline: 12 Jul 2006

L9 ANSWER 5 OF 93 MEDLINE on STN

Full Text

AN 2006264840 MEDLINE
DN PubMed ID: 16689342
TI Hormone replacement therapy.
AU Nozaki Masahiro
CS Department of Obstetrics and Gynecology, Graduate School of Medical
Sciences, Kyushu University.
SO Nippon rinsho. Japanese journal of clinical medicine, (2006 Apr) Vol. 64
Suppl 4, pp. 406-10. Ref: 15
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Japanese
FS Priority Journals
EM 200606
ED Entered STN: 13 May 2006
Last Updated on STN: 1 Jul 2006
Entered Medline: 30 Jun 2006

L9 ANSWER 6 OF 93 MEDLINE on STN

Full Text

AN 2006067888 MEDLINE
DN PubMed ID: 16451049
TI A **selective estrogen receptor modulator** for the treatment of hot flushes.
AU Wallace Owen B; Lauwers Kenneth S; Dodge Jeffrey A; May Scott A; Calvin
Joel R; Hinklin Ronald; Bryant Henry U; Shetler Pamela K; Adrian Mary D;
Geiser Andrew G; Sato Masahiko; Burris Thomas P
CS Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, IN 46285, USA.. owen.wallace@lilly.com
SO Journal of medicinal chemistry, (2006 Feb 9) Vol. 49, No. 3, pp. 843-6.
Journal code: 9716531. ISSN: 0022-2623.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200603
ED Entered STN: 3 Feb 2006
Last Updated on STN: 30 Mar 2006
Entered Medline: 29 Mar 2006

L9 ANSWER 7 OF 93 MEDLINE on STN

Full Text

AN 2006034876 MEDLINE
DN PubMed ID: 16422310
TI Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal women.
AU He Weili; Deng Weiping
CS Clinical Biostatistics, Merck Research Laboratories, RY34-A316, 126 Lincoln Avenue, Rahway, NJ 07065, USA.. weili_he@merck.com
SO Clinical trials (London, England), (2005) Vol. 2, No. 6, pp. 497-508.
Journal code: 101197451. ISSN: 1740-7745.
CY England: United Kingdom
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200603
ED Entered STN: 21 Jan 2006
Last Updated on STN: 18 Mar 2006
Entered Medline: 17 Mar 2006

L9 ANSWER 8 OF 93 MEDLINE on STN

Full Text

AN 2005550268 MEDLINE
DN PubMed ID: 16227740
TI Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer.
AU Yamamoto Yutaka; Kawazoe Teru; Iwase Hirotaka
CS Dept. of Breast & Endocrine Surgery, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University.
SO Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Oct) Vol. 32, No. 10, pp. 1415-9.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 200511
ED Entered STN: 18 Oct 2005
Last Updated on STN: 9 Nov 2005
Entered Medline: 8 Nov 2005

L9 ANSWER 9 OF 93 MEDLINE on STN

Full Text

AN 2005390217 MEDLINE
DN PubMed ID: 16048357
TI Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
AU Cranney Ann; Adachi Jonathan D
CS Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
SO Drug safety : an international journal of medical toxicology and drug experience, (2005) Vol. 28, No. 8, pp. 721-30. Ref: 74
Journal code: 9002928. ISSN: 0114-5916.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200510
ED Entered STN: 29 Jul 2005
Last Updated on STN: 1 Nov 2005
Entered Medline: 31 Oct 2005

L9 ANSWER 10 OF 93 MEDLINE on STN

Full Text

AN 2005265706 MEDLINE
DN PubMed ID: 15908903
TI Treatment of menopause-related mood disturbances.
AU Soares Claudio N; Prouty Jennifer; Born Leslie; Steiner Meir
CS Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada.
SO CNS spectrums, (2005 Jun) Vol. 10, No. 6, pp. 489-97. Ref: 100
Journal code: 9702877. ISSN: 1092-8529.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200510
ED Entered STN: 24 May 2005
Last Updated on STN: 12 Oct 2005
Entered Medline: 11 Oct 2005

L9 ANSWER 11 OF 93 MEDLINE on STN

Full Text

AN 2005236210 MEDLINE
DN PubMed ID: 15772568
TI Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.
AU Komi Janne; Lankinen Kari S; Harkonen Pirkko; DeGregorio Michael W; Voipio Sari; Kivinen Seppo; Tuimala Risto; Vihtamaki Tarja; Vihko Kimmo; Ylikorkala Olavi; Erkkola Risto
CS Hormos Medical Corporation, Turku, Finland.
SO Menopause (New York, N.Y.), (2005 Mar) Vol. 12, No. 2, pp. 202-9.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200507
ED Entered STN: 6 May 2005
Last Updated on STN: 22 Jul 2005
Entered Medline: 21 Jul 2005

L9 ANSWER 12 OF 93 MEDLINE on STN

Full Text

AN 2005072224 MEDLINE
DN PubMed ID: 15701885
TI TAS-108: a novel steroidal antiestrogen.
AU Buzdar Aman U
CS University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.. abuzdar@mdanderson.org
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2005 Jan 15) Vol. 11, No. 2 Pt 2, pp. 906s-8s. Ref: 17
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200505
ED Entered STN: 10 Feb 2005
Last Updated on STN: 10 May 2005
Entered Medline: 6 May 2005

L9 ANSWER 13 OF 93 MEDLINE on STN

Full Text

AN 2004615625 MEDLINE
DN PubMed ID: 15592280
TI Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
AU Aldrighi Jose M; Quail Deborah C; Levy-Frebault Jacques; Aguas Fernanda; Kosian Kurt; Garrido Lurdes; Bosio-Le Goux Brigitte; Sarachaga Max; Graebe Alice; Nino Antonio J; Nickelsen Thomas
CS Faculdade De Saude Publica Da Universidade De Sao Paulo, Brazil.
SO American journal of obstetrics and gynecology, (2004 Dec) Vol. 191, No. 6, pp. 1979-88.
Journal code: 0370476. ISSN: 0002-9378.
CY United States
DT (CLINICAL TRIAL)

Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200501
ED Entered STN: 20 Dec 2004
Last Updated on STN: 28 Jan 2005
Entered Medline: 27 Jan 2005

L9 ANSWER 14 OF 93 MEDLINE on STN
Full Text
AN 2004603075 MEDLINE
DN PubMed ID: 15577140
TI Which is the better choice, estrogen or SERMs in postmenopausal women?.
AU Shintani Masafumi
CS Department of Obstetrics and Gynecology, Nara Prefectural Mimuro Hospital.
SO Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 105-10. Ref: 17
Journal code: 9433326. ISSN: 0917-5857.
CY Japan
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA Japanese
FS Priority Journals
EM 200502
ED Entered STN: 4 Dec 2004
Last Updated on STN: 1 Mar 2005
Entered Medline: 25 Feb 2005

L9 ANSWER 15 OF 93 MEDLINE on STN
Full Text
AN 2004603074 MEDLINE
DN PubMed ID: 15577139
TI Safety profile of raloxifene.
AU Morii Hirotooshi
CS Osaka City University.
SO Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 100-4. Ref: 22
Journal code: 9433326. ISSN: 0917-5857.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA Japanese
FS Priority Journals
EM 200502
ED Entered STN: 4 Dec 2004
Last Updated on STN: 1 Mar 2005
Entered Medline: 25 Feb 2005

L9 ANSWER 16 OF 93 MEDLINE on STN
Full Text
AN 2004530641 MEDLINE
DN PubMed ID: 15500420
TI The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa).
AU Huntley Alyson
CS Universities of Exeter and Plymouth, Complementary Medicine, Peninsula Medical School, 25 Victoria Park Road, Exeter, EX2 4NT, UK..
alyson.huntley@pms.ac.uk
SO Expert opinion on drug safety, (2004 Nov) Vol. 3, No. 6, pp. 615-23. Ref: 60
Journal code: 101163027. E-ISSN: 1744-764X.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA English
FS Priority Journals
EM 200510
ED Entered STN: 26 Oct 2004
Last Updated on STN: 6 Oct 2005

Entered Medline: 5 Oct 2005

L9 ANSWER 17 OF 93 MEDLINE on STN

Full Text

AN 2004425202 MEDLINE
DN PubMed ID: 15330494
TI Belamcanda chinensis and the thereof purified tectorigenin have
selective estrogen receptor modulator activities.
AU Seidlova-Wuttke D; Hesse O; Jarry H; Rimoldi G; Thelen P; Christoffel V;
Wuttke W
CS Department of Clinical and Experimental Endocrinology, University of
Goettingen, Robert-Koch-Strasse 40, D-37075 Goettingen, Germany.
SO Phytomedicine : international journal of phytotherapy and
phytopharmacology, (2004 Jul) Vol. 11, No. 5, pp. 392-403.
Journal code: 9438794. ISSN: 0944-7113.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200409
ED Entered STN: 28 Aug 2004
Last Updated on STN: 17 Sep 2004
Entered Medline: 16 Sep 2004

L9 ANSWER 18 OF 93 MEDLINE on STN

Full Text

AN 2004390355 MEDLINE
DN PubMed ID: 15295352
TI Raloxifene is not associated with biologically relevant changes in hot
flushes in postmenopausal women for whom therapy is appropriate.
AU Palacios Santiago; Farias Maria Lucia F; Luebbert Horst; Gomez Gustavo;
Yabur Juan A; Quail Deborah C; Turbi Carmen; Kayath Marcia J; Almeida
Maria J; Monnig Elisabeth; Nickelsen Thomas
CS Instituto Palacios, Madrid, Spain.
SO American journal of obstetrics and gynecology, (2004 Jul) Vol. 191, No. 1,
pp. 121-31.
Journal code: 0370476. ISSN: 0002-9378.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200409
ED Entered STN: 6 Aug 2004
Last Updated on STN: 15 Sep 2004
Entered Medline: 14 Sep 2004

L9 ANSWER 19 OF 93 MEDLINE on STN

Full Text

AN 2004390192 MEDLINE
DN PubMed ID: 15293890
TI Verapride administered in combination with raloxifene decreases hot
flushes and improves bone density in early postmenopausal women.
AU Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
CS Department of Pediatrics, Obstetrics and Reproductive Medicine, University
of Siena, Siena, Italy.
SO Gynecological endocrinology : the official journal of the International
Society of Gynecological Endocrinology, (2004 Apr) Vol. 18, No. 4, pp.
194-8.
Journal code: 8807913. ISSN: 0951-3590.
CY England: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200408
ED Entered STN: 6 Aug 2004

Last Updated on STN: 20 Aug 2004
Entered Medline: 19 Aug 2004

L9 ANSWER 20 OF 93 MEDLINE on STN

Full Text

AN 2004188613 MEDLINE
DN PubMed ID: 15084236
TI Isoflavones and women's health.
AU Powles Trevor
CS Parkside Hospital, Wimbledon, London.. amccabe@parkside-hospital.co.uk
SO Breast cancer research : BCR, (2004) Vol. 6, No. 3, pp. 140-2. Electronic
Publication: 2004-04-06.
Journal code: 100927353. E-ISSN: 1465-542X.
CY England: United Kingdom
DT Commentary
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
FS ISRCTN
NCT ISRCTN42940165
EM 200407
ED Entered STN: 16 Apr 2004
Last Updated on STN: 28 Jul 2004
Entered Medline: 27 Jul 2004

L9 ANSWER 21 OF 93 MEDLINE on STN

Full Text

AN 2004171210 MEDLINE
DN PubMed ID: 15021446
TI Transition from estrogen therapy to raloxifene in postmenopausal women:
effects on treatment satisfaction and the endometrium-a pilot study.
AU Davis Susan R; O'Neill Sheila M; Eden John; Baber Rodney; Ekangaki Abie;
Stocks Jodie M; Thiebaud Daniel
CS Jean Hailes Foundation, Melbourne, Australia..
susan.davis@jeanhailes.org.au
SO Menopause (New York, N.Y.), (2004 Mar-Apr) Vol. 11, No. 2, pp. 167-75.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200405
ED Entered STN: 7 Apr 2004
Last Updated on STN: 10 May 2004
Entered Medline: 7 May 2004

L9 ANSWER 22 OF 93 MEDLINE on STN

Full Text

AN 2004157072 MEDLINE
DN PubMed ID: 15050912
TI Selective estrogen receptor modulation: concept and consequences
in cancer.
AU Jordan V Craig
CS Northwestern University, Chicago, IL, USA.. vcjordan@northwestern.edu
NC P50 CA089018-04S1 (NCI)
SO Cancer cell, (2004 Mar) Vol. 5, No. 3, pp. 207-13. Ref: 56
Journal code: 101130617. ISSN: 1535-6108.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200405
ED Entered STN: 31 Mar 2004
Last Updated on STN: 18 May 2004

Entered Medline: 17 May 2004

L9 ANSWER 23 OF 93 MEDLINE on STN

Full Text

AN 2004132490 MEDLINE
DN PubMed ID: 15025087
TI Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.
AU Rollins Gina
SO Report on medical guidelines & outcomes research, (2004 Mar 5) Vol. 15, No. 5, pp. 7-9.
Journal code: 9106372. ISSN: 1050-5636.
CY United States
DT (COMPARATIVE STUDY)
News Announcement
LA English
FS Health Technology
EM 200404
ED Entered STN: 18 Mar 2004
Last Updated on STN: 10 Apr 2004
Entered Medline: 9 Apr 2004

L9 ANSWER 24 OF 93 MEDLINE on STN

Full Text

AN 2004105346 MEDLINE
DN PubMed ID: 14997058
TI Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.
AU Pandya Kishan J; Thummala Anuradha R; Griggs Jennifer J; Rosenblatt Joseph D; Sahasrabudhe Deepak M; Guttuso Thomas J; Morrow Gary R; Roscoe Joseph A
CS James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642 USA.. kishan.pandya@urmc.rochester.edu
SO Breast cancer research and treatment, (2004 Jan) Vol. 83, No. 1, pp. 87-9.
Journal code: 8111104. ISSN: 0167-6806.
CY Netherlands
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200405
ED Entered STN: 4 Mar 2004
Last Updated on STN: 14 May 2004
Entered Medline: 13 May 2004

L9 ANSWER 25 OF 93 MEDLINE on STN

Full Text

AN 2003588632 MEDLINE
DN PubMed ID: 14669536
TI [The effects of tamoxifen on the female genital tract].
Tamoxifen en gynaecologische bijwerkingen.
AU Mourits M J; van der Zee A G; Willemse P H; Hollema H; de Vries E G
CS Afd. Gynaecologische Oncologie, Academisch Ziekenhuis Groningen, Hanzeplein 1, 9711 EZ Groningen.. m.j.e.mourits@og.azg.nl
SO Nederlands tijdschrift voor geneeskunde, (2003 Nov 22) Vol. 147, No. 47, pp. 2315-20. Ref: 31
Journal code: 0400770. ISSN: 0028-2162.
CY Netherlands
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Dutch
FS Priority Journals
EM 200401
ED Entered STN: 16 Dec 2003
Last Updated on STN: 9 Jan 2004
Entered Medline: 8 Jan 2004

L9 ANSWER 26 OF 93 MEDLINE on STN

Full Text

AN 2003569139 MEDLINE
DN PubMed ID: 14652237
TI Active tamoxifen metabolite plasma concentrations after coadministration

of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
 AU Stearns Vered; Johnson Michael D; Rae James M; Morocho Alan; Novielli
 Antonella; Bhargava Pankaj; Hayes Daniel F; Desta Zeruesenay; Flockhart
 David A
 CS The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center,
 Georgetown University Medical Center, Washington, DC, USA.
 NC 5T32-GM-08425 (NIGMS)
 R-01 GM56898 (NIGMS)
 U-01 GM61373 (NIGMS)
 SO Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
 pp. 1758-64.
 Journal code: 7503089. E-ISSN: 1460-2105.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 200401
 ED Entered STN: 16 Dec 2003
 Last Updated on STN: 6 Jan 2004
 Entered Medline: 5 Jan 2004

L9 ANSWER 27 OF 93 MEDLINE on STN
Full Text
 AN 2003569130 MEDLINE
 DN PubMed ID: 14652227
 TI A hot flash on tamoxifen metabolism.
 AU Goetz Matthew P; Loprinzi Charles L
 SO Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
 pp. 1734-5. Ref: 23
 Journal code: 7503089. E-ISSN: 1460-2105.
 CY United States
 DT Commentary
 Editorial
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200401
 ED Entered STN: 16 Dec 2003
 Last Updated on STN: 6 Jan 2004
 Entered Medline: 5 Jan 2004

L9 ANSWER 28 OF 93 MEDLINE on STN
Full Text
 AN 2003490049 MEDLINE
 DN PubMed ID: 14567481
 TI Common causes of night sweats in various populations.
 AU Taylor Roslyn D
 SO American family physician, (2003 Oct 1) Vol. 68, No. 7, pp. 1264.
 Journal code: 1272646. ISSN: 0002-838X.
 CY United States
 DT Commentary
 Letter
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200310
 ED Entered STN: 22 Oct 2003
 Last Updated on STN: 1 Nov 2003
 Entered Medline: 31 Oct 2003

L9 ANSWER 29 OF 93 MEDLINE on STN
Full Text
 AN 2003476408 MEDLINE
 DN PubMed ID: 14555500
 TI Fulvestrant in postmenopausal women with advanced breast cancer.
 AU Bross Peter F; Baird Amy; Chen Gang; Jee Josephine M; Lostritto Richard T;
 Morse David E; Rosario Liliam A; Williams Gene M; Yang Peiling; Rahman
 Atiqur; Williams Grant; Pazdur Richard
 CS Division of Oncology Drug Products, Center for Drug Evaluation and
 Research, Food and Drug Administration, Rockville, Maryland 20852, USA.

SO Clinical cancer research : an official journal of the American Association
for Cancer Research, (2003 Oct 1) Vol. 9, No. 12, pp. 4309-17. Ref: 22
Journal code: 9502500. ISSN: 1078-0432.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200405
ED Entered STN: 14 Oct 2003
Last Updated on STN: 21 May 2004
Entered Medline: 20 May 2004

L9 ANSWER 30 OF 93 MEDLINE on STN
Full Text
AN 2003445171 MEDLINE
DN PubMed ID: 12952416
TI Black cohosh acts as a mixed competitive ligand and partial agonist of the
serotonin receptor.
AU Burdette Joanna E; Liu Jianghua; Chen Shao-Nong; Fabricant Daniel S;
Piersen Colleen E; Barker Eric L; Pezzuto John M; Mesecar Andrew; Van
Breemen Richard B; Farnsworth Norman R; Bolton Judy L
CS Department of Medicinal Chemistry and Pharmacognosy and UIC/NIH Center for
Botanical and Dietary Supplements Research, College of Pharmacy, 833 South
Wood Street, University of Illinois at Chicago, Chicago, IL 60612, USA.
NC F31 AT 00800 (NCCAM)
P50 AT 00155 (NCCAM)
SO Journal of agricultural and food chemistry, (2003 Sep 10) Vol. 51, No. 19,
pp. 5661-70.
Journal code: 0374755. ISSN: 0021-8561.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200311
ED Entered STN: 25 Sep 2003
Last Updated on STN: 13 Nov 2003
Entered Medline: 12 Nov 2003

L9 ANSWER 31 OF 93 MEDLINE on STN
Full Text
AN 2003441488 MEDLINE
DN PubMed ID: 14501605
TI Effects of ospemifene, a novel SERM, on hormones, genital tract,
climacteric symptoms, and quality of life in postmenopausal women: a
double-blind, randomized trial.
AU Rutanen Eeva-Marja; Heikkinen Jorma; Halonen Kaija; Komi Janne;
Lammintausta Risto; Ylikorkala Olavi
CS Department of Obstetrics and Gynecology, Helsinki University Central
Hospital, Helsinki, Finland.. eeva-marja.rutanen@hus.fi
SO Menopause (New York, N.Y.), (2003 Sep-Oct) Vol. 10, No. 5, pp. 433-9.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 23 Sep 2003
Last Updated on STN: 18 Dec 2003
Entered Medline: 8 Dec 2003

L9 ANSWER 32 OF 93 MEDLINE on STN
Full Text
AN 2003415716 MEDLINE
DN PubMed ID: 12954049
TI Discovery and preclinical characterization of (+)-3-[4-(1-
piperidinoethoxy)phenyl]spiro[indene- 1,1'-indane]-5,5'-diol
hydrochloride: a promising nonsteroidal estrogen receptor agonist for hot

flush.
 AU Watanabe Nobuhide; Ikeno Akihisa; Minato Hisao; Nakagawa Hiroshi;
 Kohayakawa Chie; Tsuji Jun-ichi
 CS Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd.,
 Enoki-cho 33-94, Suita, Osaka 564-0053, Japan.. [nobuhide-
 watanabe@dainippon-pharm.co.jp](mailto:nobuhide-watanabe@dainippon-pharm.co.jp)
 SO Journal of medicinal chemistry, (2003 Sep 11) Vol. 46, No. 19, pp. 3961-4.
 Journal code: 9716531. ISSN: 0022-2623.
 CY United States
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200311
 ED Entered STN: 5 Sep 2003
 Last Updated on STN: 11 Nov 2003
 Entered Medline: 10 Nov 2003

L9 ANSWER 33 OF 93 MEDLINE on STN

Full Text

AN 2003390761 MEDLINE
 DN PubMed ID: 12928005
 TI Arzoxifene as therapy for endometrial cancer.
 AU Burke Thomas W; Walker Cheryl L
 CS Department of Gynecologic Oncology, The University of Texas M. D. Anderson
 Cancer Center, Houston, TX 77030, USA.. tburke@mdanderson.org
 SO Gynecologic oncology, (2003 Aug) Vol. 90, No. 2 Pt 2, pp. S40-6. Ref: 55
 Journal code: 0365304. ISSN: 0090-8258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200309
 ED Entered STN: 21 Aug 2003
 Last Updated on STN: 1 Oct 2003
 Entered Medline: 30 Sep 2003

L9 ANSWER 34 OF 93 MEDLINE on STN

Full Text

AN 2003381095 MEDLINE
 DN PubMed ID: 12916292
 TI Selective estrogen-receptor modulators.
 AU Cosman Felicia
 CS Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA..
cosmanf@helenhayeshosp.org
 SO Clinics in geriatric medicine, (2003 May) Vol. 19, No. 2, pp. 371-9. Ref:
 58
 Journal code: 8603766. ISSN: 0749-0690.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200310
 ED Entered STN: 15 Aug 2003
 Last Updated on STN: 3 Oct 2003
 Entered Medline: 2 Oct 2003

L9 ANSWER 35 OF 93 MEDLINE on STN

Full Text

AN 2003373456 MEDLINE
 DN PubMed ID: 12851517
 TI Prevention of osteoporosis and uterine effects in postmenopausal women
 taking raloxifene for 5 years.
 AU Jolly Elaine E; Bjarnason Nina H; Neven Patrick; Plouffe Leo Jr; Johnston
 C Conrad Jr; Watts Steven D; Arnaud Claude D; Mason Timothy M; Crans
 Gerald; Akers Robin; Draper Michael W
 CS Department of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa,
 Canada.
 SO Menopause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 337-44.
 Journal code: 9433353. ISSN: 1072-3714.

CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200310

ED Entered STN: 12 Aug 2003

Last Updated on STN: 8 Oct 2003

Entered Medline: 7 Oct 2003

L9 ANSWER 36 OF 93 MEDLINE on STN

Full Text

AN 2003370970 MEDLINE

DN PubMed ID: 12808384

TI Anti-osteoporotic medications: traditional and nontraditional.

AU Cohen David P

CS Department of Obstetrics and Gynecology, University of Chicago, Illinois
60637, USA.. dcohen@babies.bsd.uchicago.edu

SO Clinical obstetrics and gynecology, (2003 Jun) Vol. 46, No. 2, pp. 341-8.
Ref: 29

Journal code: 0070014. ISSN: 0009-9201.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200309

ED Entered STN: 9 Aug 2003

Last Updated on STN: 23 Sep 2003

Entered Medline: 22 Sep 2003

L9 ANSWER 37 OF 93 MEDLINE on STN

Full Text

AN 2003294123 MEDLINE

DN PubMed ID: 12821343

TI A phase II trial of arzoxifene, a selective estrogen response modulator,
in patients with recurrent or advanced endometrial cancer.

AU McMeekin D Scott; Gordon Alan; Fowler Jeffrey; Melemed Allen; Buller

Richard; Burke Thomas; Bloss Jeffery; Sabbatini Paul

CS University of Oklahoma, Oklahoma City, OK 73190, USA..

scott-mcmeekin@ouhsc.edu

SO Gynecologic oncology, (2003 Jul) Vol. 90, No. 1, pp. 64-9.

Journal code: 0365304. ISSN: 0090-8258.

CY United States

DT (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LA English

FS Priority Journals

EM 200307

ED Entered STN: 25 Jun 2003

Last Updated on STN: 25 Jul 2003

Entered Medline: 24 Jul 2003

L9 ANSWER 38 OF 93 MEDLINE on STN

Full Text

AN 2003278012 MEDLINE

DN PubMed ID: 12804015

TI Efficacy of soyfoods and soybean isoflavone supplements for alleviating
menopausal symptoms is positively related to initial hot flush frequency.

AU Messina Mark; Hughes Claude

CS Department of Nutrition, Loma Linda University, Loma Linda, CA 92350,

USA.. markm@olympus.net

SO Journal of medicinal food, (2003 Spring) Vol. 6, No. 1, pp. 1-11. Ref: 86

Journal code: 9812512. ISSN: 1096-620X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals
EM 200310
ED Entered STN: 14 Jun 2003
Last Updated on STN: 8 Oct 2003
Entered Medline: 7 Oct 2003

L9 ANSWER 39 OF 93 MEDLINE on STN

Full Text

AN 2003134335 MEDLINE
DN PubMed ID: 12648026
TI Pharmacokinetics of selective estrogen receptor modulators.
AU Morello Karla C; Wurz Gregory T; DeGregorio Michael W
CS Department of Internal Medicine, University of California, Davis,
Sacramento, California 95817, USA.
SO Clinical pharmacokinetics, (2003) Vol. 42, No. 4, pp. 361-72. Ref: 73
Journal code: 7606849. ISSN: 0312-5963.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200306
ED Entered STN: 22 Mar 2003
Last Updated on STN: 12 Jun 2003
Entered Medline: 11 Jun 2003

L9 ANSWER 40 OF 93 MEDLINE on STN

Full Text

AN 2003113346 MEDLINE
DN PubMed ID: 12626034
TI Hormone replacement therapy in women with a history of breast cancer.
AU Ylikorkala O; Metsa-Heikkila M
CS Department of Obstetrics and Gynecology, Helsinki University Central
Hospital, Helsinki, Finland.
SO Gynecological endocrinology : the official journal of the International
Society of Gynecological Endocrinology, (2002 Dec) Vol. 16, No. 6, pp.
469-78. Ref: 73
Journal code: 8807913. ISSN: 0951-3590.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200306
ED Entered STN: 11 Mar 2003
Last Updated on STN: 28 Jun 2003
Entered Medline: 27 Jun 2003

L9 ANSWER 41 OF 93 MEDLINE on STN

Full Text

AN 2003097716 MEDLINE
DN PubMed ID: 12609561
TI The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a
double-blind placebo-controlled study: effects on menopause symptoms and
bone markers.
AU Wuttke W; Seidlova-Wuttke D; Gorkow C
CS Department of Clinical and Experimental Endocrinology, University of
Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany..
ufkendo@med.uni-goettingen.de
SO Maturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S67-77.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200307
ED Entered STN: 2 Mar 2003
Last Updated on STN: 18 Jul 2003

Entered Medline: 17 Jul 2003

L9 ANSWER 42 OF 93 MEDLINE on STN

Full Text

AN 2003097710 MEDLINE
DN PubMed ID: 12609555
TI Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?
AU Wuttke Wolfgang; Jarry Hubertus; Becker Tamara; Schultens Alexander; Christoffel Volker; Gorkow Christoph; Seidlova-Wuttke Dana
CS Department of Clinical and Experimental Endocrinology, University of Gottingen, Robert-Koch-Strasse 40, 37075 Gottingen, Germany.. ufkendo@med.unigoettingen.de
SO Maturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S9-20. Ref: 59
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200307
ED Entered STN: 2 Mar 2003
Last Updated on STN: 18 Jul 2003
Entered Medline: 17 Jul 2003

L9 ANSWER 43 OF 93 MEDLINE on STN

Full Text

AN 2002739799 MEDLINE
DN PubMed ID: 12456626
TI Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
AU Palomba Stefano; Russo Tiziana; Orio Francesco Jr; Tauchmanova Libuse; Zupi Errico; Panici Pier Luigi Benedetti; Nappi Carmine; Colao Annamaria; Lombardi Gaetano; Zullo Fulvio
CS Department of Obstetrics Gynecology, University 'Magna Graecia' of Catanzaro, Catanzaro.. stefanopalomba@tin.it
SO Human reproduction (Oxford, England), (2002 Dec) Vol. 17, No. 12, pp. 3213-9.
Journal code: 8701199. ISSN: 0268-1161.
CY England: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200306
ED Entered STN: 31 Dec 2002
Last Updated on STN: 5 Jun 2003
Entered Medline: 4 Jun 2003

L9 ANSWER 44 OF 93 MEDLINE on STN

Full Text

AN 2002728697 MEDLINE
DN PubMed ID: 12490735
TI FDA drug approval summaries: fulvestrant.
AU Bross Peter F; Cohen Martin H; Williams Grant A; Pazdur Richard
CS Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, USA.. brossp@cder.fda.gov
SO The oncologist, (2002) Vol. 7, No. 6, pp. 477-80.
Journal code: 9607837. ISSN: 1083-7159.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 20 Dec 2002
Last Updated on STN: 7 Feb 2003
Entered Medline: 6 Feb 2003

L9 ANSWER 45 OF 93 MEDLINE on STN

Full Text

AN 2002683049 MEDLINE
DN PubMed ID: 12443837
TI Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
AU Voipio S K; Komi J; Kangas L; Halonen K; DeGregorio M W; Erkkola R U
CS Department of Obstetrics and Gynecology, Turku University Central Hospital, FIN-20520, Turku, Finland.
SO Maturitas, (2002 Nov 20) Vol. 43, No. 3, pp. 207-14.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200303
ED Entered STN: 22 Nov 2002
Last Updated on STN: 31 Mar 2003
Entered Medline: 28 Mar 2003

L9 ANSWER 46 OF 93 MEDLINE on STN

Full Text

AN 2002634715 MEDLINE
DN PubMed ID: 12394205
TI Tamoxifen as an ergogenic agent in women body builders.
AU Seehusen Dean A; Gloriosso John E
CS Department of Family Practice and Emergency Medical Services, Tripler Army Medical Center, Hawaii 96859, USA.
SO Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, (2002 Sep) Vol. 12, No. 5, pp. 313-4.
Journal code: 9103300. ISSN: 1050-642X.
CY United States
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200211
ED Entered STN: 24 Oct 2002
Last Updated on STN: 13 Dec 2002
Entered Medline: 12 Nov 2002

L9 ANSWER 47 OF 93 MEDLINE on STN

Full Text

AN 2002629431 MEDLINE
DN PubMed ID: 12387278
TI ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. **Selective estrogen receptor modulators.**
AU Anonymous
CS American College of Obstetricians and Gynecologists.
SO Obstetrics and gynecology, (2002 Oct) Vol. 100, No. 4, pp. 835-43.
Journal code: 0401101. ISSN: 0029-7844.
CY United States
DT (GUIDELINE)
Journal; Article; (JOURNAL ARTICLE)
(PRACTICE GUIDELINE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200211
ED Entered STN: 22 Oct 2002
Last Updated on STN: 13 Dec 2002
Entered Medline: 7 Nov 2002

L9 ANSWER 48 OF 93 MEDLINE on STN

Full Text

AN 2002443702 MEDLINE
DN PubMed ID: 12202467
TI Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of

postmenopausal osteoporosis.
 AU Cranney Ann; Tugwell Peter; Zytaruk Nicole; Robinson Vivian; Weaver Bruce;
 Adachi Jonathan; Wells George; Shea Beverley; Guyatt Gordon
 CS Osteoporosis Methodology Group and The Osteoporosis Research Advisory
 Group.
 SO Endocrine reviews, (2002 Aug) Vol. 23, No. 4, pp. 524-8. Ref: 19
 Journal code: 8006258. ISSN: 0163-769X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (META-ANALYSIS)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200302
 ED Entered STN: 31 Aug 2002
 Last Updated on STN: 3 Apr 2003
 Entered Medline: 7 Feb 2003

L9 ANSWER 49 OF 93 MEDLINE on STN

Full Text

AN 2002431393 MEDLINE
 DN PubMed ID: 12188398
 TI Climacteric: concept, consequence and care.
 AU Taechakraichana Nimit; Jaisamrarn Unnop; Panyakhamlerd Krasean;
 Chaikittisilpa Sukanya; Limpaphayom Khunying Kobchitt
 CS Department of Obstetrics and Gynecology, Faculty of Medicine,
 Chulalongkorn University, Bangkok, Thailand.
 SO Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
 (2002 Jun) Vol. 85 Suppl 1, pp. S1-15. Ref: 74
 Journal code: 7507216. ISSN: 0125-2208.
 CY Thailand
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200209
 ED Entered STN: 22 Aug 2002
 Last Updated on STN: 18 Sep 2002
 Entered Medline: 17 Sep 2002

L9 ANSWER 50 OF 93 MEDLINE on STN

Full Text

AN 2002354979 MEDLINE
 DN PubMed ID: 12098608
 TI SERMs: current status and future trends.
 AU Morello Karla C; Wurz Gregory T; DeGregorio Michael W
 CS Department of Internal Medicine, Division of Hematology/Oncology, Cancer
 Center, University of California, Davis, 4501 X Street Room 3016,
 Sacramento, CA 95817, USA.
 SO Critical reviews in oncology/hematology, (2002 Jul) Vol. 43, No. 1, pp.
 63-76. Ref: 99
 Journal code: 8916049. ISSN: 1040-8428.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200307
 ED Entered STN: 7 Jul 2002
 Last Updated on STN: 11 Dec 2002
 Entered Medline: 11 Jul 2003

L9 ANSWER 51 OF 93 MEDLINE on STN

Full Text

AN 2002350308 MEDLINE
 DN PubMed ID: 12093250
 TI Chemoprevention of breast cancer: a summary of the evidence for the U.S.
 Preventive Services Task Force.
 AU Kinsinger Linda S; Harris Russell; Woolf Steven H; Sox Harold C; Lohr
 Kathleen N
 CS Cecil G. Sheps Center for Health Services Research, Program on Prevention,

CB# 7508, Wing D, Room 383, University of North Carolina School of
Medicine, Chapel Hill, NC 27599-7508, USA.

NC 290-97-0011

SO Annals of internal medicine, (2002 Jul 2) Vol. 137, No. 1, pp. 59-69.
Ref: 73
Journal code: 0372351. E-ISSN: 1539-3704.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200207

ED Entered STN: 3 Jul 2002
Last Updated on STN: 18 Jul 2002
Entered Medline: 10 Jul 2002

L9 ANSWER 52 OF 93 MEDLINE on STN
Full Text

AN 2002249322 MEDLINE

DN PubMed ID: 11988138

TI Raloxifene is associated with less side effects than tamoxifen in women
with early breast cancer: a questionnaire study from one physician's
practice.

AU Rohatgi Nitin; Blau Robbin; Lower Elyse E

CS Department of Internal Medicine, Division of Hematology/Oncology,
University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0562,
USA.

SO Journal of women's health & gender-based medicine, (2002 Apr) Vol. 11, No.
3, pp. 291-301.
Journal code: 100888719. ISSN: 1524-6094.

CY United States

DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200206

ED Entered STN: 5 May 2002
Last Updated on STN: 20 Jun 2002
Entered Medline: 19 Jun 2002

L9 ANSWER 53 OF 93 MEDLINE on STN
Full Text

AN 2002230023 MEDLINE

DN PubMed ID: 11966388

TI A 60-year-old woman trying to discontinue hormone replacement therapy.

AU Grady Deborah

CS University of California, San Francisco, 74 New Montgomery St, Suite 600,
San Francisco, CA 94105, USA.. dgrady@itsa.ucsf.edu

SO JAMA : the journal of the American Medical Association, (2002 Apr 24) Vol.
287, No. 16, pp. 2130-7.
Journal code: 7501160. ISSN: 0098-7484.

CY United States

DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200205

ED Entered STN: 23 Apr 2002
Last Updated on STN: 14 Dec 2002
Entered Medline: 2 May 2002

L9 ANSWER 54 OF 93 MEDLINE on STN
Full Text

AN 2002205258 MEDLINE

DN PubMed ID: 11937433

TI Complementary/alternative therapies for reducing **hot flashes** in
prostate cancer patients: reevaluating the existing indirect data from
studies of breast cancer and postmenopausal women.

AU Moyad Mark A

CS Department of Urology, University of Michigan Medical Center, Ann Arbor,

Michigan 48109-0330, USA.. moyad@umich.edu
SO Urology, (2002 Apr) Vol. 59, No. 4 Suppl 1, pp. 20-33. Ref: 148
Journal code: 0366151. E-ISSN: 1527-9995.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 9 Apr 2002
Last Updated on STN: 12 Apr 2002
Entered Medline: 10 Apr 2002

L9 ANSWER 55 OF 93 MEDLINE on STN
Full Text
AN 2002189514 MEDLINE
DN PubMed ID: 11921648
TI [Hormone replacement therapy in peri- and postmenopause. Routine use is
not indicated].
Hormonersatztherapie in der Peri- und Postmenopause. Ein routinemassiger
Einsatz ist nicht indiziert.
AU Emons G; Westphalen S
CS Klinik fur Gynakologie und Geburtshilfe, Georg-August-Universitat
Gottingen.. emons@med.uni-goettingen.de
SO MMW Fortschritte der Medizin, (2002 Feb 28) Vol. 144, No. 9, pp. 30-3.
Journal code: 100893959. ISSN: 1438-3276.
CY Germany: Germany, Federal Republic of
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 200204
ED Entered STN: 3 Apr 2002
Last Updated on STN: 30 Apr 2002
Entered Medline: 29 Apr 2002

L9 ANSWER 56 OF 93 MEDLINE on STN
Full Text
AN 2002172483 MEDLINE
DN PubMed ID: 11906441
TI Chemoprevention for high-risk women: tamoxifen and beyond.
AU Fabian C J; Kimler B F
CS University of Kansas Medical Center, Kansas City, Kansas 66160, USA..
cfabian@kumc.edu
SO The breast journal, (2001 Sep-Oct) Vol. 7, No. 5, pp. 311-20. Ref: 117
Journal code: 9505539. ISSN: 1075-122X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 22 Mar 2002
Last Updated on STN: 19 Apr 2002
Entered Medline: 18 Apr 2002

L9 ANSWER 57 OF 93 MEDLINE on STN
Full Text
AN 2002112745 MEDLINE
DN PubMed ID: 11845111
TI Use of alternatives to estrogen for treatment of menopause.
AU Pinkerton J V; Santen R
CS Department of Obstetrics/Gynecology and the Women's Place, and The
Department of Medicine, Division of Endocrinology, University of Virginia
Health System, Charlottesville, Virginia, USA.
SO Minerva endocrinologica, (2002 Mar) Vol. 27, No. 1, pp. 21-41. Ref: 100
Journal code: 8406505. ISSN: 0391-1977.
CY Italy
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English

FS Priority Journals
EM 200206
ED Entered STN: 15 Feb 2002
Last Updated on STN: 4 Jun 2002
Entered Medline: 3 Jun 2002

L9 ANSWER 58 OF 93 MEDLINE on STN

Full Text

AN 2002069894 MEDLINE
DN PubMed ID: 11795370
TI Developing a **SERM**: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.
AU Komm B S; Lyttle C R
CS Women's Health Research Institute, Wyeth-Ayerst Research, Collegeville, Pennsylvania 19426, USA.. kommmb@war.wyeth.com
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 317-26. Ref: 166
Journal code: 7506858. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 25 Jan 2002
Last Updated on STN: 22 Feb 2002
Entered Medline: 21 Feb 2002

L9 ANSWER 59 OF 93 MEDLINE on STN

Full Text

AN 2002069890 MEDLINE
DN PubMed ID: 11795366
TI Raloxifene: risks and benefits.
AU Barrett-Connor E
CS Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093, USA.. ebarrettconnor@ucsd.edu
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 295-303. Ref: 23
Journal code: 7506858. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 25 Jan 2002
Last Updated on STN: 22 Feb 2002
Entered Medline: 21 Feb 2002

L9 ANSWER 60 OF 93 MEDLINE on STN

Full Text

AN 2002069886 MEDLINE
DN PubMed ID: 11795362
TI What would be the properties of an ideal **SERM**?
AU Anthony M; Williams J K; Dunn B K
CS Georgetown University Medical Center, Washington, DC 20007, USA.
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 261-78. Ref: 123
Journal code: 7506858. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 25 Jan 2002
Last Updated on STN: 22 Feb 2002
Entered Medline: 21 Feb 2002

L9 ANSWER 61 OF 93 MEDLINE on STN

Full Text

AN 2002069883 MEDLINE

DN PubMed ID: 11795359
 TI Effect of **selective estrogen receptor modulators** on reproductive tissues other than endometrium.
 AU Hendrix S L; McNeeley S G
 CS Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, Michigan 48201, USA.. shendrix@med.wayne.edu
 SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 243-50. Ref: 31
 Journal code: 7506858. ISSN: 0077-8923.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200202
 ED Entered STN: 25 Jan 2002
 Last Updated on STN: 22 Feb 2002
 Entered Medline: 21 Feb 2002

L9 ANSWER 62 OF 93 MEDLINE on STN
Full Text
 AN 2002069870 MEDLINE
 DN PubMed ID: 11795346
 TI Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.
 AU Day R
 CS Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA. (National Surgical Adjuvant Breast and Bowel Project P-1 study (NSABP-1)). day@nsabp.pitt.edu
 SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 143-50.
 Journal code: 7506858. ISSN: 0077-8923.
 CY United States
 DT (CLINICAL TRIAL)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 LA English
 FS Priority Journals
 EM 200202
 ED Entered STN: 25 Jan 2002
 Last Updated on STN: 22 Feb 2002
 Entered Medline: 21 Feb 2002

L9 ANSWER 63 OF 93 MEDLINE on STN
Full Text
 AN 2002060340 MEDLINE
 DN PubMed ID: 11779264
 TI Serum estradiol level and risk of breast cancer during treatment with raloxifene.
 AU Cummings Steven R; Duong Tu; Kenyon Emily; Cauley Jane A; Whitehead Malcolm; Krueger Kathryn A
 CS Coordinating Center, University of California, Suite 600, 74 New Montgomery St, San Francisco, CA 94105, USA. (Multiple Outcomes of Raloxifene Evaluation (MORE) Trial). scummings@psg.ucsf.edu
 SO JAMA : the journal of the American Medical Association, (2002 Jan 9) Vol. 287, No. 2, pp. 216-20.
 Journal code: 7501160. ISSN: 0098-7484.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200202
 ED Entered STN: 25 Jan 2002
 Last Updated on STN: 3 Apr 2003
 Entered Medline: 5 Feb 2002

L9 ANSWER 64 OF 93 MEDLINE on STN

Full Text

AN 2001542165 MEDLINE
DN PubMed ID: 11589065
TI **Selective estrogen-receptor modulators in 2001.**
AU O'Regan R M; Gradishar W J
CS Division of Hematology and Medical Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
SO Oncology (Williston Park, N.Y.), (2001 Sep) Vol. 15, No. 9, pp. 1177-85, 1189-90; discussion 1190-4.
Journal code: 8712059. ISSN: 0890-9091.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 9 Oct 2001
Last Updated on STN: 25 Jan 2002
Entered Medline: 7 Jan 2002

L9 ANSWER 65 OF 93 MEDLINE on STN

Full Text

AN 2001536554 MEDLINE
DN PubMed ID: 11584060
TI **Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.**
AU Jordan V C; Gapstur S; Morrow M
CS Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA..
vcjordan@nwu.edu
NC CA89018-01 (NCI)
SO Journal of the National Cancer Institute, (2001 Oct 3) Vol. 93, No. 19, pp. 1449-57. Ref: 96
Journal code: 7503089. ISSN: 0027-8874.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 4 Oct 2001
Last Updated on STN: 22 Jan 2002
Entered Medline: 4 Dec 2001

L9 ANSWER 66 OF 93 MEDLINE on STN

Full Text

AN 2001515400 MEDLINE
DN PubMed ID: 11332140
TI **The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.**
AU Pritchard K I
CS Division of Clinical Trials and Epidemiology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Canada.
SO Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, (2001 Mar) Vol. 12, No. 3, pp. 301-10. Ref: 89
Journal code: 9007735. ISSN: 0923-7534.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200109
ED Entered STN: 24 Sep 2001
Last Updated on STN: 24 Sep 2001
Entered Medline: 20 Sep 2001

L9 ANSWER 67 OF 93 MEDLINE on STN

Full Text

AN 2001477639 MEDLINE
DN PubMed ID: 11521122
TI **Alternatives for women through menopause.**

AU Gass M L; Taylor M B
 CS Department of Obstetrics and Gynecology, University Menopause and Osteoporosis Center, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
 SO American journal of obstetrics and gynecology, (2001 Aug) Vol. 185, No. 2 Suppl, pp. S47-56. Ref: 67
 Journal code: 0370476. ISSN: 0002-9378.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200109
 ED Entered STN: 27 Aug 2001
 Last Updated on STN: 17 Sep 2001
 Entered Medline: 13 Sep 2001

L9 ANSWER 68 OF 93 MEDLINE on STN
Full Text
 AN 2001460389 MEDLINE
 DN PubMed ID: 11348629
 TI Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats.
 AU Berendsen H H; Weekers A H; Kloosterboer H J
 CS Pharmacology Department, NV Organon, P.O. Box 20, 5340 BH, Oss, Netherlands.. H.Berendsen@organon.oss.akzonobel.nl
 SO European journal of pharmacology, (2001 May 4) Vol. 419, No. 1, pp. 47-54.
 Journal code: 1254354. ISSN: 0014-2999.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 20 Aug 2001
 Last Updated on STN: 20 Aug 2001
 Entered Medline: 16 Aug 2001

L9 ANSWER 69 OF 93 MEDLINE on STN
Full Text
 AN 2001441220 MEDLINE
 DN PubMed ID: 11486708
 TI Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
 AU Dhingra K
 CS Hoffmann-La Roche, Inc., Nutley, New Jersey 07110, USA..
kapil.dhingra@Roche.com
 SO Cancer investigation, (2001) Vol. 19, No. 6, pp. 649-59. Ref: 67
 Journal code: 8307154. ISSN: 0735-7907.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 13 Aug 2001
 Last Updated on STN: 27 Aug 2001
 Entered Medline: 23 Aug 2001

L9 ANSWER 70 OF 93 MEDLINE on STN
Full Text
 AN 2001334440 MEDLINE
 DN PubMed ID: 11402436
 TI Tamoxifen to raloxifene and beyond.
 AU O'Regan R M; Jordan V C
 CS Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E Chicago Ave., Chicago, IL 60611, USA..
 SO Seminars in oncology, (2001 Jun) Vol. 28, No. 3, pp. 260-73. Ref: 119
 Journal code: 0420432. ISSN: 0093-7754.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)

LA English
FS Priority Journals
EM 200107
ED Entered STN: 16 Jul 2001
Last Updated on STN: 16 Jul 2001
Entered Medline: 12 Jul 2001

L9 ANSWER 71 OF 93 MEDLINE on STN

Full Text

AN 2001304783 MEDLINE
DN PubMed ID: 11108432
TI Clinical pharmacokinetics of toremifene.
AU Taras T L; Wurz G T; Linares G R; DeGregorio M W
CS Department of Internal Medicine, Cancer Center, University of California, Davis, Sacramento 95817, USA.
NC T32ES07059 (NIEHS)
SO Clinical pharmacokinetics, (2000 Nov) Vol. 39, No. 5, pp. 327-34. Ref: 26
Journal code: 7606849. ISSN: 0312-5963.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 4 Jun 2001
Last Updated on STN: 4 Jun 2001
Entered Medline: 31 May 2001

L9 ANSWER 72 OF 93 MEDLINE on STN

Full Text

AN 2001236869 MEDLINE
DN PubMed ID: 11283133
TI Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
AU Munster P N; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
CS Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2001 Apr 1) Vol. 19, No. 7, pp. 2002-9.
Journal code: 8309333. ISSN: 0732-183X.
CY United States
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 17 May 2001
Last Updated on STN: 17 May 2001
Entered Medline: 3 May 2001

L9 ANSWER 73 OF 93 MEDLINE on STN

Full Text

AN 2001220436 MEDLINE
DN PubMed ID: 11309635
TI Cognitive function in postmenopausal women treated with raloxifene.
AU Yaffe K; Krueger K; Sarkar S; Grady D; Barrett-Connor E; Cox D A; Nickelsen T
CS Department of Psychiatry, University of California at San Francisco, 94121, USA. (Multiple Outcomes of Raloxifene Evaluation Investigators).
NC K23-AG00888 (NIA)
SO The New England journal of medicine, (2001 Apr 19) Vol. 344, No. 16, pp. 1207-13.
Journal code: 0255562. ISSN: 0028-4793.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

(RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200105
 ED Entered STN: 17 May 2001
 Last Updated on STN: 17 May 2001
 Entered Medline: 3 May 2001

L9 ANSWER 74 OF 93 MEDLINE on STN
Full Text
 AN 2001084172 MEDLINE
 DN PubMed ID: 10948439
 TI Managing menopausal problems.
 AU Cobleigh M A
 CS Rush-Presbyterian-St. Luke's Medical Center, USA.
 SO Cancer treatment and research, (2000) Vol. 103, pp. 1-23. Ref: 111
 Journal code: 8008541. ISSN: 0927-3042.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200101
 ED Entered STN: 22 Mar 2001
 Last Updated on STN: 22 Mar 2001
 Entered Medline: 18 Jan 2001

L9 ANSWER 75 OF 93 MEDLINE on STN
Full Text
 AN 2001078370 MEDLINE
 DN PubMed ID: 11112238
 TI Long-term effects of raloxifene on bone mineral density, bone turnover,
 and serum lipid levels in early postmenopausal women: three-year data from
 2 double-blind, randomized, placebo-controlled trials.
 AU Johnston C C Jr; Bjarnason N H; Cohen F J; Shah A; Lindsay R; Mitlak B H;
 Huster W; Draper M W; Harper K D; Heath H 3rd; Gennari C; Christiansen C;
 Arnaud C D; Delmas P D
 CS Indiana University School of Medicine, Emerson Hall Room 421, 545 Barnhill
 Dr, Indianapolis, IN 46202, USA.
 SO Archives of internal medicine, (Dec 11-25 2000) Vol. 160, No. 22, pp.
 3444-50.
 Journal code: 0372440. ISSN: 0003-9926.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200101
 ED Entered STN: 22 Mar 2001
 Last Updated on STN: 22 Mar 2001
 Entered Medline: 11 Jan 2001

L9 ANSWER 76 OF 93 MEDLINE on STN
Full Text
 AN 2001038660 MEDLINE
 DN PubMed ID: 11075748
 TI Soy isoflavones: are they useful in menopause?.
 AU Vincent A; Fitzpatrick L A
 CS Division of Endocrinology, Metabolism, Nutrition and Internal Medicine,
 Mayo Clinic, Rochester, Minn 55905, USA.
 SO Mayo Clinic proceedings. Mayo Clinic, (2000 Nov) Vol. 75, No. 11, pp.
 1174-84. Ref: 91
 Journal code: 0405543. ISSN: 0025-6196.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200011

ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 30 Nov 2000

L9 ANSWER 77 OF 93 MEDLINE on STN

Full Text

AN 2000452135 MEDLINE
DN PubMed ID: 11006795
TI Raloxifene hydrochloride.
AU Snyder K R; Sparano N; Malinowski J M
CS Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA 18766, USA.. snyder@wilkes.edu
SO American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, (2000 Sep 15) Vol. 57, No. 18, pp. 1669-75; quiz 1676-8. Ref: 27
Journal code: 9503023. ISSN: 1079-2082.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200101
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 5 Jan 2001

L9 ANSWER 78 OF 93 MEDLINE on STN

Full Text

AN 2000196877 MEDLINE
DN PubMed ID: 10732328
TI Selective estrogen receptor modulators (SERMs) in clinical practice.
AU Plouffe L Jr
CS Eli Lilly and Co., US Medical Endocrine Division, Indianapolis, Indiana, USA.
SO Journal of the Society for Gynecologic Investigation, (2000 Jan-Feb) Vol. 7, No. 1 Suppl, pp. S38-46. Ref: 103
Journal code: 9433806. ISSN: 1071-5576.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200004
ED Entered STN: 5 May 2000
Last Updated on STN: 5 May 2000
Entered Medline: 26 Apr 2000

L9 ANSWER 79 OF 93 MEDLINE on STN

Full Text

AN 2000150592 MEDLINE
DN PubMed ID: 10687884
TI Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
AU Cohen F J; Lu Y
CS Lilly Research Laboratories, Indianapolis, IN 46285, USA..
fjcohen@lilly.com
SO Maturitas, (2000 Jan 15) Vol. 34, No. 1, pp. 65-73.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200005
ED Entered STN: 12 May 2000
Last Updated on STN: 12 May 2000
Entered Medline: 4 May 2000

L9 ANSWER 80 OF 93 MEDLINE on STN

Full Text

AN 2000144327 MEDLINE
 DN PubMed ID: 10680075
 TI Chemoprevention of breast cancer in the older patient.
 AU Minton S E
 CS Department of Medicine, H. Lee Moffitt Cancer Center and Research
 Institute, University of South Florida, Tampa, USA.
 SO Hematology/oncology clinics of North America, (2000 Feb) Vol. 14, No. 1,
 pp. 113-30. Ref: 99
 Journal code: 8709473. ISSN: 0889-8588.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200003
 ED Entered STN: 27 Mar 2000
 Last Updated on STN: 27 Mar 2000
 Entered Medline: 10 Mar 2000

L9 ANSWER 81 OF 93 MEDLINE on STN

Full Text

AN 2000127246 MEDLINE
 DN PubMed ID: 10665480
 TI Antiestrogens--tamoxifen, SERMs and beyond.
 AU Dhingra K
 CS Hoffman-La Roche Inc., Nutley, NJ 07110, USA.
 SO Investigational new drugs, (1999) Vol. 17, No. 3, pp. 285-311. Ref: 247
 Journal code: 8309330. ISSN: 0167-6997.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200002
 ED Entered STN: 29 Feb 2000
 Last Updated on STN: 29 Feb 2000
 Entered Medline: 17 Feb 2000

L9 ANSWER 82 OF 93 MEDLINE on STN

Full Text

AN 2000000052 MEDLINE
 DN PubMed ID: 10532252
 TI Tolerability profile of SERMs.
 AU Agnusdei D; Iori N
 CS Skeletal Diseases, Eli Lilly & Co., Eli Lilly Italy, Firenze, Italy.
 SO Journal of endocrinological investigation, (1999 Sep) Vol. 22, No. 8, pp.
 641-5. Ref: 27
 Journal code: 7806594. ISSN: 0391-4097.
 CY Italy
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 199911
 ED Entered STN: 11 Jan 2000
 Last Updated on STN: 11 Jan 2000
 Entered Medline: 17 Nov 1999

L9 ANSWER 83 OF 93 MEDLINE on STN

Full Text

AN 1999450119 MEDLINE
 DN PubMed ID: 10520416
 TI [Results of international clinical trials with raloxifene].
 Resultats des etudes cliniques internationales du raloxifene.
 AU Agnusdei D; Liu-Leage S; Augendre-Ferrante B
 CS Eli Lilly & Co., Florence, Italie.. agnusdeidonato@lilly.com
 SO Annales d'endocrinologie, (1999 Sep) Vol. 60, No. 3, pp. 242-6. Ref: 18
 Journal code: 0116744. ISSN: 0003-4266.
 CY France
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)

LA French
FS Priority Journals
EM 199911
ED Entered STN: 11 Jan 2000
Last Updated on STN: 11 Jan 2000
Entered Medline: 23 Nov 1999

L9 ANSWER 84 OF 93 MEDLINE on STN

Full Text

AN 1999256919 MEDLINE
DN PubMed ID: 10326987
TI **Selective estrogen receptor modulators: a controversial approach**
for managing postmenopausal health.
AU Curtis M G
CS Department of Obstetrics, Gynecology, and Reproductive Medicine,
University of Texas at Houston, 77026, USA.
SO Journal of women's health / the official publication of the Society for
the Advancement of Women's Health Research, (1999 Apr) Vol. 8, No. 3, pp.
321-33. Ref: 151
Journal code: 9208978. ISSN: 1059-7115.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199907
ED Entered STN: 14 Jul 1999
Last Updated on STN: 14 Jul 1999
Entered Medline: 1 Jul 1999

L9 ANSWER 85 OF 93 MEDLINE on STN

Full Text

AN 1999156327 MEDLINE
DN PubMed ID: 10068418
TI Clinical effects of raloxifene hydrochloride in women.
AU Khovidhunkit W; Shoback D M
CS University of California, San Francisco, and Veterans Affairs Medical
Center, 94121, USA.
NC DK 43400 (NIDDK)
SO Annals of internal medicine, (1999 Mar 2) Vol. 130, No. 5, pp. 431-9.
Ref: 86
Journal code: 0372351. ISSN: 0003-4819.
CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199903
ED Entered STN: 16 Mar 1999
Last Updated on STN: 3 Mar 2000
Entered Medline: 4 Mar 1999

L9 ANSWER 86 OF 93 MEDLINE on STN

Full Text

AN 1999098006 MEDLINE
DN PubMed ID: 9881331
TI The effect of estrogens and antiestrogens in a rat model for hot flush.
AU Merchensthaler I; Funkhouser J M; Carver J M; Lundeen S G; Ghosh K;
Winneker R C
CS Functional Morphology Division, Women's Health Research Institute,
Wyeth-Ayerst Research, Radnor, PA 19087, USA.. Merchel@war.wyeth.com
SO Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 307-16.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199903

ED Entered STN: 13 Apr 1999
Last Updated on STN: 13 Apr 1999
Entered Medline: 26 Mar 1999

L9 ANSWER 87 OF 93 MEDLINE on STN

Full Text

AN 1999097998 MEDLINE
DN PubMed ID: 9881323
TI Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health.
AU Termine J D; Wong M
CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
SO Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 241-5. Ref: 42
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199903
ED Entered STN: 13 Apr 1999
Last Updated on STN: 13 Apr 1999
Entered Medline: 26 Mar 1999

L9 ANSWER 88 OF 93 MEDLINE on STN

Full Text

AN 1999078785 MEDLINE
DN PubMed ID: 9861792
TI Hormone replacement therapy and breast cancer: revisiting the issues.
AU DeGregorio M W; Taras T L
CS Department of Internal Medicine, University of California, Sacramento 95817, USA.. mwdegregorio@ucdavis.edu
NC 5T32ES07059 (NIEHS)
SO Journal of the American Pharmaceutical Association (Washington, D.C. : 1996), (1998 Nov-Dec) Vol. 38, No. 6, pp. 738-44; quiz 744-6. Ref: 51
Journal code: 9601004. ISSN: 1086-5802.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199901
ED Entered STN: 15 Jan 1999
Last Updated on STN: 15 Jan 1999
Entered Medline: 6 Jan 1999

L9 ANSWER 89 OF 93 MEDLINE on STN

Full Text

AN 1998001916 MEDLINE
DN PubMed ID: 9342556
TI Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
AU Maenpaa J U; Ala-Fossi S L
CS Department of Obstetrics and Gynecology, University Hospital, Tampere, Finland.
SO Drugs & aging, (1997 Oct) Vol. 11, No. 4, pp. 261-70. Ref: 53
Journal code: 9102074. ISSN: 1170-229X.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199712
ED Entered STN: 9 Jan 1998
Last Updated on STN: 9 Jan 1998
Entered Medline: 3 Dec 1997

L9 ANSWER 90 OF 93 MEDLINE on STN

Full Text

AN 94108991 MEDLINE
DN PubMed ID: 8281625

TI Phase I trial of droloxifene in patients with metastatic breast cancer.
 AU Buzdar A U; Kau S; Hortobagyi G N; Theriault R L; Booser D; Holmes F A;
 Walters R; Krakoff I H
 CS Department of Medical Oncology/Medical Breast Service, University of Texas
 M.D. Anderson Cancer Center, Houston 77030.
 SO Cancer chemotherapy and pharmacology, (1994) Vol. 33, No. 4, pp. 313-6.
 Journal code: 7806519. ISSN: 0344-5704.
 CY GERMANY: Germany, Federal Republic of
 DT (CLINICAL TRIAL)
 (CLINICAL TRIAL, PHASE I)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 199402
 ED Entered STN: 28 Feb 1994
 Last Updated on STN: 29 Jan 1999
 Entered Medline: 17 Feb 1994

L9 ANSWER 91 OF 93 MEDLINE on STN

Full Text

AN 93205190 MEDLINE
 DN PubMed ID: 8384328
 TI Clinical and radiographic response in a minority of patients with
 recurrent malignant gliomas treated with high-dose tamoxifen.
 AU Couldwell W T; Weiss M H; DeGiorgio C M; Weiner L P; Hinton D R; Ehresmann
 G R; Conti P S; Apuzzo M L
 CS Department of Neurological Surgery, University of Southern California, Los
 Angeles.
 SO Neurosurgery, (1993 Mar) Vol. 32, No. 3, pp. 485-9; discussion 489-90.
 Journal code: 7802914. ISSN: 0148-396X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199304
 ED Entered STN: 7 May 1993
 Last Updated on STN: 7 May 1993
 Entered Medline: 20 Apr 1993

L9 ANSWER 92 OF 93 MEDLINE on STN

Full Text

AN 92044719 MEDLINE
 DN PubMed ID: 1834808
 TI Phase I study of toremifene in patients with advanced cancer.
 AU Hamm J T; Tormey D C; Kohler P C; Haller D; Green M; Shemano I
 CS Department of Medicine, University of Louisville, KY 40292.
 SO Journal of clinical oncology : official journal of the American Society of
 Clinical Oncology, (1991 Nov) Vol. 9, No. 11, pp. 2036-41.
 Journal code: 8309333. ISSN: 0732-183X.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 199112
 ED Entered STN: 24 Jan 1992
 Last Updated on STN: 24 Jan 1992
 Entered Medline: 6 Dec 1991

L9 ANSWER 93 OF 93 MEDLINE on STN

Full Text

AN 86079062 MEDLINE
 DN PubMed ID: 3940620
 TI Trioxifene mesylate in the treatment of advanced breast cancer.
 AU Lee R W; Buzdar A U; Blumenschein G R; Hortobagyi G N
 SO Cancer, (1986 Jan 1) Vol. 57, No. 1, pp. 40-3.
 Journal code: 0374236. ISSN: 0008-543X.

CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 198602
 ED Entered STN: 21 Mar 1990
 Last Updated on STN: 6 Feb 1995
 Entered Medline: 12 Feb 1986

=> d 19 an ti au so ab kwic 69 70 77 78 79 81 82 84 85 86 87 88

L9 ANSWER 69 OF 93 MEDLINE on STN

Full Text

AN 2001441220 MEDLINE

TI **Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.**

AU Dhingra K

SO Cancer investigation, (2001) Vol. 19, No. 6, pp. 649-59. Ref: 67
 Journal code: 8307154. ISSN: 0735-7907.

AB Female hormones, especially estrogens, play an important role in the pathogenesis of breast neoplasms and are a principal determinant of their biological behavior. Endocrine manipulation through medical or surgical means can often lead to objective shrinkage of breast tumors. Tamoxifen, a triphenylethylene estrogen receptor modulator, is currently the most widely used hormonal treatment for breast cancer. It has been conclusively demonstrated to reduce the risk of relapse following definitive local therapy (and systemic chemotherapy, when indicated) of invasive or noninvasive breast cancer. Recently, it has also been shown to reduce the incidence of breast cancer in healthy women who are at high risk of developing the disease. In addition, it can prevent osteoporosis and reduce the risk of fractures in postmenopausal women. However, its use is also complicated by an increased incidence of endometrial hyperplasia/carcinoma, venous thromboembolism, cataracts, and in some cases, emergence of tamoxifen-dependent clones of breast cancer. These side effects (except cataracts) are believed to be related to estrogen-agonist effects of tamoxifen. Newer drugs, which are "pure antiestrogens" or inhibitors of estrogen biosynthesis, are devoid of such estrogen-agonist activity and may not have the liability of many of these side effects. However, these agents would also be expected to lack the potentially beneficial effects of tamoxifen on lipids and skeletal system. The ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of **selective estrogen-receptor modulation. Selective estrogen receptor modulators (SERMs)**, which are devoid of estrogen-agonist effects on the uterus or breast cancer cells but retain potentially beneficial effects on bones and lipids, have been described as "ideal" SERMs. A number of such compounds are currently being tested. Raloxifene is already approved for prevention of osteoporosis and has potential efficacy for prevention and treatment of breast cancer. An analogue of raloxifene, LY353381, is currently in Phase II clinical trials for treatment of breast cancer, with promising early results. EM800 and CP336156 are other promising ideal SERMs in clinical trials. These compounds may provide better treatment and chemoprevention alternatives for breast cancer as compared to tamoxifen, aromatase inhibitors, and pure antiestrogens. In addition, they may also prove to be useful for the treatment and prevention of prostate cancer as well as for treating benign gynecological diseases such as fibroids and endometriosis. Future laboratory efforts should focus on further broadening the efficacy profile of SERMs (e.g., prevention of Alzheimer's disease and elevation of high-density lipoproteins to improve the likelihood of cardiovascular benefit) and narrowing their side-effect profile (e.g., risk of thromboembolism and hot flashes).

TI **Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.**

AB ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of **selective estrogen-receptor modulation. Selective estrogen receptor modulators (SERMs)**, which are devoid of estrogen-agonist effects on the uterus or breast cancer cells but retain potentially

beneficial effects on. . . . of high-density lipoproteins to improve the likelihood of cardiovascular benefit) and narrowing their side-effect profile (e.g., risk of thromboembolism and **hot flashes**).

L9 ANSWER 70 OF 93 MEDLINE on STN

Full Text

AN 2001334440 MEDLINE

TI Tamoxifen to raloxifene and beyond.

AU O'Regan R M; Jordan V C

SO Seminars in oncology, (2001 Jun) Vol. 28, No. 3, pp. 260-73. Ref: 119
Journal code: 0420432. ISSN: 0093-7754.

AB Tamoxifen, a **selective estrogen receptor modulator (SERM)**, is the treatment of choice for all stages of hormone-responsive breast cancer and has been shown to prevent breast cancer in high-risk women. Despite acting as an **antiestrogen** on the breast, tamoxifen has partial estrogenic effects on other target tissues. These partial estrogen agonistic actions produce beneficial effects on bones and the lipid profile in postmenopausal women. However, tamoxifen is associated with an increase in endometrial cancer. Additionally, its antiestrogenic effects in the central nervous system result in **hot flashes** in postmenopausal women. Raloxifene is another SERM approved for the prevention of osteoporosis in postmenopausal women. Like tamoxifen, raloxifene appears to prevent breast cancer in high-risk women and has not, to date, been noted to increase the incidence of endometrial cancer. The Study of Tamoxifen and Raloxifene will compare the effects of the two agents on breast cancer prevention and endometrial cancer risk. A number of new agents are being developed for breast cancer treatment and prevention and osteoporosis prevention. These include other SERMs, selective estrogen receptor downregulators (SERDs), and aromatase inhibitors. It is hoped that one of these new agents will be the ideal agent, acting as an **antiestrogen** on breast and endometrium while having estrogenic effects on bones, the lipid profile, and the central nervous system. Semin Oncol 28:260-273.

Copyright 2001 by W.B. Saunders Company.

AB Tamoxifen, a **selective estrogen receptor modulator (SERM)**, is the treatment of choice for all stages of hormone-responsive breast cancer and has been shown to prevent breast cancer in high-risk women. Despite acting as an **antiestrogen** on the breast, tamoxifen has partial estrogenic effects on other target tissues. These partial estrogen agonistic actions produce beneficial effects. . . . tamoxifen is associated with an increase in endometrial cancer. Additionally, its antiestrogenic effects in the central nervous system result in **hot flashes** in postmenopausal women. Raloxifene is another **SERM** approved for the prevention of osteoporosis in postmenopausal women. Like tamoxifen, raloxifene appears to prevent breast cancer in high-risk women. . . . and aromatase inhibitors. It is hoped that one of these new agents will be the ideal agent, acting as an **antiestrogen** on breast and endometrium while having estrogenic effects on bones, the lipid profile, and the central nervous system. Semin Oncol. . . .

CT

Hormone-Dependent: DT, drug therapy

Neoplasms, Hormone-Dependent: PC, prevention & control

Raloxifene: CH, chemistry

Raloxifene: PD, pharmacology

*Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators: TU, therapeutic use

Tamoxifen: AA, analogs & derivatives

Tamoxifen: CH, chemistry

Tamoxifen: PD, pharmacology

*Tamoxifen: TU, therapeutic.

CN 0 (Aromatase Inhibitors); 0 (Estrogen Antagonists); 0 (**Selective Estrogen Receptor Modulators**)

L9 ANSWER 77 OF 93 MEDLINE on STN

Full Text

AN 2000452135 MEDLINE

TI Raloxifene hydrochloride.

AU Snyder K R; Sparano N; Malinowski J M

SO American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, (2000 Sep 15) Vol. 57, No. 18, pp. 1669-75; quiz 1676-8. Ref: 27
Journal code: 9503023. ISSN: 1079-2082.

AB The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene is a **selective estrogen-receptor modulator (SERM)** that has been approved for use in the prevention and treatment of osteoporosis in postmenopausal women. A SERM interacts with estrogen receptors, functioning as an agonist in some tissues and an antagonist in other tissues. Because of their unique pharmacologic properties, these agents can achieve the desired effects of estrogen without the possible stimulatory effects on the breasts or uterus. Raloxifene is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass glucuronidation. Approximately 60% of a dose is absorbed; however, absolute bioavailability is only 2%. The volume of distribution is 2348 L/kg for a single oral dose of 30-150 mg, and the elimination half-life averages 32.5 hours. In clinical trials in postmenopausal women, raloxifene had an estrogen-like effect on bone turnover and increased bone mineral density. It reduced the risk of fractures in women with osteoporosis. Raloxifene also seemed to reduce the risk of breast cancer and positively influenced blood lipid markers of cardiovascular disease. Raloxifene is generally well tolerated; the most common adverse effects are **hot flashes** and leg cramps. A serious adverse effect is venous thromboembolism. The recommended dosage is 60 mg/day orally without regard to meals. Ultimately, it will be information on cardiovascular or breast cancer benefits that will determine the future role of raloxifene. Raloxifene is an alternative to traditional hormone replacement therapy for the prevention and treatment of osteoporosis in selected postmenopausal women. More study is needed to verify possible benefits related to heart disease and breast cancer.

AB The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene is a **selective estrogen-receptor modulator (SERM)** that has been approved for use in the prevention and treatment of osteoporosis in postmenopausal women. A SERM interacts with estrogen receptors, functioning as an agonist in some tissues and an antagonist in other tissues. Because of their. . . and positively influenced blood lipid markers of cardiovascular disease. Raloxifene is generally well tolerated; the most common adverse effects are **hot flashes** and leg cramps. A serious adverse effect is venous thromboembolism. The recommended dosage is 60 mg/day orally without regard to. . .

CT

Postmenopausal: PC, prevention & control

*Raloxifene

Raloxifene: AE, adverse effects

Raloxifene: ME, metabolism

Raloxifene: PK, pharmacokinetics

Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators: AE, adverse effects

Selective Estrogen Receptor Modulators: ME, metabolism

Selective Estrogen Receptor Modulators: PK, pharmacokinetics

Selective Estrogen Receptor Modulators: TU, therapeutic use

Tissue Distribution

CN 0 (Selective Estrogen Receptor Modulators)

L9 ANSWER 78 OF 93 MEDLINE on STN

Full Text

AN 2000196877 MEDLINE

TI Selective estrogen receptor modulators (SERMs) in clinical practice.

AU Plouffe L Jr

SO Journal of the Society for Gynecologic Investigation, (2000 Jan-Feb) Vol. 7, No. 1 Suppl, pp. S38-46. Ref: 103
Journal code: 9433806. ISSN: 1071-5576.

AB The objective of this literature review is to familiarize the reader with the clinical data on **selective estrogen receptor modulators** (SERMs) and antiestrogens currently in use in the US, excluding data on breast effects. Four compounds in the SERM and **antiestrogen** families are presently in clinical use in the US: clomiphene (CC), tamoxifen (TAM), toremifene (TOR), and raloxifene (RLX). The clinical database on these compounds is among the largest available. Each compound demonstrates a specific profile for its target tissue effects, and this may differ between premenopausal and postmenopausal women. CC is the most widely used agent for ovulation induction. TAM is indicated in the management of breast cancer and for prevention in women at high risk. TAM may have

additional effects on the cardiovascular and skeletal systems. TOR also is used for its effects on breast tissue and may have positive cardiovascular effects. RLX is approved in the management of osteoporosis with data supporting favorable effects on the cardiovascular system and breast tissue. TAM and TOR appear to have stimulatory effects on the uterus and endometrium, whereas RLX is neutral. Few adverse events have been attributed to these agents, with **hot flashes** being the most common one. There appears to be an increased risk of thromboembolic events with continuous use of TAM, TOR, and RLX. SERMs and antiestrogens continue to be studied extensively. Their evolving profiles support key roles for these agents in modern day medicine, particularly in the management of postmenopausal women's health.

TI **Selective estrogen receptor modulators (SERMs) in clinical practice.**
AB The objective of this literature review is to familiarize the reader with the clinical data on **selective estrogen receptor modulators** (SERMs) and antiestrogens currently in use in the US, excluding data on breast effects. Four compounds in the SERM and **antiestrogen** families are presently in clinical use in the US: clomiphene (CC), tamoxifen (TAM), toremifene (TOR), and raloxifene (RLX). The clinical . . . effects on the uterus and endometrium, whereas RLX is neutral. Few adverse events have been attributed to these agents, with **hot flashes** being the most common one. There appears to be an increased risk of thromboembolic events with continuous use of TAM, . . .

CT
therapeutic use

Estrogen Antagonists: TU, therapeutic use

Humans

Osteoporosis, Postmenopausal: PC, prevention & control

Ovulation Induction

Raloxifene: TU, therapeutic use

***Selective Estrogen Receptor Modulators: TU, therapeutic use**

Tamoxifen: TU, therapeutic use

Toremifene: TU, therapeutic use

CN 0 (Estrogen Antagonists); 0 (Selective Estrogen Receptor Modulators)

L9 ANSWER 79 OF 93 MEDLINE on STN

Full Text

AN 2000150592 MEDLINE

TI Characterization of **hot flashes** reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.

AU Cohen F J; Lu Y

SO Maturitas, (2000 Jan 15) Vol. 34, No. 1, pp. 65-73.

Journal code: 7807333. ISSN: 0378-5122.

AB **OBJECTIVE:** Raloxifene, a **selective estrogen receptor modulator**, is estrogen-like in the skeleton and cardiovascular system and antiestrogenic in reproductive tissues. In contrast to estrogens, raloxifene is not indicated for the treatment of **hot flashes**. This study was designed to examine the characteristics of **hot flashes** among healthy postmenopausal women participating in osteoporosis prevention trials who were receiving raloxifene or placebo. **METHODS:** Adverse event data from three randomized, double-blind trials (N = 876) comparing raloxifene 60 mg/day with placebo for 30 months were integrated and analyzed. Two of the three trials (one European, two North American) were identically designed and were open to healthy postmenopausal women ages 45 through 60 without regard to prior hysterectomy. The third trial was multinational, was open to women ages 40 through 60, and all enrollees had prior hysterectomy at baseline. Women were questioned in general terms about the occurrence of adverse events at 3-6-month intervals. Treatment-emergent adverse events pertaining to **hot flashes** were included in the current study. **RESULTS:** At baseline, 12% of women randomly assigned to placebo and 13% assigned to raloxifene reported prevalent **hot flashes**. After 30 months, the cumulative incidence of **hot flashes** was 21% for placebo and 28% for raloxifene (P = 0.022), with the difference in incidence rate confined to the first 6 months of therapy. There was no difference between placebo and raloxifene in reported maximum severity of or early discontinuations as a result of **hot flashes** (< or = 3% per group for both outcomes). Among women whose **hot flashes** had stopped completely during the 30-month study period, the median total duration of the event prior to becoming symptom-free was 246 days for placebo and 205 days for raloxifene. Among all women reporting a hot flash, the extrapolated total duration of

hot flashes was the same for women treated with either raloxifene or placebo. No subgroup-by-therapy interactions were detected. Multivariable regression analysis revealed several factors that were independently weakly predictive of hot flashes. CONCLUSIONS: Raloxifene slightly affects the incidence but not the natural history of hot flashes in healthy postmenopausal women seeking prevention therapy.

TI Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.

AB OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, is estrogen-like in the skeleton and cardiovascular system and antiestrogenic in reproductive tissues. In contrast to estrogens, raloxifene is not indicated for the treatment of hot flashes. This study was designed to examine the characteristics of hot flashes among healthy postmenopausal women participating in osteoporosis prevention trials who were receiving raloxifene or placebo. METHODS: Adverse event data from. . . Women were questioned in general terms about the occurrence of adverse events at 3-6-month intervals. Treatment-emergent adverse events pertaining to hot flashes were included in the current study. RESULTS: At baseline, 12% of women randomly assigned to placebo and 13% assigned to raloxifene reported prevalent hot flashes. After 30 months, the cumulative incidence of hot flashes was 21% for placebo and 28% for raloxifene ($P = 0.022$), with the difference in incidence rate confined to the. . . There was no difference between placebo and raloxifene in reported maximum severity of or early discontinuations as a result of hot flashes ($\leq 3\%$ per group for both outcomes). Among women whose hot flashes had stopped completely during the 30-month study period, the median total duration of the event prior to becoming symptom-free was 246 days for placebo and 205 days for raloxifene. Among all women reporting a hot flash, the extrapolated total duration of hot flashes was the same for women treated with either raloxifene or placebo. No subgroup-by-therapy interactions were detected. Multivariable regression analysis revealed several factors that were independently weakly predictive of hot flashes. CONCLUSIONS: Raloxifene slightly affects the incidence but not the natural history of hot flashes in healthy postmenopausal women seeking prevention therapy.

CT Check Tags: Female
Adult
Double-Blind Method
Estrogen Antagonists: AE, adverse effects
*Estrogen Antagonists: TU, therapeutic use
Hot Flashes: CI, chemically induced
*Hot Flashes: EP, epidemiology
Humans
Incidence
Middle Aged
*Osteoporosis, Postmenopausal: PC, prevention & control
Raloxifene: AE, adverse effects
*Raloxifene: TU, therapeutic use
Randomized Controlled Trials
Risk Factors
Selective Estrogen Receptor Modulators: AE, adverse effects
*Selective Estrogen Receptor Modulators: TU, therapeutic use
Severity of Illness Index
Time Factors

CN 0 (Estrogen Antagonists); 0 (Selective Estrogen Receptor Modulators)

L9 ANSWER 81 OF 93 MEDLINE on STN

Full Text

AN 2000127246 MEDLINE

TI Antiestrogens--tamoxifen, SERMs and beyond.

AU Dhingra K

SO Investigational new drugs, (1999) Vol. 17, No. 3, pp. 285-311. Ref: 247
Journal code: 8309330. ISSN: 0167-6997.

AB Estrogens play a central role in reproductive physiology. The cellular effects of estrogens are mediated by binding to nuclear receptors (ER) which activate transcription of genes involved in cellular growth control. At least two such receptors, designated ERalpha and ERbeta, mediate these effects in conjunction with a number of coactivators. These receptors can directly interact with other members of the steroid receptor superfamily. A complex cross-talk exists between the estrogen-signaling pathways and the downstream signaling events initiated by growth factors, such as

epidermal growth factor and insulin-like growth factors. Estrogens are also a causative factor in the pathogenesis of a variety of neoplastic and non-neoplastic diseases, including breast cancer, endometrial cancer, endometriosis, and uterine fibroids, among others. Antiestrogens, such as tamoxifen, are widely used for the treatment of breast cancer. Tamoxifen produces objective tumor shrinkage in advanced breast cancer, reduces the risk of relapse in women treated for invasive breast cancer, and prevents breast cancer in high-risk women. Although, initially developed as an antiestrogen, tamoxifen can also prevent postmenopausal osteoporosis as well as reduce cholesterol, due to its estrogen-agonist effects. Its estrogen-agonist activity, however, can lead to significant side-effects such as endometrial cancer and thromboembolic phenomena. This has led to the concept of "ideal" selective estrogen receptor modulators (SERMs), drugs that would have the desired, tissue selective, estrogen-agonist or -antagonist effects. Raloxifene is a SERM which has the desirable mixed agonist/antagonist effects of tamoxifen but does not cause uterine stimulation. "Pure" antiestrogens may provide very potent estrogen-antagonist drugs, but are likely to be devoid of beneficial effects on bone and lipids. Future drug development efforts should focus on developing superior SERMs that have a greater efficacy against ER-positive tumors and do not cause hot flashes or thromboembolism, and explore combination strategies to simultaneously target hormone-dependent as well as hormone-independent breast cancer.

AB . . . relapse in women treated for invasive breast cancer, and prevents breast cancer in high-risk women. Although, initially developed as an antiestrogen, tamoxifen can also prevent postmenopausal osteoporosis as well as reduce cholesterol, due to its estrogen-agonist effects. Its estrogen-agonist activity, however, . . . can lead to significant side-effects such as endometrial cancer and thromboembolic phenomena. This has led to the concept of "ideal" selective estrogen receptor modulators (SERMs), drugs that would have the desired, tissue selective, estrogen-agonist or -antagonist effects. Raloxifene is a SERM which has the desirable mixed agonist/antagonist effects of tamoxifen but does not cause uterine stimulation. "Pure" antiestrogens may provide very. . . development efforts should focus on developing superior SERMs that have a greater efficacy against ER-positive tumors and do not cause hot flashes or thromboembolism, and explore combination strategies to simultaneously target hormone-dependent as well as hormone-independent breast cancer.

L9 ANSWER 82 OF 93 MEDLINE on STN

Full Text

AN 2000000052 MEDLINE

TI Tolerability profile of SERMs.

AU Agnusdei D; Iori N

SO Journal of endocrinological investigation, (1999 Sep) Vol. 22, No. 8, pp. 641-5. Ref: 27

Journal code: 7806594. ISSN: 0391-4097.

CT Check Tags: Female

Animals

Estrogen Replacement Therapy: AE, adverse effects

Hot Flashes: CI, chemically induced

Humans

Osteoporosis, Postmenopausal: PC, prevention & control

Raloxifene: AE, adverse effects

Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators: AE, adverse effects

*Selective Estrogen Receptor Modulators: TU, therapeutic use

Tamoxifen: AE, adverse effects

Tamoxifen: TU, therapeutic use

Venous Thrombosis: CI, chemically induced

CN 0 (Selective Estrogen Receptor Modulators)

L9 ANSWER 84 OF 93 MEDLINE on STN

Full Text

AN 1999256919 MEDLINE

TI Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health.

AU Curtis M G

SO Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research, (1999 Apr) Vol. 8, No. 3, pp. 321-33. Ref: 151

Journal code: 9208978. ISSN: 1059-7115.

AB Hormone replacement therapy (HRT) is considered the standard of care for managing the acute (e.g., hot flashes, vaginal dryness) and long-term (e.g., increased risk of cardiovascular disease, osteoporosis) sequelae of menopause. A group of synthetic nonsteroidal compounds, which act on the estrogen receptor, have been promoted for use as an alternative to hormonal therapy for postmenopausal women. Originally called antiestrogens because of their ability to antagonize the action of estrogen, these compounds possess both agonist and antagonist properties of estrogen action. They are now referred to as **selective estrogen receptor modulators** (SERMs). This article reviews the mechanism of action and the efficacy and safety data for SERMs currently used for clinical purposes. These data may indicate why the use of SERMs is a controversial alternative to HRT.

TI **Selective estrogen receptor modulators: a controversial approach** for managing postmenopausal health.

AB Hormone replacement therapy (HRT) is considered the standard of care for managing the acute (e.g., hot flashes, vaginal dryness) and long-term (e.g., increased risk of cardiovascular disease, osteoporosis) sequelae of menopause. A group of synthetic nonsteroidal compounds, . . . action of estrogen, these compounds possess both agonist and antagonist properties of estrogen action. They are now referred to as **selective estrogen receptor modulators** (SERMs). This article reviews the mechanism of action and the efficacy and safety data for SERMs currently used for clinical.

L9 ANSWER 85 OF 93 MEDLINE on STN

Full Text

AN 1999156327 MEDLINE

TI Clinical effects of raloxifene hydrochloride in women.

AU Khovidhunkit W; Shoback D M

SO Annals of internal medicine, (1999 Mar 2) Vol. 130, No. 5, pp. 431-9.
Ref: 86

Journal code: 0372351. ISSN: 0003-4819.

AB PURPOSE: To review clinical data on raloxifene hydrochloride, a **selective estrogen receptor modulator** that was recently approved for the prevention of osteoporosis in postmenopausal women. DATA SOURCES: English-language articles published from 1980 to May 1998 were identified through MEDLINE searches. Bibliographies, book chapters, and meeting abstracts were reviewed for additional relevant publications. STUDY SELECTION: Publications that contained information on the background of development, structure, mechanism of action, tissue-selective effects, and adverse effects of raloxifene hydrochloride were included. DATA EXTRACTION: Data in selected articles were reviewed, and relevant clinical information was extracted. DATA SYNTHESIS: Raloxifene hydrochloride was developed in an effort to find a treatment for breast cancer and osteoporosis. It binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as **selective estrogen receptor modulators**. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen receptor subtypes in various tissues, and intracellular events after ligand binding. Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. An increase in bone mineral density at the spine, total hip, and total body has been reported with raloxifene but seems to be less than that seen with estrogen or alendronate therapy. Raloxifene has been shown to produce a reduction in total and low-density lipoprotein cholesterol concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholesterol and triglyceride concentrations do not increase during raloxifene therapy. In the uterus, raloxifene does not stimulate the endometrium. Long-term data on the effects of raloxifene in reduction of risk for fracture; prevention of cardiovascular events; cognitive function; and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is **hot flashes**. CONCLUSIONS: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug of choice for hormonal therapy in most postmenopausal women, raloxifene may be an alternative in certain groups of women at risk for osteoporosis.

AB PURPOSE: To review clinical data on raloxifene hydrochloride, a **selective estrogen receptor modulator** that was recently approved

for the prevention of osteoporosis in postmenopausal women. DATA SOURCES: English-language articles published from 1980 to. . . binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as **selective estrogen receptor modulators**. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen. . . and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is **hot flashes**. CONCLUSIONS: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug. . .

L9 ANSWER 86 OF 93 MEDLINE on STN

Full Text

AN 1999098006 MEDLINE

TI The effect of estrogens and antiestrogens in a rat model for hot flush.

AU Merchanthaler I; Funkhouser J M; Carver J M; Lundeen S G; Ghosh K; Winneker R C

SO Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 307-16.

Journal code: 7807333. ISSN: 0378-5122.

AB The present studies evaluated the effect of estrogens and the **selective estrogen receptor modulator** (SERM) tamoxifen and raloxifene in a rat model for hot flush. In this model, ovariectomized rats were treated for 8 or 9 days either sc or po. Rats were dependent to morphine by implanting a morphine pellet (75 mg each) sc on days 3 and 5 of treatment. On the last day of treatment, a thermistor, connected to a data acquisition system, was placed on the tail of each animal and morphine addiction was withdrawn by naloxone injection (1.0 mg/kg, sc). Temperature measurements were taken for 1 h under ketamine (80 mg/kg, im) anesthesia. In general, vehicle treated rats showed a 5-6 degrees C elevation of their tail skin temperature with the peak occurring about 15 min after naloxone injection. 17 alpha-Ethinyl estradiol (EE) was evaluated both sc and po using a broad range of doses. The IC50 for inhibition of tail skin temperature rise was approximately 0.1 mg/kg, sc and 0.2 mg/kg, po. 17 beta-Estradiol and 17 alpha-estradiol were also active in this model whereas non-estrogenic steroids were inactive. Raloxifene and tamoxifen were tested for estrogen agonist and antagonist activity administered sc and po. Raloxifene did not demonstrate reproducible estrogen agonist activity at doses up to 10 mg/kg, whereas it demonstrated significant antagonistic activity at the 10 mg/kg dose regardless of the route of administration. Tamoxifen exhibited significant estrogen agonist activity at all doses tested (0.1-10.0 mg/kg) and was a significant antagonist of EE at the 1.0 mg/kg dose. Our results demonstrate the potential utility of this model to evaluate and discriminate among classes of compounds with varying degrees of estrogen agonist and antagonist activity.

AB The present studies evaluated the effect of estrogens and the **selective estrogen receptor modulator** (SERM) tamoxifen and raloxifene in a rat model for hot flush. In this model, ovariectomized rats were treated for 8 or. . .

CT

*Body Temperature: DE, drug effects
Disease Models, Animal
*Estrogen Antagonists: TU, therapeutic use
*Estrogens: AG, agonists
*Estrogens: TU, therapeutic use
*Hot Flashes: DT, drug therapy
Hot Flashes: ME, metabolism
Random Allocation
Rats
Rats, Sprague-Dawley

L9 ANSWER 87 OF 93 MEDLINE on STN

Full Text

AN 1999097998 MEDLINE

TI Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health.

AU Termine J D; Wong M

SO Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 241-5. Ref: 42

Journal code: 7807333. ISSN: 0378-5122.

AB OBJECTIVE: To briefly summarize the therapeutic choices for osteoporosis prevention which are currently available to post-menopausal women.

METHODS: Results of randomized clinical trials and epidemiological studies in postmenopausal women, and pre-clinical studies in ovariectomized rats were summarized. RESULTS: Estrogen combined with progestogen in hormone replacement therapy (HRT) is effective in relieving perimenopausal symptoms and maintaining bone mineral density. However, the increased breast cancer risk associated with long-term HRT use makes it a less desirable option for many women. **Selective estrogen receptor modulators** (SERMs), such as raloxifene, are also effective in maintaining bone density, without stimulating the breast or uterus. However, SERMs do not relieve perimenopausal **hot flashes**. CONCLUSION: HRT is effective for acute relief of perimenopausal symptoms, but for women who are unwilling or unable to take HRT long-term, SERMs such as raloxifene are a useful therapy for the prevention of osteoporosis.

AB . . . However, the increased breast cancer risk associated with long-term HRT use makes it a less desirable option for many women. **Selective estrogen receptor modulators** (SERMs), such as raloxifene, are also effective in maintaining bone density, without stimulating the breast or uterus. However, SERMs do not relieve perimenopausal **hot flashes**. CONCLUSION: HRT is effective for acute relief of perimenopausal symptoms, but for women who are unwilling or unable to take. . .

L9 ANSWER 88 OF 93 MEDLINE on STN

Full Text

AN 1999078785 MEDLINE

TI Hormone replacement therapy and breast cancer: revisiting the issues.

AU DeGregorio M W; Taras T L

SO Journal of the American Pharmaceutical Association (Washington, D.C. : 1996), (1998 Nov-Dec) Vol. 38, No. 6, pp. 738-44; quiz 744-6. Ref: 51
Journal code: 9601004. ISSN: 1086-5802.

AB OBJECTIVE: To assess current ideas about the benefits and risks of estrogen and hormone replacement therapy (ERT/HRT) in postmenopausal women. DATA SOURCES: MEDLINE searches, supplemented by various texts, of the literature on HRT, ERT, and **selective estrogen receptor modulators** (SERMs): tamoxifen, toremifene, and raloxifene. DATA SYNTHESIS: HRT is primarily used for improving quality of life in women suffering from vasomotor symptoms associated with menopause. HRT is beneficial in postmenopausal women for preventing cardiovascular disease, osteoporosis, and Alzheimer's disease. Review of meta-analyses of clinical trials showed that ERT/HRT ever-users (patients who have ever used ERT/HRT) did not have an increased risk of breast cancer, but current users did have an increased risk, with some studies reporting increasing risk with duration of ERT. No relationship was found between dose or the addition of progestin to ERT and increased breast cancer risk. Overall breast cancer mortality rates associated with HRT were decreased in current users. In general, HRT does not increase the risk of breast cancer in women with a family history of the disease, compared with those without a family history. New HRT strategies that could potentially prevent breast cancer are now being developed. The SERMs tamoxifen and toremifene appear to have positive clinical effects on bone and serum lipids; they are currently being investigated for use as breast cancer chemopreventive agents. Raloxifene, a new **SERM** used for the prevention of osteoporosis, is an alternative for women who cannot tolerate HRT. Unfortunately, these SERMs have anti-estrogenic effects and thus cause vasomotor adverse effects such as **hot flashes** and vaginal dryness. In addition, SERMs do not protect against heart disease or prevent osteoporosis as well as does HRT. CONCLUSION: Presently, SERMs will not become first-line HRT, as the positive effects of ERT/HRT may outweigh any potentially increased risk of breast cancer. The development of new agents with pharmacodynamic profiles similar to that of ERT/HRT but lacking its adverse effects would be greatly beneficial for postmenopausal women.

AB . . . therapy (ERT/HRT) in postmenopausal women. DATA SOURCES: MEDLINE searches, supplemented by various texts, of the literature on HRT, ERT, and **selective estrogen receptor modulators** (SERMs): tamoxifen, toremifene, and raloxifene. DATA SYNTHESIS: HRT is primarily used for improving quality of life in women suffering from. . . on bone and serum lipids; they are currently being investigated for use as breast cancer chemopreventive agents. Raloxifene, a new **SERM** used for the prevention of osteoporosis, is an alternative for women who cannot tolerate HRT. Unfortunately, these SERMs have anti-estrogenic effects and thus cause vasomotor adverse effects such as **hot flashes** and vaginal

dryness. In addition, SERMs do not protect against heart disease or prevent osteoporosis as well as does HRT.. . .

=> d his

(FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007)

FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007

E TAMOXIFEN/CN
L1 1 S E3
E RALOXIFENE/CN
L2 1 S E3
E TOREMIFENE/CN
L3 1 S E3
E TRIPHENYLETHYLENE/CN
L4 1 S E3

FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007

L5 5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
L6 12869 S L1 OR L2 OR L3 OR L4
L7 16501 S (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE)
L8 1538 S (HOT FLASH?)
L9 93 S L5 AND L8
L10 16501 S L6 OR L7
L11 182 S L8 AND L10

=> d 1-182

L11 ANSWER 1 OF 182 MEDLINE on STN

Full Text

AN 2007090333 MEDLINE
DN PubMed ID: 17200148
TI Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
AU Coates Alan S; Keshaviah Aparna; Thurlimann Beat; Mouridsen Henning; Mauriac Louis; Forbes John F; Paridaens Robert; Castiglione-Gertsch Monica; Gelber Richard D; Colleoni Marco; Lang Istvan; Del Mastro Lucia; Smith Ian; Chirgwin Jacquie; Nogaret Jean-Marie; Pienkowski Tadeusz; Wardley Andrew; Jakobsen Erik H; Price Karen N; Goldhirsch Aron
CS International Breast Cancer Study Group (IBCSG), IBCSG Coordinating Center, Bern, Switzerland.. alan.coates@ibcsq.org
NC CA-75362 (NCI)
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2007 Feb 10) Vol. 25, No. 5, pp. 486-92. Electronic Publication: 2007-01-02.
Journal code: 8309333. E-ISSN: 1527-7755.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)
LA English
FS Priority Journals
EM 200703
ED Entered STN: 10 Feb 2007
Last Updated on STN: 16 Mar 2007
Entered Medline: 15 Mar 2007

L11 ANSWER 2 OF 182 MEDLINE on STN

Full Text

AN 2007028979 MEDLINE
DN PubMed ID: 17225620
TI Psychological well-being improves in women with breast cancer after treatment with applied relaxation or electro-acupuncture for vasomotor symptom.
AU Nedstrand Elizabeth; Wyon Yvonne; Hammar Mats; Wijma Klaas
CS Division of Obstetrics and Gynecology, Faculty of Health Sciences, Linköping University Hospital, Linköping, Sweden..

elizabeth.nedstrand@lio.se

SO Journal of psychosomatic obstetrics and gynaecology, (2006 Dec) Vol. 27,
No. 4, pp. 193-9.
Journal code: 8308648. ISSN: 0167-482X.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)

LA English

FS Priority Journals

EM 200703

ED Entered STN: 18 Jan 2007
Last Updated on STN: 2 Mar 2007
Entered Medline: 1 Mar 2007

L11 ANSWER 3 OF 182 MEDLINE on STN

Full Text

AN 2007013928 MEDLINE

DN PubMed ID: 17211091

TI Therapeutic agents for disorders of bone and calcium metabolism:
Bazedoxifene.

AU Chaki Osamu

CS Yokohama City University Medical Center, Section of Gynecology.

SO Clinical calcium, (2007 Jan) Vol. 17, No. 1, pp. 30-5. Ref: 8
Journal code: 9433326. ISSN: 0917-5857.

CY Japan

DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA Japanese

FS Priority Journals

EM 200703

ED Entered STN: 10 Jan 2007
Last Updated on STN: 24 Mar 2007
Entered Medline: 23 Mar 2007

L11 ANSWER 4 OF 182 MEDLINE on STN

Full Text

AN 2006719192 MEDLINE

DN PubMed ID: 17162554

TI Long-term administration of mifepristone (RU486): clinical tolerance
during extended treatment of meningioma.

AU Grunberg Steven M; Weiss Martin H; Russell Christy A; Spitz Irving M;
Ahmadi Jamshid; Sadun Alfredo; Sitruk-Ware Regine

CS Division of Hematology/Oncology, University of Vermont College of
Medicine, Burlington, Vermont, USA.. steven.grunberg@uvm.edu

NC 2P30 CA14089 (NCI)

SO Cancer investigation, (2006 Dec) Vol. 24, No. 8, pp. 727-33.
Journal code: 8307154. ISSN: 0735-7907.

CY United States

DT (CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)

LA English

FS Priority Journals

EM 200703

ED Entered STN: 13 Dec 2006
Last Updated on STN: 6 Mar 2007
Entered Medline: 5 Mar 2007

L11 ANSWER 5 OF 182 MEDLINE on STN

Full Text

AN 2006715159 MEDLINE

DN PubMed ID: 16936184

TI Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole
after 5 years of tamoxifen in postmenopausal women with early stage
breast cancer.

AU Moy B; Tu D; Pater J L; Ingle J N; Shepherd L E; Whelan T J; Goss P E

CS Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114,

USA.. bmoy@partners.org

SO Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, (2006 Nov) Vol. 17, No. 11, pp. 1637-43. Electronic Publication: 2006-08-25.
Journal code: 9007735. ISSN: 0923-7534.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(CLINICAL TRIAL)

LA English

FS Priority Journals

EM 200702

ED Entered STN: 13 Dec 2006
Last Updated on STN: 2 Feb 2007
Entered Medline: 1 Feb 2007

L11 ANSWER 6 OF 182 MEDLINE on STN

Full Text

AN 2006713123 MEDLINE

DN PubMed ID: 16971671

TI Menopausal-type symptoms in young breast cancer survivors.

AU Leining M G; Gelber S; Rosenberg R; Przypyszny M; Winer E P; Partridge A H

CS Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA.

SO Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, (2006 Dec) Vol. 17, No. 12, pp. 1777-82. Electronic Publication: 2006-09-13.
Journal code: 9007735. ISSN: 0923-7534.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200703

ED Entered STN: 12 Dec 2006
Last Updated on STN: 2 Mar 2007
Entered Medline: 1 Mar 2007

L11 ANSWER 7 OF 182 MEDLINE on STN

Full Text

AN 2006552765 MEDLINE

DN PubMed ID: 16978958

TI Side effects of aromatase inhibitors versus **tamoxifen**: the patients' perspective.

AU Garreau Jennifer R; Delamelena Tammy; Walts Deb; Karamlou Kasra; Johnson Nathalie

CS OHSU Department of Surgery, Portland, OR 97210, USA.. garreauj@ohsu.edu

SO American journal of surgery, (2006 Oct) Vol. 192, No. 4, pp. 496-8.
Journal code: 0370473. ISSN: 0002-9610.

CY United States

DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200611

ED Entered STN: 19 Sep 2006
Last Updated on STN: 7 Nov 2006
Entered Medline: 6 Nov 2006

L11 ANSWER 8 OF 182 MEDLINE on STN

Full Text

AN 2006534953 MEDLINE

DN PubMed ID: 16958819

TI Effectiveness of **raloxifene** on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.

AU Song E K; Yeom J-H; Shin H T; Kim S H; Shin W G; Oh J M

CS Department of Pharmacy, Sejong General Hospital, Seoul, Korea.

SO Journal of clinical pharmacy and therapeutics, (2006 Oct) Vol. 31, No. 5, pp. 421-7.
Journal code: 8704308. ISSN: 0269-4727.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM 200612
ED Entered STN: 9 Sep 2006
Last Updated on STN: 19 Dec 2006
Entered Medline: 15 Dec 2006

L11 ANSWER 9 OF 182 MEDLINE on STN

Full Text

AN 2006495512 MEDLINE
DN PubMed ID: 16921052
TI Influence of hormone replacement therapy on **tamoxifen**-induced vasomotor symptoms.
AU Sestak Ivana; Kealy Roseann; Edwards Robert; Forbes John; Cuzick Jack
CS Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, United Kingdom.
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2006 Aug 20) Vol. 24, No. 24, pp. 3991-6.
Journal code: 8309333. E-ISSN: 1527-7755.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200609
ED Entered STN: 22 Aug 2006
Last Updated on STN: 13 Sep 2006
Entered Medline: 12 Sep 2006

L11 ANSWER 10 OF 182 MEDLINE on STN

Full Text

AN 2006492805 MEDLINE
DN PubMed ID: 16916481
TI A Canadian observational study of the optimal method of transition from postmenopausal hormone therapy to **raloxifene**.
AU Lorraine Joanne; Lee Bobbie
CS Eli Lilly Canada, Toronto ON.
SO Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, (2006 Jul) Vol. 28, No. 7, pp. 583-94.
Journal code: 101126664. ISSN: 1701-2163.
CY Canada
DT Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)
LA English
FS Priority Journals
EM 200609
ED Entered STN: 19 Aug 2006
Last Updated on STN: 19 Sep 2006
Entered Medline: 18 Sep 2006

L11 ANSWER 11 OF 182 MEDLINE on STN

Full Text

AN 2006453370 MEDLINE
DN PubMed ID: 16877740
TI Polymorphism in the CYP2D6 **tamoxifen**-metabolizing gene influences clinical effect but not hot flashes: data from the Italian **Tamoxifen** Trial.
AU Bonanni Bernardo; Macis Debora; Maisonneuve Patrick; Johansson Harriet A; Gucciardo Giacomo; Oliviero Pasquale; Travaglini Roberto; Muraca Maria G; Rotmensz Nicole; Veronesi Umberto; Decensi Andrea U
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2006 Aug 1) Vol. 24, No. 22, pp. 3708-9; author reply 3709.
Journal code: 8309333. E-ISSN: 1527-7755.
CY United States
DT Commentary
Letter
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English

FS Priority Journals
EM 200608
ED Entered STN: 1 Aug 2006
Last Updated on STN: 15 Aug 2006
Entered Medline: 14 Aug 2006

L11 ANSWER 12 OF 182 MEDLINE on STN

Full Text

AN 2006414662 MEDLINE
DN PubMed ID: 16735939
TI Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study.
AU Gold Ellen B; Flatt Shirley W; Pierce John P; Bardwell Wayne A; Hajek Richard A; Newman Vicky A; Rock Cheryl L; Stefanick Marcia L
CS Division of Epidemiology, Department of Public Health Sciences, University of California, Davis, Davis, CA 95616, USA.
NC CA69375 (NCI)
M01-RR00070 (NCRR)
M01-RR00079 (NCRR)
M01-RR00827 (NCRR)
SO Menopause (New York, N.Y.), (2006 May-Jun) Vol. 13, No. 3, pp. 423-33.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200608
ED Entered STN: 14 Jul 2006
Last Updated on STN: 3 Aug 2006
Entered Medline: 2 Aug 2006

L11 ANSWER 13 OF 182 MEDLINE on STN

Full Text

AN 2006355459 MEDLINE
DN PubMed ID: 16770112
TI Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer.
AU Tsukagoshi Shigeru
CS The Tokyo Cooperative Oncology Group.
SO Gan to kagaku ryoho. Cancer & chemotherapy, (2006 Jun) Vol. 33, No. 6, pp. 859-63. Ref: 11
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Japanese
FS Priority Journals
EM 200607
ED Entered STN: 14 Jun 2006
Last Updated on STN: 6 Jul 2006
Entered Medline: 5 Jul 2006

L11 ANSWER 14 OF 182 MEDLINE on STN

Full Text

AN 2006343989 MEDLINE
DN PubMed ID: 16757696
TI Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
AU Vastag Brian
SO Journal of the National Cancer Institute, (2006 Jun 7) Vol. 98, No. 11, pp. 733-5.
Journal code: 7503089. E-ISSN: 1460-2105.
CY United States
DT News Announcement
LA English
FS Priority Journals
EM 200606
ED Entered STN: 8 Jun 2006
Last Updated on STN: 24 Jun 2006

Entered Medline: 23 Jun 2006

L11 ANSWER 15 OF 182 MEDLINE on STN

Full Text

AN 2006251095 MEDLINE
DN PubMed ID: 16675918
TI Inherited gene affects tamoxifen's benefit in some breast cancers.
AU Anonymous
SO Mayo Clinic women's healthsource, (2006 Jun) Vol. 10, No. 6, pp. 3.
Journal code: 9891120. ISSN: 1091-0220.
CY United States
DT News Announcement
LA English
FS Consumer Health
EM 200606
ED Entered STN: 6 May 2006
Last Updated on STN: 28 Jun 2006
Entered Medline: 27 Jun 2006

L11 ANSWER 16 OF 182 MEDLINE on STN

Full Text

AN 2006154614 IN-PROCESS
DN PubMed ID: 16542048
TI Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms.
AU Stearns Vered
CS Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
SO Treatments in endocrinology, (2006) Vol. 5, No. 2, pp. 83-7.
Journal code: 101132977. ISSN: 1175-6349.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 18 Mar 2006
Last Updated on STN: 12 Dec 2006

L11 ANSWER 17 OF 182 MEDLINE on STN

Full Text

AN 2006123472 MEDLINE
DN PubMed ID: 16509835
TI Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
AU Kimmick Gretchen G; Lovato James; McQuellon Richard; Robinson Emily; Muss Hyman B
CS Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina, USA..
gretchen.kimmick@duke.edu
SO The breast journal, (2006 Mar-Apr) Vol. 12, No. 2, pp. 114-22.
Journal code: 9505539. ISSN: 1075-122X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(CLINICAL TRIAL)
LA English
FS Priority Journals
EM 200604
ED Entered STN: 3 Mar 2006
Last Updated on STN: 5 Apr 2006
Entered Medline: 4 Apr 2006

L11 ANSWER 18 OF 182 MEDLINE on STN

Full Text

AN 2006039179 MEDLINE
DN PubMed ID: 16428125
TI Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life.
AU Gupta P; Sturdee D W; Palin S L; Majumder K; Fear R; Marshall T; Paterson J
CS Women's Unit, Solihull Hospital, Heart of England NHS Foundation Trust, Solihull.

SO Climacteric : the journal of the International Menopause Society, (2006 Feb) Vol. 9, No. 1, pp. 49-58.
 Journal code: 9810959. ISSN: 1369-7137.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200604
 ED Entered STN: 24 Jan 2006
 Last Updated on STN: 21 Apr 2006
 Entered Medline: 20 Apr 2006

L11 ANSWER 19 OF 182 MEDLINE on STN

Full Text

AN 2006034876 MEDLINE
 DN PubMed ID: 16422310
 TI Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal women.
 AU He Weili; Deng Weiping
 CS Clinical Biostatistics, Merck Research Laboratories, RY34-A316, 126 Lincoln Avenue, Rahway, NJ 07065, USA.. weili_he@merck.com
 SO Clinical trials (London, England), (2005) Vol. 2, No. 6, pp. 497-508.
 Journal code: 101197451. ISSN: 1740-7745.
 CY England: United Kingdom
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200603
 ED Entered STN: 21 Jan 2006
 Last Updated on STN: 18 Mar 2006
 Entered Medline: 17 Mar 2006

L11 ANSWER 20 OF 182 MEDLINE on STN

Full Text

AN 2006034298 MEDLINE
 DN PubMed ID: 16329712
 TI Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.
 AU Baber Rodney; Hickey Martha; Kwik Michelle
 CS Division of Women's and Children's Health, Royal North Shore Hospital of Sydney, Sydney, New South Wales, Australia.
 SO Drug safety : an international journal of medical toxicology and drug experience, (2005) Vol. 28, No. 12, pp. 1085-100. Ref: 124
 Journal code: 9002928. ISSN: 0114-5916.
 CY New Zealand
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200703
 ED Entered STN: 21 Jan 2006
 Last Updated on STN: 12 Dec 2006
 Entered Medline: 14 Mar 2007

L11 ANSWER 21 OF 182 MEDLINE on STN

Full Text

AN 2006009528 MEDLINE
 DN PubMed ID: 16390756
 TI Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study.
 AU Nedstrand E; Wijma K; Wyon Y; Hammar M
 CS Division of Obstetrics and Gynecology and Unit of Medical Psychology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping, Sweden.
 SO Climacteric : the journal of the International Menopause Society, (2005 Sep) Vol. 8, No. 3, pp. 243-50.
 Journal code: 9810959. ISSN: 1369-7137.
 CY United States

DT Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(CLINICAL TRIAL)

LA English

FS Priority Journals

EM 200602

ED Entered STN: 7 Jan 2006

Last Updated on STN: 1 Mar 2006

Entered Medline: 28 Feb 2006

L11 ANSWER 22 OF 182 MEDLINE on STN

Full Text

AN 2005676831 MEDLINE

DN PubMed ID: 16343926

TI Hot flushes in breast cancer patients.

AU Mom Constantijne H; Buijs Ciska; Willemse Pax H B; Mourits Marian J E; de Vries Elisabeth G E

CS Department of Medical Oncology, University Medical Center, P.O. Box 30001, 9700 RB Groningen, The Netherlands.

SO Critical reviews in oncology/hematology, (2006 Jan) Vol. 57, No. 1, pp. 63-77. Ref: 94

Journal ccde: 8916049. ISSN: 1040-8428.

CY Ireland

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200603

ED Entered STN: 22 Dec 2005

Last Updated on STN: 30 Mar 2006

Entered Medline: 29 Mar 2006

L11 ANSWER 23 OF 182 MEDLINE on STN

Full Text

AN 2005673349 MEDLINE

DN PubMed ID: 16361630

TI Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

AU Goetz Matthew P; Rae James M; Suman Vera J; Safgren Stephanie L; Ames Matthew M; Visscher Daniel W; Reynolds Carol; Couch Fergus J; Lingle Wilma L; Flockhart David A; Desta Zeruesenay; Perez Edith A; Ingle James N

CS Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.. goetz.matthew@mayo.edu

NC CA 90628-03 (NCI)

U-01 GM61373 (NIGMS)

SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2005 Dec 20) Vol. 23, No. 36, pp. 9312-8.

Journal code: 8309333. ISSN: 0732-183X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)

(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200602

ED Entered STN: 21 Dec 2005

Last Updated on STN: 3 Feb 2006

Entered Medline: 3 Feb 2006

L11 ANSWER 24 OF 182 MEDLINE on STN

Full Text

AN 2005664555 MEDLINE

DN PubMed ID: 16352931

TI Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B.

AU Mitsuyama Shosyu; Nomura Yasuo; Ohno Shinji; Miyauchi Mitsuru; Yamamoto Naoto; Kimura Tsunehito; Saku Motonori; Miura Shigeto; Yoshikawa Nobuteru; Tsujinaka Toshimasa; Koh Junichi; Ishida Tsunehiro; Abe Osahiko; Ohashi Yasuo

CS Dept. of Surgery, Kitakyushu Municipal Medical Center.

SO Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Dec) Vol. 32, No. 13,
pp. 2071-7.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(CLINICAL TRIAL)
LA Japanese
FS Priority Journals
EM 200601
ED Entered STN: 18 Dec 2005
Last Updated on STN: 7 Jan 2006
Entered Medline: 6 Jan 2006

L11 ANSWER 25 OF 182 MEDLINE on STN

Full Text

AN 2005616357 MEDLINE
DN PubMed ID: 16297087
TI Quality of life in Brazilian breast cancer survivors age 45-65 years:
associated factors.
AU Conde Delio Marques; Pinto-Neto Aarao Mendes; Cabello Cesar; Santos-Sa
Danielle; Costa-Paiva Lucia; Martinez Edson Zangiacomi
CS Department of Gynecology and Obstetrics, Universidade Estadual de
Campinas, Campinas, Brazil.. condedelio@uol.com.br
SO The breast journal, (2005 Nov-Dec) Vol. 11, No. 6, pp. 425-32.
Journal code: 9505539. ISSN: 1075-122X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200512
ED Entered STN: 22 Nov 2005
Last Updated on STN: 18 Dec 2005
Entered Medline: 13 Dec 2005

L11 ANSWER 26 OF 182 MEDLINE on STN

Full Text

AN 2005550268 MEDLINE
DN PubMed ID: 16227740
TI Experience of high-dose toremifene treatment for postmenopausal women
with metastatic breast cancer.
AU Yamamoto Yutaka; Kawazoe Teru; Iwase Hirotaka
CS Dept. of Breast & Endocrine Surgery, Faculty of Medical and Pharmaceutical
Sciences, Kumamoto University.
SO Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Oct) Vol. 32, No. 10,
pp. 1415-9.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 200511
ED Entered STN: 18 Oct 2005
Last Updated on STN: 9 Nov 2005
Entered Medline: 8 Nov 2005

L11 ANSWER 27 OF 182 MEDLINE on STN

Full Text

AN 2005506720 MEDLINE
DN PubMed ID: 16088965
TI New aromatase inhibitors as second-line endocrine therapy in
postmenopausal patients with metastatic breast carcinoma: a pooled
analysis of the randomized trials.
AU Carlini Paolo; Bria Emilio; Giannarelli Diana; Ferretti Gianluigi; Felici
Alessandra; Papaldo Paola; Fabi Alessandra; Nistico Cecilia; Di Cosimo
Serena; Figgeri Enzo Maria; Milella Michele; Mottolese Marcella; Terzoli
Edmondo; Cognetti Francesco
CS Department of Medical Oncology, Regina Elena Cancer Institute, Rome,
Italy. p.carlini@iol.it. p.carlini@yahoo.it

SO Cancer, (2005 Oct 1) Vol. 104, No. 7, pp. 1335-42. Ref: 31
 Journal code: 0374236. ISSN: 0008-543X.
 CY United States
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200512
 ED Entered STN: 24 Sep 2005
 Last Updated on STN: 15 Dec 2005
 Entered Medline: 1 Dec 2005

L11 ANSWER 28 OF 182 MEDLINE on STN

Full Text

AN 2005503730 MEDLINE
 DN PubMed ID: 16175702
 TI Opinions of research participants about study paperwork.
 AU Walker Gay; de Valois Beverly; Davies Raten; Young Teresa; Maher Jane
 CS Lynda Jackson Macmillan Centre, Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK.. GayW@mvh-ljmc.org
 SO Bulletin of medical ethics, (2005 Feb) No. 205, pp. 21-4.
 Journal code: 9103287. ISSN: 0962-9564.
 Report No.: KIE-122340.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Bioethics
 EM 200512
 ED Entered STN: 23 Sep 2005
 Last Updated on STN: 18 Dec 2005
 Entered Medline: 13 Dec 2005

L11 ANSWER 29 OF 182 MEDLINE on STN

Full Text

AN 2005474704 MEDLINE
 DN PubMed ID: 16143229
 TI Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.
 AU Biglia N; Torta Riccardo; Roagna R; Maggiorotto F; Cacciari F; Ponzzone R; Kubatzki F; Sismondi P
 CS Academic Gynaecological Oncology Department, University of Turin, IRCC (Institute for Cancer Research and Treatment) of Candiolo, Turin and Mauriziano Umberto I Hospital, Largo Turati 62, Torino 10128, Italy..
nbiglia@mauriziano.it
 SO Maturitas, (2005 Sep 16) Vol. 52, No. 1, pp. 78-85.
 Journal code: 7807333. ISSN: 0378-5122.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (CLINICAL TRIAL)
 LA English
 FS Priority Journals
 EM 200512
 ED Entered STN: 7 Sep 2005
 Last Updated on STN: 18 Dec 2005
 Entered Medline: 9 Dec 2005

L11 ANSWER 30 OF 182 MEDLINE on STN

Full Text

AN 2005393435 MEDLINE
 DN PubMed ID: 16037759
 TI Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer.
 AU Conde Delio M; Pinto-Neto Aarao M; Cabello Cesar; Sa Danielle S; Costa-Paiva Lucia; Martinez Edson Z
 CS Department of Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil.
 SO Menopause (New York, N.Y.), (2005 Jul-Aug) Vol. 12, No. 4, pp. 436-43.
 Electronic Publication: 2005-07-21.
 Journal code: 9433352. ISSN: 1072-3714.

CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200512
ED Entered STN: 31 Jul 2005
Last Updated on STN: 18 Dec 2005
Entered Medline: 13 Dec 2005

L11 ANSWER 31 OF 182 MEDLINE on STN

Full Text

AN 2005390217 MEDLINE
DN PubMed ID: 16048357
TI Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
AU Cranney Ann; Adachi Jonathan D
CS Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
SO Drug safety : an international journal of medical toxicology and drug
experience, (2005) Vol. 28, No. 8, pp. 721-30. Ref: 74
Journal code: 9002928. ISSN: 0114-5916.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200510
ED Entered STN: 29 Jul 2005
Last Updated on STN: 1 Nov 2005
Entered Medline: 31 Oct 2005

L11 ANSWER 32 OF 182 MEDLINE on STN

Full Text

AN 2005236210 MEDLINE
DN PubMed ID: 15772568
TI Effects of ospemifene and raloxifene on hormonal status, lipids, genital
tract, and tolerability in postmenopausal women.
AU Komi Janne; Lankinen Kari S; Harkonen Pirkko; DeGregorio Michael W; Voipio
Sari; Kivinen Seppo; Tuimala Risto; Vihtamaki Tarja; Vihko Kimmo;
Ylikorkala Olavi; Erkkola Risto
CS Hormos Medical Corporation, Turku, Finland.
SO Menopause (New York, N.Y.), (2005 Mar) Vol. 12, No. 2, pp. 202-9.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200507
ED Entered STN: 6 May 2005
Last Updated on STN: 22 Jul 2005
Entered Medline: 21 Jul 2005

L11 ANSWER 33 OF 182 MEDLINE on STN

Full Text

AN 2005138116 MEDLINE
DN PubMed ID: 15770000
TI Tamoxifen pharmacogenetics moves closer to reality.
AU Garber Ken
SO Journal of the National Cancer Institute, (2005 Mar 16) Vol. 97, No. 6,
pp. 412-3.
Journal code: 7503089. E-ISSN: 1460-2105.
CY United States
DT News Announcement
LA English
FS Priority Journals
EM 200503
ED Entered STN: 17 Mar 2005
Last Updated on STN: 23 Mar 2005
Entered Medline: 22 Mar 2005

L11 ANSWER 34 OF 182 MEDLINE on STN

Full Text

AN 2005118744 MEDLINE
DN PubMed ID: 15750360
TI Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial.
AU Jacobs Jennifer; Herman Patricia; Heron Krista; Olsen Steven; Vaughters Lucy
CS Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA, USA.. jjacobs@igc.org
SO Journal of alternative and complementary medicine (New York, N.Y.), (2005 Feb) Vol. 11, No. 1, pp. 21-7.
Journal code: 9508124. ISSN: 1075-5535.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 200505
ED Entered STN: 8 Mar 2005
Last Updated on STN: 25 May 2005
Entered Medline: 24 May 2005

L11 ANSWER 35 OF 182 MEDLINE on STN

Full Text

AN 2005115366 MEDLINE
DN PubMed ID: 15746052
TI Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
AU Love Richard R; Hutson Paul R; Havighurst Thomas C; Cleary James F
CS Department of Medicine, University of Wisconsin, 610 Walnut Street, 256 Warf Office Building, Madison, WI 53726, USA.. rrlove@facstaff.wisc.edu
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2005 Feb 15) Vol. 11, No. 4, pp. 1500-3.
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200507
ED Entered STN: 5 Mar 2005
Last Updated on STN: 29 Jul 2005
Entered Medline: 28 Jul 2005

L11 ANSWER 36 OF 182 MEDLINE on STN

Full Text

AN 2005072224 MEDLINE
DN PubMed ID: 15701885
TI TAS-108: a novel steroidal antiestrogen.
AU Buzdar Aman U
CS University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.. abuzdar@mdanderson.org
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2005 Jan 15) Vol. 11, No. 2 Pt 2, pp. 906s-8s. Ref: 17
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200505
ED Entered STN: 10 Feb 2005
Last Updated on STN: 10 May 2005
Entered Medline: 6 May 2005

L11 ANSWER 37 OF 182 MEDLINE on STN

Full Text

AN 2005036327 MEDLINE
 DN PubMed ID: 15663589
 TI The effect of tibolone in postmenopausal women receiving **tamoxifen** after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
 AU Kroiss R; Fentiman I S; Helmond F A; Rymer J; Foidart J M; Bundred N; Mol-Arts M; Kubista E
 CS Medical University of Vienna, Ludwig Boltzmann Institute for Clinical Experimental Oncology, Austria.
 SO BJOG : an international journal of obstetrics and gynaecology, (2005 Feb) Vol. 112, No. 2, pp. 228-33.
 Journal code: 100935741. ISSN: 1470-0328.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200502
 ED Entered STN: 25 Jan 2005
 Last Updated on STN: 18 Feb 2005
 Entered Medline: 17 Feb 2005

L11 ANSWER 38 OF 182 MEDLINE on STN

Full Text

AN 2005006638 MEDLINE
 DN PubMed ID: 15632378
 TI CYP2D6 genotype, antidepressant use, and **tamoxifen** metabolism during adjuvant breast cancer treatment.
 AU Jin Yan; Desta Zeruesenay; Stearns Vered; Ward Bryan; Ho Herbert; Lee Kyung-Hoon; Skaar Todd; Storniolo Anna Maria; Li Lang; Araba Adjei; Blanchard Rebecca; Nguyen Anne; Ullmer Lynda; Hayden Jill; Lemler Suzanne; Weinshilboum Richard M; Rae James M; Hayes Daniel F; Flockhart David A
 CS Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
 NC 5T32-GM-08425 (NIGMS)
 R-01 GM56898 (NIGMS)
 U-01 GM61373 (NIGMS)
 SO Journal of the National Cancer Institute, (2005 Jan 5) Vol. 97, No. 1, pp. 30-9.
 Journal code: 7503089. E-ISSN: 1460-2105.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 200501
 ED Entered STN: 6 Jan 2005
 Last Updated on STN: 22 Jan 2005
 Entered Medline: 21 Jan 2005

L11 ANSWER 39 OF 182 MEDLINE on STN

Full Text

AN 2004615625 MEDLINE
 DN PubMed ID: 15592280
 TI Predictors of hot flushes in postmenopausal women who receive **raloxifene** therapy.
 AU Aldrichi Jose M; Quail Deborah C; Levy-Frebault Jacques; Aguas Fernanda; Kosian Kurt; Garrido Lurdes; Bosio-Le Goux Brigitte; Sarachaga Max; Graebe Alice; Nino Antonio J; Nickelsen Thomas
 CS Faculdade De Saude Publica Da Universidade De Sao Paulo, Brazil.
 SO American journal of obstetrics and gynecology, (2004 Dec) Vol. 191, No. 6, pp. 1979-83.
 Journal code: 0370476. ISSN: 0002-9378.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200501
ED Entered STN: 20 Dec 2004
Last Updated on STN: 28 Jan 2005
Entered Medline: 27 Jan 2005

L11 ANSWER 40 OF 182 MEDLINE on STN

Full Text

AN 2004603075 MEDLINE
DN PubMed ID: 15577140
TI Which is the better choice, estrogen or SERMs in postmenopausal women?.
AU Shintani Masafumi
CS Department of Obstetrics and Gynecology, Nara Prefectural Mimuro Hospital.
SO Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 105-10. Ref: 17
Journal code: 9433326. ISSN: 0917-5857.
CY Japan
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Japanese
FS Priority Journals
EM 200502
ED Entered STN: 4 Dec 2004
Last Updated on STN: 1 Mar 2005
Entered Medline: 25 Feb 2005

L11 ANSWER 41 OF 182 MEDLINE on STN

Full Text

AN 2004603074 MEDLINE
DN PubMed ID: 15577139
TI Safety profile of raloxifene.
AU Morii Hirotoshi
CS Osaka City University.
SO Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 100-4. Ref: 22
Journal code: 9433326. ISSN: 0917-5857.
CY Japan
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Japanese
FS Priority Journals
EM 200502
ED Entered STN: 4 Dec 2004
Last Updated on STN: 1 Mar 2005
Entered Medline: 25 Feb 2005

L11 ANSWER 42 OF 182 MEDLINE on STN

Full Text

AN 2004597013 MEDLINE
DN PubMed ID: 15501350
TI [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore].
Menopause en 2004: le "traitement hormonal substitutif" n'est plus ce qu'il etait.
AU Azoulay C
CS Service de gynécologie, hopital intercommunal, 40, avenue de Verdun, 94010 Creteil cedex, France. catherine.azoulay@chicreteil.fr.
<catherine.azoulay@chicreteil.fr>
SO La Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne, (2004 Nov) Vol. 25, No. 11, pp. 806-15.
Ref: 62
Journal code: 8101383. ISSN: 0248-8663.
CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 200502
ED Entered STN: 2 Dec 2004

Last Updated on STN: 16 Feb 2005
Entered Medline: 15 Feb 2005

L11 ANSWER 43 OF 182 MEDLINE on STN

Full Text

AN 2004592433 MEDLINE
DN PubMed ID: 15565808
TI Pilot evaluation of black cohosh for the treatment of **hot flashes** in women.
AU Pockaj Barbara A; Loprinzi Charles L; Sloan Jeff A; Novotny Paul J; Barton Debra L; Hagenmaier Andrea; Zhang Huayan; Lambert George H; Reeser Kristine A; Wisbey Joyce A
CS Department of Surgery, Mayo Clinic, Scottsdale, Arizona 85259, USA..
pockaj.barbara@mayo.edu
SO Cancer investigation, (2004) Vol. 22, No. 4, pp. 515-21.
Journal code: 8307154. ISSN: 0735-7907.
CY United States
DT (CLINICAL TRIAL)
LA English
FS Priority Journals
EM 200412
ED Entered STN: 30 Nov 2004
Last Updated on STN: 20 Dec 2004
Entered Medline: 7 Dec 2004

L11 ANSWER 44 OF 182 MEDLINE on STN

Full Text

AN 2004526546 MEDLINE
DN PubMed ID: 15494636
TI Acute effects of **tamoxifen** and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
AU Morales Leilani; Neven Patrick; Timmerman Dirk; Christiaens Marie-Rose; Vergote Ignace; Van Limbergen Erik; Carbonez An; Van Huffel Sabine; Ameys Lieveke; Paridaens Robert
CS Department of Medical Oncology, University Hospitals, Leuven, Belgium.
SO Anti-cancer drugs, (2004 Sep) Vol. 15, No. 8, pp. 753-60.
Journal code: 9100823. ISSN: 0959-4973.
CY England: United Kingdom
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200412
ED Entered STN: 23 Oct 2004
Last Updated on STN: 20 Dec 2004
Entered Medline: 16 Dec 2004

L11 ANSWER 45 OF 182 MEDLINE on STN

Full Text

AN 2004511174 MEDLINE
DN PubMed ID: 15356404
TI Association of breast cancer and its therapy with menopause-related symptoms.
AU Crandall Carolyn; Petersen Laura; Ganz Patricia A; Greendale Gail A
CS Division of General Internal Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 90095-7023, USA..
cgrandall@mednet.ucla.edu
NC P30 CA16042 (NCI)
SO Menopause (New York, N.Y.), (2004 Sep-Oct) Vol. 11, No. 5, pp. 519-30.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200501
ED Entered STN: 15 Oct 2004

Last Updated on STN: 19 Jan 2005
Entered Medline: 18 Jan 2005

L11 ANSWER 46 OF 182 MEDLINE on STN

Full Text

AN 2004422164 MEDLINE
DN PubMed ID: 15328180
TI A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
AU Blakely L Johnetta; Buzdar Aman; Chang Hsiu-Yin; Frye Debra; Theriault Richard; Valero Vicente; Rivera Edgardo; Booser Daniel; Kuritani Jun; Tsuda Masuhiro
CS Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Aug 15) Vol. 10, No. 16, pp. 5425-31.
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200502
ED Entered STN: 26 Aug 2004
Last Updated on STN: 18 Feb 2005
Entered Medline: 17 Feb 2005

L11 ANSWER 47 OF 182 MEDLINE on STN

Full Text

AN 2004417646 MEDLINE
DN PubMed ID: 15243274
TI Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors.
AU Carpenter Janet S; Gilchrist Janet M; Chen Kong; Gautam Shiva; Freedman Robert R
CS Indiana University School of Nursing, 1111 Middle Drive NU 340D, Indianapolis, IN 46202-5107, USA.. carpentj@iupui.edu
NC RR 00095 (NCRR)
SO Menopause (New York, N.Y.), (2004 Jul-Aug) Vol. 11, No. 4, pp. 375-81.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200409
ED Entered STN: 25 Aug 2004
Last Updated on STN: 29 Sep 2004
Entered Medline: 28 Sep 2004

L11 ANSWER 48 OF 182 MEDLINE on STN

Full Text

AN 2004390352 MEDLINE
DN PubMed ID: 15295352
TI Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
AU Palacios Santiago; Farias Maria Lucia F; Luebbert Horst; Gomez Gustavo; Yabur Juan A; Quail Deborah C; Turbi Carmen; Kayath Marcia J; Almeida Maria J; Konnig Elisabeth; Nickelsen Thomas
CS Instituto Palacios, Madrid, Spain.
SO American journal of obstetrics and gynecology, (2004 Jul) Vol. 191, No. 1, pp. 121-37.
Journal code: 0370476. ISSN: 0002-9378.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200409
 ED Entered STN: 6 Aug 2004
 Last Updated on STN: 15 Sep 2004
 Entered Medline: 14 Sep 2004

L11 ANSWER 49 OF 182 MEDLINE on STN
Full Text
 AN 2004390192 MEDLINE
 DN PubMed ID: 15293890
 TI Veralipride administered in combination with **raloxifene** decreases hot flushes and improves bone density in early postmenopausal women.
 AU Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
 CS Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy.
 SO Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, (2004 Apr) Vol. 18, No. 4, pp. 194-8.
 Journal code: 8807913. ISSN: 0951-3590.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200408
 ED Entered STN: 6 Aug 2004
 Last Updated on STN: 20 Aug 2004
 Entered Medline: 19 Aug 2004

L11 ANSWER 50 OF 182 MEDLINE on STN
Full Text
 AN 2004171210 MEDLINE
 DN PubMed ID: 15021446
 TI Transition from estrogen therapy to **raloxifene** in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
 AU Davis Susan R; O'Neill Sheila M; Eden John; Baber Rodney; Ekangaki Abie; Stocks Jodie M; Thiebaud Daniel
 CS Jean Hailes Foundation, Melbourne, Australia..
susan.davis@jeanhailes.org.au
 SO Menopause (New York, N.Y.), (2004 Mar-Apr) Vol. 11, No. 2, pp. 167-75.
 Journal code: 9433353. ISSN: 1072-3714.
 CY United States
 DT (CLINICAL TRIAL)
 (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 7 Apr 2004
 Last Updated on STN: 10 May 2004
 Entered Medline: 7 May 2004

L11 ANSWER 51 OF 182 MEDLINE on STN
Full Text
 AN 2004157070 MEDLINE
 DN PubMed ID: 15050912
 TI Selective estrogen receptor modulation: concept and consequences in cancer.
 AU Jordan V Craig
 CS Northwestern University, Chicago, IL, USA.. vcjordan@northwestern.edu
 NC P50 CA089118-04S1 (NCI)
 SO Cancer cell, (2004 Mar) Vol. 5, No. 3, pp. 207-13. Ref: 56
 Journal code: 101130617. ISSN: 1535-6108.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)

(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 General Review; (REVIEW)

LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 31 Mar 2004
 Last Updated on STN: 18 May 2004
 Entered Medline: 17 May 2004

L11 ANSWER 52 OF 182 MEDLINE on STN
Full Text
 AN 200414600 MEDLINE
 DN PubMed ID: 15039600
 TI Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
 AU Gallicchio Lisa; Lord Gwyn; Tkaczuk Katherine; Danton Malcolm; Lewis Lynn M; Lim Chang K; Flaws Jodi A
 CS Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
 SO Breast cancer research and treatment, (2004 May) Vol. 85, No. 1, pp. 89-97.
 Journal code: 8111104. ISSN: 0167-6806.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
 LA English
 FS Priority Journals
 EM 200406
 ED Entered STN: 25 Mar 2004
 Last Updated on STN: 2 Jun 2004
 Entered Medline: 1 Jun 2004

L11 ANSWER 53 OF 182 MEDLINE on STN
Full Text
 AN 200413249 MEDLINE
 DN PubMed ID: 15025087
 TI Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.
 AU Rollins Gena
 SO Report on medical guidelines & outcomes research, (2004 Mar 5) Vol. 15, No. 5, pp. 7-9.
 Journal code: 9106372. ISSN: 1050-5636.
 CY United States
 DT (COMPARATIVE STUDY)
 News Announcement
 LA English
 FS Health Technology
 EM 200404
 ED Entered STN: 18 Mar 2004
 Last Updated on STN: 10 Apr 2004
 Entered Medline: 9 Apr 2004

L11 ANSWER 54 OF 182 MEDLINE on STN
Full Text
 AN 200410534 MEDLINE
 DN PubMed ID: 14997058
 TI Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.
 AU Pandya Kishan J; Thummala Anuradha R; Griggs Jennifer J; Rosenblatt Joseph D; Sahasrabudhe Deepak M; Guttuso Thomas J; Morrow Gary R; Roscoe Joseph A
 CS James P. Allmott Cancer Center, University of Rochester, Rochester, NY 14642 USA. kishan_pandya@urmc.rochester.edu
 SO Breast cancer research and treatment, (2004 Jan) Vol. 83, No. 1, pp. 87-9.
 Journal code: 8111104. ISSN: 0167-6806.
 CY Netherlands
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 4 Mar 2004

Last Updated on STN: 14 May 2004
Entered Medline: 13 May 2004

L11 ANSWER 55 OF 182 MEDLINE on STN

Full Text

AN 2004076418 MEDLINE
DN PubMed ID: 14965585
TI Exemestane: a review of its clinical efficacy and safety.
AU Lonning P E
CS Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen, Norway.. plon@haukeland.no
SO Breast (Edinburgh, Scotland), (2001 Jun) Vol. 10, No. 3, pp. 198-208.
Journal code: 9213011. ISSN: 0960-9776.
CY Scotland; United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; PUBMED-NOT-MEDLINE
EM 200402
ED Entered STN: 18 Feb 2004
Last Updated on STN: 2 Mar 2004
Entered Medline: 26 Feb 2004

L11 ANSWER 56 OF 182 MEDLINE on STN

Full Text

AN 2004054126 MEDLINE
DN PubMed ID: 14754694
TI Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
AU Gordon Stephen; Walsh Brian W; Ciaccia Angelina V; Siddhanti Suresh; Rosen Amy S; Plouffe Leo Jr
CS Women's Health and Internal Medicine, Comprehensive NeuroScience, Inc, 6065 Roswell, Suite 820, Atlanta, GA 30328, USA.. flashmd4919@msn.com
SO Obstetrics and gynecology, (2004 Feb) Vol. 103, No. 2, pp. 267-73.
Journal code: 0401101. ISSN: 0029-7844.
CY United States
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200403
ED Entered STN: 3 Feb 2004
Last Updated on STN: 9 Mar 2004
Entered Medline: 8 Mar 2004

L11 ANSWER 57 OF 182 MEDLINE on STN

Full Text

AN 2004040541 MEDLINE
DN PubMed ID: 14740790
TI Nonhormonal alternatives for the treatment of hot flashes.
AU Sicat Brigitte L; Brokaw Deborah K
CS Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
SO Pharmacotherapy, (2004 Jan) Vol. 24, No. 1, pp. 79-93. Ref: 55
Journal code: 8111305. ISSN: 0277-0008.
CY United States
DT (EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200406
ED Entered STN: 27 Jan 2004
Last Updated on STN: 18 Jun 2004
Entered Medline: 17 Jun 2004

L11 ANSWER 58 OF 182 MEDLINE on STN

Full Text

AN 20035385 MEDLINE
DN PubMed ID: 14669536

TI [The effects of tamoxifen on the female genital tract].
Tamoxifen en gynaecologische bijwerkingen.

AU Mourits M J; van der Zee A G; Willemse P H; Hollema H; de Vries E G

CS Afd. Gynaecologische Oncologie, Academisch Ziekenhuis Groningen,
Hanzeplein 1, 9711 EZ Groningen.. m.j.e.mourits@azg.nl

SO Nederlands tijdschrift voor geneeskunde, (2003 Nov 22) Vol. 147, No. 47,
pp. 2315-20. Ref: 31
Journal code: 0400770. ISSN: 0028-2162.

CY Netherlands

DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA Dutch

FS Priority Journals

EM 200401

ED Entered STM: 16 Dec 2003
Last Updated on STM: 9 Jan 2004
Entered Medline: 8 Jan 2004.

L11 ANSWER 59 OF 182 MEDLINE on STM

Full Text

AN 2 03569138 MEDLINE

DN PubMed ID: 14652237

TI Active tamoxifen metabolite plasma concentrations after coadministration
of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

AU Stearns Vred; Johnson Michael D; Rae James M; Morocho Alan; Novielli
Antonella; Bhargava Pankaj; Hayes Daniel F; Desta Zeruesenay; Flockhart
David A

CS The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center,
Georgetown University Medical Center, Washington, DC, USA.

NC 5732-GM-0425 (NIGMS)
R-01 GM56298 (NIGMS)
U-01 GM61273 (NIGMS)

SO Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
pp. 1758-64.
Journal code: 7503089. E-ISSN: 1460-2105.

CY United States

DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LA English

FS Priority Journals

EM 200401

ED Entered STM: 16 Dec 2003
Last Updated on STM: 6 Jan 2004
Entered Medline: 5 Jan 2004

L11 ANSWER 60 OF 182 MEDLINE on STM

Full Text

AN 2 03569138 MEDLINE

DN PubMed ID: 14652227

TI A hot flash on tamoxifen metabolism.

AU Gietz Matthew P; Loprinzi Charles L

SO Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
pp. 1734-5. Ref: 23
Journal code: 7503089. E-ISSN: 1460-2105.

CY United States

DT Commentary
Editorial
General Review; (REVIEW)

LA English

FS Priority Journals

EM 2 0401

ED Entered STM: 16 Dec 2003
Last Updated on STM: 6 Jan 2004
Entered Medline: 5 Jan 2004

L11 ANSWER 61 OF 182 MEDLINE on STM

Full Text

AN 2001 2523 MEDLINE

DN PubMed ID: 14551341

TI A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

AU Goss Paul E; Ingle James N; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Tu Dongsheng; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Therasse Patrick; Palmer Michael J; Pater Joseph L

CS Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada. p.goss@interlog.com

NC CA211115 (NCI)
CA25224 (NCI)
CA31946 (NCI)
CA32102 (NCI)
CA38926 (NCI)

SO The New England journal of medicine, (2003 Nov 6) Vol. 349, No. 19, pp. 1793-802. Electronic Publication: 2003-10-09.
Journal code: 0255562. E-ISSN: 1533-4406.

CY United States

DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE III)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200311

ED Entered STM: 7 Nov 2003
Last Updated on STN: 11 Nov 2003
Entered Medline: 10 Nov 2003

L11 ANSWER 62 OF 182 MEDLINE on STN

Full Text

AN 2003507720 MEDLINE

DN PubMed ID: 14584060

TI Anastrozole alone or in combination with **tamoxifen** versus **tamoxifen** alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, **Tamoxifen** Alone or in Combination) trial efficacy and safety update analyses.

AU Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T

CS University College London, London, United Kingdom. (The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group).

SO Cancer, (2003 Nov 1) Vol. 98, No. 9, pp. 1802-10.
Journal code: 0374236. ISSN: 0008-543X.

CY United States

DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200311

ED Entered STM: 31 Oct 2003
Last Updated on STN: 5 Nov 2003
Entered Medline: 5 Nov 2003

L11 ANSWER 63 OF 182 MEDLINE on STN

Full Text

AN 2003 764 MEDLINE

DN PubMed ID: 14555500

TI Fulvestrant in postmenopausal women with advanced breast cancer.

AU Bross Peter F; Baird Amy; Chen Gang; Jee Josephine M; Lostritto Richard T; Morse David E; Rosario Liliam A; Williams Gene M; Yang Peiling; Rahman Atiqur; Williams Grant; Pazdur Richard

CS Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852, USA.

SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2003 Oct 1) Vol. 9, No. 12, pp. 4309-17. Ref: 22
Journal code: 9502500. ISSN: 1078-0432.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA English

FS Priority Journals
EM 200403
ED Entered STN: 14 Oct 2003
Last Updated on STN: 21 May 2004
Entered Medline: 20 May 2004

L11 ANSWER 6 OF 182 MEDLINE on STN

Full Text

AN 2003441433 MEDLINE
DN PubMed ID: 14501605
TI Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.
AU Rutanen Eeva-Marja; Heikkinen Jorma; Halonen Kaija; Komi Janne; Lamintausta Risto; Ylikorkala Olavi
CS Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.. eeva-maria.rutanen@hus.fi
SO Menopause (New York, N.Y.), (2003 Sep-Oct) Vol. 10, No. 5, pp. 433-9. Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 23 Sep 2003
Last Updated on STN: 13 Dec 2003
Entered Medline: 8 Dec 2003

L11 ANSWER 6 OF 182 MEDLINE on STN

Full Text

AN 2003428812 MEDLINE
DN PubMed ID: 12968972
TI Hot flashes in breast cancer survivors.
AU Hoda Daanish; Perez Domingo G; Loprinzi Charles L
CS Mayo Clinic, Rochester, Minnesota 55905, USA.
SO The breast journal, (2003 Sep-Oct) Vol. 9, No. 5, pp. 431-8. Ref: 93
Journal code: 9505539. ISSN: 1075-122X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200401
ED Entered STN: 13 Sep 2003
Last Updated on STN: 17 Jan 2004
Entered Medline: 16 Jan 2004

L11 ANSWER 66 OF 182 MEDLINE on STN

Full Text

AN 2003331095 MEDLINE
DN PubMed ID: 12916292
TI Selective estrogen-receptor modulators.
AU Cosman Felicia
CS Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA..
ccosman@hennhaveshosp.org
SO Clinics in geriatric medicine, (2003 May) Vol. 19, No. 2, pp. 371-9. Ref: 58
Journal code: 8603766. ISSN: 0749-0690.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200310
ED Entered STN: 15 Aug 2003
Last Updated on STN: 3 Oct 2003
Entered Medline: 2 Oct 2003

L11 ANSWER 67 OF 182 MEDLINE on STN

Full Text

AN 2003373455 MEDLINE
DN PubMed ID: 12851517
TI Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
AU Jolly Elaine E; Bjarnason Nina H; Neven Patrick; Plouffe Leo Jr; Johnston C Conrad Jr; Watts Steven D; Arnaud Claude D; Mason Timothy M; Crans Gerald; Peters Robin; Draper Michael W
CS Department of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa, Canada.
SO Menopause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 337-44.
Journal code: 9433353. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200310
ED Entered STN: 12 Aug 2003
Last Updated on STN: 8 Oct 2003
Entered Medline: 7 Oct 2003

L11 ANSWER 68 OF 182 MEDLINE on STN

Full Text

AN 2003367824 MEDLINE
DN PubMed ID: 12902876
TI Examining quality of life issues in relation to endocrine therapy for breast cancer.
AU Thomas Robert
CS Addenbrooke's Hospital, Cambridge, United Kingdom.
SO American journal of clinical oncology, (2003 Aug) Vol. 26, No. 4, pp. S40-4.
Journal code: 8207754. E-ISSN: 1537-453X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200308
ED Entered STN: 7 Aug 2003
Last Updated on STN: 29 Jan 2004
Entered Medline: 28 Jan 2004

L11 ANSWER 6 OF 182 MEDLINE on STN

Full Text

AN 2003352238 MEDLINE
DN PubMed ID: 12384894
TI The homeopathic approach to the treatment of symptoms of oestrogen withdrawal in breast cancer patients. A prospective observational study.
AU Thompson E A; Reilly D
CS Glasgow Homeopathic Hospital, 1053 Great Western Road, Glasgow, Scotland, G12 0XQ, UK.. elizabeth.thompson@ubht.swest.nhs.uk
SO Homeopathy : the journal of the Faculty of Homeopathy, (2003 Jul) Vol. 92, No. 3, pp. 131-4.
Journal code: 101140517. ISSN: 1475-4916.
CY Scotland; United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 30 Jul 2003
Last Updated on STN: 20 Dec 2003
Entered Medline: 19 Dec 2003

L11 ANSWER 7 OF 182 MEDLINE on STN

Full Text

AN 200335653 MEDLINE
DN PubMed ID: 12351710
TI Estrogen replacement therapy in breast cancer survivors: a matched controlled series.
AU Duggan David A; Pettinga Jane E; VanderVelde Nancy; Huang Raywin R; Kestin

Larry; Burdakin John H
 CS Department of Medicine, William Beaumont Hospital, Royal Oak-Troy, MI
 48072, USA.. jdecker@beaumont.edu
 SO Menopause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 277-85.
 Journal code: 9433353. ISSN: 1072-3714.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200310
 ED Entered STN: 10 Jul 2003
 Last Updated on STN: 8 Oct 2003
 Entered Medline: 7 Oct 2003

L11 ANSWER 73 OF 182 MEDLINE on STN

Full Text

AN 200314440 MEDLINE
 DN PubMed ID: 12843154
 TI Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal
 Asian women.
 AU Kong Anne W C; Chao Hsiang-Tai; Huang Ko-En; Need Allan G;
 Teedhakarnichana Nimit; Loh Foo-Hoe; Gonzaga Florante; Sriram Usha; Ismail
 Nik Mohd Nasri; Farooqi Abid; Rachman Ichramsjah Azim; Crans Gerald G;
 Wong Mayme; Thiebaud Daniel
 CS Department of Medicine, The University of Hong Kong, Division of
 Endocrinology, Queen Mary Hospital, Hong Kong, People's Republic of China.
 SO The Journal of clinical endocrinology and metabolism, (2003 Jul) Vol. 88,
 No. 7, pp. 3130-6.
 Journal code: 0375362. ISSN: 0021-972X.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200308
 ED Entered STN: 8 Jul 2003
 Last Updated on STN: 9 Aug 2003
 Entered Medline: 8 Aug 2003

L11 ANSWER 74 OF 182 MEDLINE on STN

Full Text

AN 200310742 MEDLINE
 DN PubMed ID: 12839141
 TI Counseling patients who elect to discontinue hormone therapy.
 AU Simon James A; Mack Carol J
 CS Department of Obstetrics and Gynecology, George Washington University,
 School of Medicine, Washington, D.C., USA.
 SO International journal of fertility and women's medicine, (2003 May-Jun)
 Vol. 22, No. 3, pp. 111-6; discussion 137-8. Ref: 13
 Journal code: 9796779. ISSN: 1534-892X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200310
 ED Entered STN: 4 Jul 2003
 Last Updated on STN: 11 Oct 2003
 Entered Medline: 10 Oct 2003

L11 ANSWER 75 OF 182 MEDLINE on STN

Full Text

AN 2003021612 MEDLINE
 DN PubMed ID: 12753941
 TI Menopause after breast cancer: a survey on breast cancer survivors.
 AU Figliola Nicoletta; Comzarella Marilena; Cacciari Franca; Ponzzone Riccardo;
 Pagani Riccardo; Maggiorotto Furio; Sismondi Piero
 CS Anatomia Department of Gynecological Oncology, University of Turin,
 Maria Vittoria Hospital and Institute for Cancer Research

and Treatment of Candiolo, Turin, Italy.. nbiglia@mauriziano.it
SO Maturitas, (2003 May 30) Vol. 45, No. 1, pp. 29-38.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200309
ED Entered STN: 20 May 2003
Last Updated on STN: 30 Sep 2003
Entered Medline: 29 Sep 2003

L11 ANSWER 74 OF 182 MEDLINE on STN
Full Text
AN 2003175723 MEDLINE
DN PubMed ID: 12693307
TI [Hormone replacement therapy after breast cancer. Yes...or no?].
Traitement hormonal apres cancer du sein. Oui ... ou non?.
AU Feidart M N; Desreux J; Lifrange E; Colin C
CS Departement de Gynecologie-Obstetrique-Senologie, CHU de Liege.
SO Revue medicale de Liege, (2003 Feb) Vol. 58, No. 2, pp. 77-82. Ref: 61
Journal code: 0424317. ISSN: 0370-629X.
CY Belgium
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 200305
ED Entered STN: 17 Apr 2003
Last Updated on STN: 22 May 2003
Entered Medline: 21 May 2003

L11 ANSWER 75 OF 182 MEDLINE on STN
Full Text
AN 2003134335 MEDLINE
DN PubMed ID: 12648026
TI Pharmacokinetics of selective estrogen receptor modulators.
AU Morello Karla C; Wurz Gregory T; DeGregorio Michael W
CS Department of Internal Medicine, University of California, Davis,
Sacramento, California 95817, USA.
SO Clinical pharmacokinetics, (2003) Vol. 42, No. 4, pp. 361-72. Ref: 73
Journal code: 7606849. ISSN: 0312-5963.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 22 Mar 2003
Last Updated on STN: 12 Jun 2003
Entered Medline: 11 Jun 2003

L11 ANSWER 76 OF 182 MEDLINE on STN
Full Text
AN 2003197715 MEDLINE
DN PubMed ID: 12609560
TI Cimicifuga racemosa for the treatment of hot flushes in women surviving
breast cancer.
AU Hernandez Munoz Gerardo; Pluchino Salvatore
CS Centro Clinico de Maternidad Leopoldo Aguerrevere, Av. Rio Manapire,
Parque Humboldt, Prados del Este, Caracas, Venezuela.. drgeher@cantv.net
SO Maturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S59-65.
Journal code: 7807333. ISSN: 0378-5122.
CY Ireland
DT (RANDOMIZED TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200307
ED Entered STN: 2 Mar 2003

Last Updated on STN: 18 Jul 2003
Entered Medline: 17 Jul 2003

L11 ANSWER 72 OF 182 MEDLINE on STN

Full Text

AN 20033732 MEDLINE

DN PubMed ID: 12198849

TI [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomized women].

Effetti del tamoxifene e della terapia estrogenica sostitutiva sul metabolismo lipidico e su altri fattori di rischio cardiovascolare. Studio prospettico in donne isterectomizzate.

AU Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
CS Dipartimento di Scienze Ginecologiche, Perinatologia e Puericultura, II Facolta di Medicina e Chirurgia, Universita degli Studi di Roma La Sapienza, Roma, Italy.. fabioimp.ginecol@tin.it

SO Minerva ginecologica, (2003 Feb) Vol. 55, No. 1, pp. 87-93.

Journal Code: 0400731. ISSN: 0026-4784.

CY Italy

DT (COMPARATIVE STUDY)

(ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

LA Italian

FS Priority Journals

EM 200303

ED Entered STN: 25 Feb 2003

Last Updated on STN: 30 Aug 2003

Entered Medline: 29 Aug 2003

L11 ANSWER 73 OF 182 MEDLINE on STN

Full Text

AN 20033207 MEDLINE

DN PubMed ID: 12694939

TI The role of aromatase inhibitors in early breast cancer.

AU Chung Cathie T; Carlson Robert W

CS Division of Oncology, Stanford University, 300 Pasteur Drive, H0274, Stanford, CA 94305, USA.. cchung@stanford.edu

SO Current treatment options in oncology, (2003 Apr) Vol. 4, No. 2, pp.

123-30. Ref: 30

Journal Code: 100900046. ISSN: 1527-2729.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, NON-U.S. GOV'T)

(General Review; (REVIEW)

LA English

FS Priority Journals

EM 200307

ED Entered STN: 22 Feb 2003

Last Updated on STN: 8 Jul 2003

Entered Medline: 7 Jul 2003

L11 ANSWER 74 OF 182 MEDLINE on STN

Full Text

AN 20034018 MEDLINE

DN PubMed ID: 12657811

TI Plant estrogens: an alternative therapy for menopause?.

AU Fabian Gail L; Fabriziant Daniel; Chadwick Lucas R; Dietz Birgit

CS University Center for Botanical Dietary Supplements Research, Program for Complementary Research in the Pharmaceutical Sciences, University of Illinois, Chicago, Illinois, USA.

NC PubMed ID: 12657811 (NCCAM)

SO Journal of clinical care : an official publication of Tufts University,

Volume 1, No. 6, pp. 283-9. Ref: 45

Journal Code: 0809671. ISSN: 1096-6781.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

(General Review; (REVIEW)

LA English

FS Priority Journals

EM 200307

ED Entered STN: 8 Feb 2003
Last Updated on STN: 23 Apr 2003
Entered Medline: 22 Apr 2003

L11 ANSWER 80 OF 182 MEDLINE on STN

Full Text

AN 200207016 MEDLINE
DN PubMed ID: 1244676
TI Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
AU Pinkerton J Ann V; Schiffen Jan L; La Valleur June; Rosen Amy; Roesinger Mary; Sirdhara Suresh
CS University of Virginia Health System, Charlottesville, VA, USA.
SO Menopause (New York, N.Y.), (2003 Jan-Feb) Vol. 10, No. 1, pp. 45-52.
Journal code: 9433384. ISSN: 1072-3714.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200304
ED Entered STN: 25 Jan 2003
Last Updated on STN: 29 Apr 2003
Entered Medline: 28 Apr 2003

L11 ANSWER 81 OF 182 MEDLINE on STN

Full Text

AN 200209709 MEDLINE
DN PubMed ID: 12456626
TI Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
AU Palomba Stefano; Russo Tiziana; Orio Francesco Jr; Tauchmanova Libuse; Zupi Errico; Panici Pier Luigi Benedetti; Nappi Carmine; Colao Annamaria; Lombardi Gaetano; Zullo Fulvio
CS Department of Obstetrics Gynecology, University 'Magna Graecia' of Catanzaro, Catanzaro. stefanopalomba@tin.it
SO Human reproduction (Oxford, England), (2002 Dec) Vol. 17, No. 12, pp. 3211-6.
Journal code: 8701100. ISSN: 0268-1161.
CY England; United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 31 Dec 2002
Last Updated on STN: 5 Jun 2003
Entered Medline: 4 Jan 2003

L11 ANSWER 82 OF 182 MEDLINE on STN

Full Text

AN 200208697 MEDLINE
DN PubMed ID: 12490735
TI FDA drug approval summaries: fulvestrant.
AU Berman Peter H; Cohen Martin H; Williams Grant A; Pazdur Richard
CS Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, USA. brossp@cder.fda.gov
SO Therapeutics, (2002) Vol. 7, No. 6, pp. 477-80.
Journal code: 5600000. ISSN: 1083-7159.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 3 Dec 2002

Last Updated on STN: 7 Feb 2003
Entered Medline: 6 Feb 2003

L11 ANSWER 83 OF 182 MEDLINE on STN

Full Text

AN 2002-83049 MEDLINE
DN PubMed ID: 12143837
TI Effects of buserifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
AU Voioja S K; Komi J; Kangas L; Halonen K; DeGregorio M W; Erkkola R U
CS Department of Obstetrics and Gynecology, Turku University Central Hospital, FIN-20520, Turku, Finland.
SO Maternal, (2002 Nov 20) Vol. 43, No. 3, pp. 207-14.
JOURNAL CODE: 7807333. ISSN: 0378-5122.
CY Ireland
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 2002
ED Entered STN: 12 Nov 2002
Last Updated on STN: 31 Mar 2003
Entered Medline: 28 Mar 2003

L11 ANSWER 84 OF 182 MEDLINE on STN

Full Text

AN 2002-84715 MEDLINE
DN PubMed ID: 12394205
TI Tamoxifen as an ergogenic agent in women body builders.
AU Seebassen Dean A; Gloriosio John E
CS Department of Family Practice and Emergency Medical Services, Tripler Army Medical Center, Hawaii 96859, USA.
SO Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, (2002 Sep) Vol. 12, No. 5, pp. 313-4.
JOURNAL CODE: 9103300. ISSN: 1050-642X.
CY United States
DT (CASE REPORT)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 2002
ED Entered STN: 4 Oct 2002
Last Updated on STN: 13 Dec 2002
Entered Medline: 10 Nov 2002

L11 ANSWER 85 OF 182 MEDLINE on STN

Full Text

AN 2002-84941 MEDLINE
DN PubMed ID: 12187278
TI ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.
AU Anonymous
CS American College of Obstetricians and Gynecologists.
SO Obstetrics and gynecology, (2002 Oct) Vol. 100, No. 4, pp. 835-43.
JOURNAL CODE: 9401101. ISSN: 0029-7844.
CY United States
DT (GUIDELINE)
Journal; Article; (JOURNAL ARTICLE)
(PRACTICE GUIDELINE)
LA English
FS Abstracted Index Medicus Journals; Priority Journals
EM 2002
ED Entered STN: 12 Oct 2002
Last Updated on STN: 13 Dec 2002
Entered Medline: 7 Nov 2002

L11 ANSWER 86 OF 182 MEDLINE on STN

Full Text

AN 2002-84600 MEDLINE

DN PubMed ID: 12471452
 TI Homeopathic treatment of hot flushes: a pilot study.
 AU Clover A; Ramsey D
 CS Tunbridge Wells Homeopathic Hospital, UK.. anne_clover@lineone.net
 SO Homeopathy: the journal of the Faculty of Homeopathy, (2002 Apr) Vol. 91, No. 1, pp. 7-9.
 Journal code: 1014-617. ISSN: 1475-4916.
 CY Scotland: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 10 Oct 2002
 Last Updated on STN: 2 Feb 2003
 Entered Medline: 31 Jan 2003

L11 ANSWER 87 OF 182 MEDLINE on STN
Full Text

AN 2002 13712 MEDLINE
 DN PubMed ID: 1202487
 TI Meta-analysis of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.
 AU Cranney Linn; Mugwell Peter; Zytaruk Nicole; Robinson Vivian; Weaver Bruce; Adachi Jonathan; Wells George; Shea Beverley; Guyatt Gordon
 CS Osteoporosis Pathology Group and The Osteoporosis Research Advisory Group.
 SO Endocrine reviews. (2002 Aug) Vol. 23, No. 4, pp. 524-8. Ref: 19
 Journal code: 8000253. ISSN: 0163-769X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (META-ANALYSIS)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200302
 ED Entered STN: 11 Aug 2002
 Last Updated on STN: 3 Apr 2003
 Entered Medline: 7 Feb 2003

L11 ANSWER 88 OF 182 MEDLINE on STN
Full Text

AN 2002 40786 MEDLINE
 DN PubMed ID: 1197822
 TI Treatment for hot flushes in women receiving tamoxifen.
 AU Bydder Susan; Spry Nigel A
 CS Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA.. sallyvd@hcgmail.com
 SO The Medical Journal of Australia, (2002 Sep 2) Vol. 177, No. 5, pp. 266.
 Journal code: 0406749. ISSN: 0025-729X.
 CY Australia
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200209
 ED Entered STN: 15 Aug 2002
 Last Updated on STN: 17 Oct 2002
 Entered Medline: 17 Oct 2002

L11 ANSWER 89 OF 182 MEDLINE on STN
Full Text

AN 2002 17671 MEDLINE
 DN PubMed ID: 1223222
 TI Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.
 AU Bertoli G; Venturini M; Del Mastro L; Bergaglio M; Sismondi P; Biglia N; Venturini S; Percile G; Pronzato P; Costantini M; Rosso R
 CS Medical Oncology, Croce General Hospital, Cuneo, Italy..
gianelli.p@rtelli.tiscali.net

SO Annals of oncology: official journal of the European Society for Medical
Oncology / (1990, (2 Jun) Vol. 13, No. 6, pp. 883-8.
Journal code: 900775. ISSN: 0923-7534.
CY England: United Kingdom
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH REPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 9 Jul 2002
Last Updated on STN: 10 Jan 2003
Entered Medline: 9 Jan 2003

L11 ANSWER 90 OF 82 MEDLINE on STN

Full Text

AN 2002354979 MEDLINE
DN PubMed ID: 12098608
TI SERMs: current status and future trends.
AU Morcello Mario C; Wang Gregory T; DeGregorio Michael W
CS Department of Internal Medicine, Division of Hematology/Oncology, Cancer
Center, University of California, Davis, 4501 X Street Room 3016,
Sacramento, CA 95817, USA.
SO Critical reviews in oncology/hematology, (2002 Jul) Vol. 43, No. 1, pp.
63-71. Ref: 9
Journal code: 891400. ISSN: 1040-8428.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200307
ED Entered STN: 1 Jul 2002
Last Updated on STN: 11 Dec 2002
Entered Medline: 11 Jul 2003

L11 ANSWER 91 OF 82 MEDLINE on STN

Full Text

AN 2002450378 MEDLINE
DN PubMed ID: 12093253
TI Chemoprevention of breast cancer: a summary of the evidence for the U.S.
Preventive Services Task Force.
AU Kinsinger Linda S; Harris Russell; Woolf Steven H; Sox Harold C; Lohr
Kathleen N
CS Cecil G. Shoyk Center for Health Services Research, Program on Prevention,
CB# 7508, King D, Room 383, University of North Carolina School of
Medicine, Chapel Hill, NC 27599-7508, USA.
NC 290-77-0011
SO Annals of internal medicine, (2002 Jul 2) Vol. 137, No. 1, pp. 59-69.
Ref: 73
Journal code: 037100. E-ISSN: 1539-3704.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH REPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Abbreviated Index; Medline Journals; Priority Journals
EM 200207
ED Entered STN: 1 Jul 2002
Last Updated on STN: 18 Jul 2002
Entered Medline: 1 Jul 2002

L11 ANSWER 92 OF 82 MEDLINE on STN

Full Text

AN 2002403100 MEDLINE
DN PubMed ID: 12085200
TI Tamoxifen effects on subjective and psychosexual well-being, in a
randomised breast cancer study comparing high-dose and standard-dose
chemotherapy
AU Mouridsen T; Blohmermann I; de Vries E G; van der Zee A G; ten Hoor K A;

van der Graaf W T; Sluiter W J; Willemse P H
 CS Department of Gynaecology, University Hospital Groningen, Hanzeplein 1,
 9713 GZ Groningen, the Netherlands.. m.j.e.mourits@og.azg.nl
 SO British journal of cancer, (2002 May 20) Vol. 86, No. 10, pp. 1546-50.
 Journal code: 0377-0733. ISSN: 0007-0920.
 CY Scotland; United Kingdom
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200205
 ED Entered STM: 7 Jun 2002
 Last Updated on STM: 3 Aug 2002
 Entered Medline: 2 Aug 2002

L11 ANSWER 91 OF 82 MEDLINE on STN

Full Text

AN 200208058 MEDLINE
 DN PubMed ID: 1218058
 TI The oncology nurse's role in educating patients on endocrine therapy for
 metastatic breast cancer--focus on fulvestrant.
 AU Lynn Jean
 CS George Washington University Medical Center, Breast Care Center, 901 23rd
 St NE, Washington, DC 20037, USA.
 SO Cancer nursing, (2002 Apr) Vol. 25 Suppl 2, pp. 12S-17S.
 Journal code: 7805358. ISSN: 0162-220X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Nursing Journals
 EM 200208
 ED Entered STM: 6 Jun 2002
 Last Updated on STM: 7 Aug 2002
 Entered Medline: 6 Aug 2002

L11 ANSWER 94 OF 82 MEDLINE on STN

Full Text

AN 200209322 MEDLINE
 DN PubMed ID: 12198122
 TI Raloxifene is associated with less side effects than tamoxifen in
 women with early breast cancer: a questionnaire study from one physician's
 practice.
 AU Rohrig B; Blom Robbin; Lower Elyse E
 CS Department of Internal Medicine, Division of Hematology/Oncology,
 University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0562,
 USA.
 SO Journal of women's health & gender-based medicine, (2002 Apr) Vol. 11, No.
 3, pp. 291-301.
 Journal code: 106838719. ISSN: 1524-6094.
 CY United States
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200205
 ED Entered STM: 5 May 2002
 Last Updated on STM: 20 Jun 2002
 Entered Medline: 20 Jun 2002

L11 ANSWER 99 OF 82 MEDLINE on STN

Full Text

AN 200210073 MEDLINE
 DN PubMed ID: 1221563
 TI A 6-week trial of women trying to discontinue hormone replacement therapy.
 AU Grady D
 CS University of California, San Francisco, 74 New Montgomery St, Suite 600,
 San Francisco, CA 94105, USA.. dgrady@itsa.ucsf.edu
 SO Journal of the American Medical Association, (2002 Apr 24) Vol.
 287, No. 16, pp. 2067-71.
 Journal code: 00007256. ISSN: 0098-7484.
 CY United States
 DT (COMPARATIVE STUDY)

Journal; Article; JOURNAL ARTICLE)
(RESEARCH SUPPORT NON-U.S. GOV'T)
LA English
FS Abstracted In: Medicus Journals; Priority Journals
EM 200203
ED Entered ATN: 3 Apr 2002
Last Updated on STN: 14 Dec 2002
Entered Medline: 14 May 2002

L11 ANSWER 96 CP 82 MEDLINE on STN
Full Text
AN 2002 29574 MEDLINE
DN PubMed ID: 12115
TI [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated.
Hormonersatztherapie in der Peri- und Postmenopause. Ein routinemassiger Einsatz ist nicht indiziert.
AU Emons G; Wehchall G
CS Klinik für Gynäkologie und Geburtshilfe, Georg-August-Universität Göttingen. gonz@uni-goettingen.de
SO MMW Fortschritte der Medizin, (2002 Feb 28) Vol. 144, No. 9, pp. 30-3.
Journal code: 1002-959. ISSN: 1438-3276.
CY Germany; Germany, Federal Republic of
DT (COMPARATIVE TRIAL)
(ENGLISH ABSTRACT)
Journal; Article; JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 200204
ED Entered STN: 3 Apr 2002
Last Updated on STN: 30 Apr 2002
Entered Medline: 29 Apr 2002

L11 ANSWER 97 CP 82 MEDLINE on STN
Full Text
AN 2002 78476 MEDLINE
DN PubMed ID: 123605
TI Effect of phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial.
AU V. Patten M; I. Olivetto Ivo A; Chambers G Keith; Gelmon Karen A; Hislop T G; Goss L; Appleton Edith; Wattie Angela; Prior Jerilynn C
CS British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver Hospital and Health Sciences Centre, and University of British Columbia, Vancouver, British Columbia, Canada.. cvpatten@bcccancer.bc.ca
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2002 Mar 15) Vol. 20, No. 6, pp. 1449-55.
Journal code: 0732-183X. ISSN: 0732-183X.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 6 Mar 2002
Last Updated on STN: 18 Apr 2002
Entered Medline: 17 Apr 2002

L11 ANSWER 98 CP 82 MEDLINE on STN
Full Text
AN 2002 66603 MEDLINE
DN PubMed ID: 12711
TI A controlled trial of hormone replacement therapy given to women previously treated for breast cancer.
AU Davies E; Borge E; Magarey C; Schwartz P; Crea P; Wren B
CS Breast Cancer Unit, Royal Hospital for Women, Barker Street, Fairfield, New South Wales, Australia.
SO Clinical journal of the International Menopause Society, (1998 Jan-Feb) Vol. 1, No. 1, pp. 137-42.
Journal code: 1369-7137. ISSN: 1369-7137.
CY United States

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2002
 ED Entered STM: 14 Mar 2002
 Last Updated on STM: 10 Apr 2002
 Entered Medline: 9 Apr 2002

L11 ANSWER 9844562 MEDLINE on STN
Full Text

AN 200202423 MEDLINE
 DN PubMed ID: 1106601
 TI Chemoprevention for high-risk women: **tamoxifen and beyond.**
 AU Fabian C J; Kralovich F
 CS University of Kansas Medical Center, Kansas City, Kansas 66160, USA..
 cfabian@kumc.edu
 SO The Breast Journal. (2001 Sep-Oct) Vol. 7, No. 5, pp. 311-20. Ref: 117
 Journal code: 9505-3071. ISSN: 1075-122X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2002
 ED Entered STM: 14 Mar 2002
 Last Updated on STM: 19 Apr 2002
 Entered Medline: 18 Apr 2002

L11 ANSWER 10045182 MEDLINE on STN
Full Text

AN 200203280 MEDLINE
 DN PubMed ID: 1109390
 TI Tamoxifen-induced hot flashes.
 AU Loprinzi C J; Sahaskey K M; Sloan J A; Novotny P J; Quella S K
 CS Mayo Clinic, Mayo Foundation, Rochester, MN, USA.. cloprinzi@mayo.edu
 SO Clinical breast cancer. (2000 Apr) Vol. 1, No. 1, pp. 52-6.
 Journal code: 106393731. ISSN: 1526-8209.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2002
 ED Entered STM: 10 Mar 2002
 Last Updated on STM: 5 Apr 2002
 Entered Medline: 5 Apr 2002

L11 ANSWER 11145181 MEDLINE on STN
Full Text

AN 200203284 MEDLINE
 DN PubMed ID: 1109390
 TI Efficacy of fluoxetine for treatment of **hot flashes.**
 AU Loprinzi C J; Sloan Jeff A; Perez Edith A; Quella Susan K; Stella
 H; Halyard Michele Y; Pruthi Sandhya; Novotny
 Paul J; Sahaskey James A
 CS Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN
 55905, USA.. cloprinzi@mayo.edu
 SO Journal of Clinical Oncology : official journal of the American Society of
 Clinical Oncology. (2002 Mar 15) Vol. 20, No. 6, pp. 1578-83.
 Journal code: 0732-183X. ISSN: 0732-183X.
 CY United States
 DT (CLINICAL TRIAL)
 (CLINICAL TRIAL, PHASE III)
 Journal; Article; (JOURNAL ARTICLE)
 (CLINICAL TRIAL)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 2002
 ED Entered STM: 14 Mar 2002
 Last Updated on STM: 18 Apr 2002
 Entered Medline: 18 Apr 2002

L11 ANS 117 187 MEDLINE on STN
Full Text
AN 20023642 MEDLINE
DN PubMed ID: 119957
TI Postmenopausal hormone-replacement therapy.
AU David Suran
SO The New England Journal of medicine, (2002 Jan 3) Vol. 346, No. 1, pp. 63-71
JOURNOL CODE: 028-4793. ISSN: 0028-4793.
CY United States
DT Letter
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 2002
ED Entered STM: 15 Jan 2002
Last Updated on STM: 25 Jan 2002
Entered MEDLINE: 27 Jan 2002

L11 ANS 118 187 MEDLINE on STN
Full Text
AN 20023980 MEDLINE
DN PubMed ID: 115270
TI Describing SERM: stringent preclinical selection criteria leading to an estrogen agonist (WAY-140424) for clinical evaluation.
AU James S. ...
CS Hormone Research Institute, Wyeth-Ayerst Research, Collegeville, Pennsylvania 19342, USA.. kornbawar@wyeth.com
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 317-331
JOURNOL CODE: 0077-8923. ISSN: 0077-8923.
CY United States
DT Journal Article (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 2002
ED Entered STM: 17 Jan 2002
Last Updated on STM: 22 Feb 2002
Entered MEDLINE: 22 Feb 2002

L11 ANS 119 187 MEDLINE on STN
Full Text
AN 20023980 MEDLINE
DN PubMed ID: 115270
TI Raloxifene: risks and benefits.
AU Barrett-Connor E
CS Department of Family and Preventive Medicine, University of California, San Diego, CA 92093, USA.. ebarrettconnor@ucsd.edu
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 332-337
JOURNOL CODE: 0077-8923. ISSN: 0077-8923.
CY United States
DT Journal Article (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 2002
ED Entered STM: 17 Jan 2002
Last Updated on STM: 22 Feb 2002
Entered MEDLINE: 22 Feb 2002

L11 ANS 120 187 MEDLINE on STN
Full Text
AN 20023980 MEDLINE
DN PubMed ID: 115270
TI What are the properties of an ideal SERM?
AU Anthony ... K; Dunn B K
CS National Cancer Institute, Medical Center, Washington, DC 20007, USA.
SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 338-343
JOURNOL CODE: 0077-8923. ISSN: 0077-8923.
CY United States

DT Journal; English; (JOURNAL ARTICLE)
 (General Article; Review)
 LA English
 FS Priority Review
 EM 2002
 ED Published 15 Feb 2002
 Last Updated: 22 Feb 2002
 Retrieved: 22 Feb 2002

L11 ANSWER 159888 MEDLINE on STN

Full Text

AN 20020508888 JOURNAL ARTICLE
 DN Published 15 Feb 2002
 TI Effect of selective estrogen receptor modulators on reproductive tissues other than the uterus.
 AU Hendrix S L, et al
 CS Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, Michigan 48201, USA.. shendrix@med.wayne.edu
 SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 143-50. 14 p.
 Journal code: 1552-8674. ISSN: 0077-8923.
 CY United States
 DT Journal; English; (JOURNAL ARTICLE)
 (General Article; Review)
 LA English
 FS Priority Review
 EM 2002
 ED Published 15 Feb 2002
 Last Updated: 22 Feb 2002
 Retrieved: 22 Feb 2002

L11 ANSWER 159889 MEDLINE on STN

Full Text

AN 20020508889 JOURNAL ARTICLE
 DN Published 15 Feb 2002
 TI Efficacy of amoxifen in a breast cancer prevention trial: a summary of results from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.
 AU Day R
 CS Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. (National Surgical Adjuvant Breast and Bowel Project study (NSABP-1)). day@nsabp.pitt.edu
 SO Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp. 143-50. 14 p.
 Journal code: 1552-8674. ISSN: 0077-8923.
 CY United States
 DT Journal; English; (JOURNAL ARTICLE)
 (CONTROLLED TRIAL)
 (JOURNAL ARTICLE)
 (QUANTITATIVE STUDY)
 LA English
 FS Priority Review
 EM 2002
 ED Published 15 Feb 2002
 Last Updated: 22 Feb 2002
 Retrieved: 22 Feb 2002

L11 ANSWER 159890 MEDLINE on STN

Full Text

AN 20020508890 JOURNAL ARTICLE
 DN Published 15 Feb 2002
 TI Multiple outcomes of tamoxifen and risk of breast cancer during treatment with tamoxifen.
 AU Cummings SR, et al
 CS Department of Biostatistics, University of California, Suite 600, 74 New Hall, San Francisco, CA 94105, USA. (Multiple Outcomes of Tamoxifen and Risk of Breast Cancer (MORE) Trial). scummings@psg.ucsf.edu
 SO Annals of the American Medical Association, (2002 Jan 9) Vol. 287, pp. 143-50. 14 p.
 Journal code: 1552-8674. ISSN: 0098-7484.
 CY United States

DT (JOURNAL ARTICLE)
(JOURNAL ARTICLE)
(ENGLISH)
(ON-U.S. GOV'T)

LA English
FS All Journals; Priority Journals
EM 2002
ED Entered MEDLINE 1002
Last Updated 3 Apr 2003
Entered MEDLINE 1002

L11 ANSWER 1002 MEDLINE on STN
Full Text
AN 20005125
DN PubMed ID: 1002
TI Impact of adjuvant therapy on symptoms, functioning, and
quality of life
AU Ganz D A
CS Department of Prevention and Control Research, Jonsson Comprehensive
Center for Cancer Research, University of California-Los Angeles, Box 956900, Rm.
AP-105 CHS, Los Angeles, CA 90095-6900, USA.. pganz@ucla.edu
SO Journal of the National Cancer Institute. Monographs, (2001) No. 30, pp.
110-4.
Journal code: JNCIMON. ISSN: 1052-6773.
CY United States
DT (JOURNAL ARTICLE)
(ENGLISH)
(ON-U.S. GOV'T)

LA English
FS Priority Journals
EM 2002
ED Entered MEDLINE 1002
Last Updated 27 Jun 2002
Entered MEDLINE 1002

L11 ANSWER 1002 MEDLINE on STN
Full Text
AN 20005118
DN PubMed ID: 1002
TI Quality of life in long-term, disease-free survivors of breast cancer: a
follow-up study
AU Ganz D A; Arora Katherine A; Leedham Beth; Rowland Julia H;
Mendenhall Thomas R
CS School of Public Health, University of California, Los Angeles 90095-6900,
USA
NC R 90095-6900
SO Journal of the National Cancer Institute, (2002 Jan 2) Vol. 94, No. 1, pp.
3-11.
Journal code: JNCI. ISSN: 0027-8874.
CY United States
DT (JOURNAL ARTICLE)
(ENGLISH)
(ON-U.S. GOV'T)
(ENGLISH)
(ON-U.S. GOV'T, NON-P.H.S.)
(ENGLISH)
(ON-U.S. GOV'T, P.H.S.)

LA English
FS Priority Journals
EM 2002
ED Entered MEDLINE 1002
Last Updated 6 Apr 2002
Entered MEDLINE 1002

L11 ANSWER 1002 MEDLINE on STN
Full Text
AN 20005114
DN PubMed ID: 1002
TI Selective estrogen receptor modulators in 2001.
AU Cella D
CS Department of Biophysics and Medical Oncology, Robert H. Lurie Comprehensive
Center for Cancer Research, Northwestern University, Chicago, Illinois, USA.
SO Cancer Research, (2001 Sep) Vol. 15, No. 9, pp. 1177-85,
1177-4.
Journal code: JCO. ISSN: 0732-183X.
CY United States

DT Journal; Article (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2001
 ED Entered MEDLINE on STN: 01 Oct 2001
 Last Updated: 25 Jan 2002
 Entered MEDLINE: 25 Jan 2002

L11 A536R 113 113 MEDLINE on STN
Full Text
 AN 2001536555 NE
 DN PubMed
 TI Selective estrogen receptor modulation and reduction in risk of breast cancer, coronary artery disease, and coronary heart disease.
 AU Jernigan M, Morrow M
 CS Rushmore Comprehensive Cancer Center, Chicago, IL 60611, USA..
 NC 1999
 SO Journal of the National Cancer Institute, (2001 Oct 3) Vol. 93, No. 19, pp. 1444-1450. Ref: 56
 JN 1999
 CY United States
 DT Journal; Article (JOURNAL ARTICLE)
 (SEARCHED ON U.S. GOV'T)
 (SEARCHED U.S. GOV'T, NON-P.H.S.)
 (SEARCHED U.S. GOV'T, P.H.S.)
 General Index (G.I.E.)
 LA English
 FS Priority Journals
 EM 2001
 ED Entered MEDLINE on STN: 01 Oct 2001
 Last Updated: 22 Jan 2002
 Entered MEDLINE: 22 Jan 2001

L11 A536R 113 113 MEDLINE on STN
Full Text
 AN 20013445 NE
 DN PubMed
 TI Tamoxifen and the risk of nonpausal sequelae in patients with breast cancer.
 AU Ridd JH
 CS Tamworth General Hospital, Sutton, Surrey, UK..
 SO Cancer Research and Clinical Oncology College of Radiologists (Great Britain)), (2001) Vol. 174-80. Ref: 56
 JN 1999
 CY United Kingdom
 DT Journal; Article (JOURNAL ARTICLE)
 General Index (G.I.E.)
 LA English
 FS Priority Journals
 EM 2001
 ED Entered MEDLINE on STN: 01 Oct 2001
 Last Updated: 22 Jan 2002
 Entered MEDLINE: 22 Jan 2001

L11 A536R 113 113 MEDLINE on STN
Full Text
 AN 20013445 NE
 DN PubMed
 TI Tamoxifen and the risk of nonpausal sequelae in patients with breast cancer.
 AU Ridd JH
 SO Cancer Research and Clinical Oncology College of Radiologists (Great Britain)), (2001) Vol. 174-80. Ref: 56
 JN 1999
 CY United Kingdom
 DT Journal; Article (JOURNAL ARTICLE)
 General Index (G.I.E.)
 LA English
 FS Priority Journals
 EM 2001
 ED Entered MEDLINE on STN: 01 Oct 2001
 Last Updated: 22 Jan 2002
 Entered MEDLINE: 22 Jan 2001

Full 5 :

L11 R S MEDLINE on STN

L11 MEDLINE on STN

L11 R 3 EDLIN on STN

82

DT JOURNAL ARTICLE)
 General Periodic (VIEW)
 LA English
 FS Priority Journals; Priority Journals
 EM 2001 5
 ED Entered: 14 Jul 2001
 Last Updated: 14 Jul 2001
 Indexed: 14 Jul 2001

L11 AMER MEDICAL MEDLINE on STN

Full Text

AN 2001-00759 JOURNAL ARTICLE
 DN Indexed ID: 2001-00759
 TI Clinical pharmacokinetics of toremifene.
 AU Tama T I; Linares G R; DeGregorio M W
 CS Department of Internal Medicine, Cancer Center, University of California, Los Angeles, Santa Monica 90417, USA.
 NC 00007079
 SO Journal of Clinical Pharmacokinetics, (2000 Nov) Vol. 39, No. 5, pp. 327-34. Ref: 26
 CY United States
 DT JOURNAL ARTICLE)
 (KODOROV, S. I.; U.S. GOV'T, P.H.S.)
 General Periodic (VIEW)
 LA English
 FS Priority Journals; Priority Journals
 EM 2001 5
 ED Entered: 4 Jun 2001
 Last Updated: 4 Jun 2001
 Indexed: May 2001

L11 AMER MEDICAL MEDLINE on STN

Full Text

AN 2001-00760 JOURNAL ARTICLE
 DN Indexed ID: 2001-00760
 TI Toremifene and its side effects: a review.
 AU Mourits M J; Willemsse P H; Ten Hoor K A; Hollema H; Van der Zant G
 CS Department of Obstetrics and Gynecology, University Hospital Groningen, Hanzeplein 1, 9713 BZ Groningen, The Netherlands.. m.j.e.mourits@og.azg.nl
 SO Obstetrics and Gynecology, (2001 May) Vol. 97, No. 5 Pt 2, pp. 855-66. Ref: 121
 CY United States
 DT JOURNAL ARTICLE)
 General Periodic (VIEW)
 LA English
 FS Priority Journals; Priority Journals
 EM 2001 5
 ED Entered: 21 May 2001
 Last Updated: 21 May 2001
 Indexed: May 2001

L11 AMER MEDICAL MEDLINE on STN

Full Text

AN 2001-00761 JOURNAL ARTICLE
 DN Indexed ID: 2001-00761
 TI Endocrine therapies for breast cancer: how informative are medical notes for 'well-tolerated' endocrine therapy?
 AU Houghton J; Saunders C M; Houghton J
 CS Oncology Group, Royal Free & University College Medical School, 1, Rowland Hill Street, London NW3 2PF, UK.
 SO British Medical Journal, (2001 Mar) Vol. 322, No. 7247, pp. 667-670. Ref: 121
 CY United States
 DT JOURNAL ARTICLE)
 (KODOROV, S. I.; U.S. GOV'T)
 LA English
 FS Priority Journals; Priority Journals
 EM 2001 9

ED Entered STN 2001
Last Updated 1 Oct 2001
Entered Medline Ser 2001

L11 ANSWER 15483 MEDLINE on STN

Full Text

AN 200115483 MEDLINE

DN PubMed

TI Randomized trial of a black cohosh for the treatment of **hot flashes** among women with a history of breast cancer.

AU Jackson GL; A B; Evans J; Klaus L; Vahdat L; Kinne D; Lo K M; Moore A; Rosen J; Kaufman E L; Neugut A I; Grann V R

CS Herbert H. Lehman Comprehensive Cancer Center and Joseph L. Mailman School of Public Health, Columbia University, and Weill-Cornell Medical College, New York, NY 10021, USA.

SO Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology. (2001 May 15) Vol. 19, No. 10, pp. 2739-45.

Journal code: 0732-183X. ISSN: 0732-183X.

CY United States

DT (CLINICAL TRIAL)
Journal: Article (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH) (NON-U.S. GOV'T)

LA English

FS Priority Journal

EM 200106

ED Entered STN 2001
Last Updated 1 Jun 2001
Entered Medline Jun 2001

L11 ANSWER 13683 MEDLINE on STN

Full Text

AN 200113683 MEDLINE

DN PubMed

TI Phase I study of a third-generation selective estrogen receptor modulator, LY353879, in metastatic breast cancer.

AU Munster J; A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman J; Theriault R; Norton L; Hudis C

CS Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

SO Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology. (2001 Apr 1) Vol. 19, No. 7, pp. 2002-9.

Journal code: 0732-183X. ISSN: 0732-183X.

CY United States

DT (CLINICAL TRIAL)
(CLINICAL TRIAL) (PHASE I)
Journal: Article (JOURNAL ARTICLE)
(MULTICENTRE TRIAL)
(RESEARCH) (NON-U.S. GOV'T)

LA English

FS Priority Journal

EM 200105

ED Entered STN 2001
Last Updated 17 May 2001
Entered Medline May 2001

L11 ANSWER 12483 MEDLINE on STN

Full Text

AN 200112483 MEDLINE

DN PubMed

TI Cognitive function in postmenopausal women treated with **raloxifene**.

AU Yaffe K; L; Scahill B; Grady D; Barrett-Connor E; Cox D A; Nickols

CS Department of Psychiatry, University of California at San Francisco, 94122, USA (for the Raloxifene Evaluation Investigators).

NC K23-AG

SO The New England Journal of Medicine. (2001 Apr 19) Vol. 344, No. 16, pp. 1207-13.

Journal code: 0028-4793. ISSN: 0028-4793.

CY United States

DT (CLINICAL TRIAL)
Journal: Article (JOURNAL ARTICLE)
(MULTICENTRE TRIAL)

(RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH FUNDING NON-U.S. GOV'T)
 (RESEARCH FUNDING U.S. GOV'T, P.H.S.)

LA English
 FS Abstr. J. Clin. Endocrinol. Journals; Priority Journals
 EM 2001 5
 ED Entered 2001 2 1
 Last Updated 2001 May 2001
 Entered 2001 2 1

L11 ANSWER MEDLINE on STN
Full Text
 AN 2001 21 1
 DN PubMed ID:
 TI What is the role of oestrogens in treating menopausal symptoms?
 AU Murkoff A; Davis S R
 SO The Medical Journal of Australia, (2000 Nov 6) Vol. 173 Suppl, pp. S97-8.
 Journal of Endocrinology ISSN: 0025-729X.
 CY Australia
 DT Journal Article (ORIGINAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2001 2
 ED Entered 2001 2 1
 Last Updated 2001 Mar 2001
 Entered 2001 2 1

L11 ANSWER MEDLINE on STN
Full Text
 AN 2001 19 12
 DN PubMed ID:
 TI Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer: related physiological effects and symptoms.
 AU Nystedt M; G; Bolund C; Brandberg Y; Fornander T; Rutqvist L E
 CS Department of Radiology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
 SO Acta Oncologica (Stockholm, Sweden), (2000) Vol. 39, No. 8, pp. 959-68.
 Journal of Endocrinology ISSN: 0284-186X.
 CY Norway
 DT (CLINICAL TRIAL)
 (CONCURRENT)
 Journal Article (ORIGINAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH FUNDING NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 2001 2
 ED Entered 2001 2 1
 Last Updated 2001 Mar 2001
 Entered 2001 2 1

L11 ANSWER MEDLINE on STN
Full Text
 AN 2001 76 3
 DN PubMed ID:
 TI Long-term effects of raloxifene on bone mineral density, bone turnover, and bone mineral density in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
 AU Johnstone C; Harrison R H; Cohen F J; Shah A; Lindsay R; Mitlak B H; Huster W J; Harper K D; Heath H 3rd; Gennari C; Christiansen C; Arnold A D
 CS Indiana University School of Medicine, Emerson Hall Room 421, 545 Barnhill Dr, Indianapolis, IN 46202, USA.
 SO Archives of Internal Medicine, (Dec 11-25 2000) Vol. 160, No. 22, pp. 3444-50.
 Journal of Endocrinology ISSN: 0003-9926.
 CY United States
 DT (CLINICAL TRIAL)
 (CONCURRENT)
 Journal Article (ORIGINAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH FUNDING NON-U.S. GOV'T)
 LA English

FS Abridged Index Medicus Journals; Priority Journals
 EM 2001
 ED Entered STN 2001
 Last Update: 20 Mar 2001
 Entered Med 2001 Jan 2001

L11 ANSWER 128 MEDLINE on STN

Full Text

AN 2001 54107
 DN PubMed ID:
 TI Hot flashes
 AU Carpentier
 CS School of Medicine, Vanderbilt University, Nashville, TN 37240-0008, USA.
 SO Seminars in Oncology Nursing, (2000 Aug) Vol. 16, No. 3, pp. 214-25. Ref: 67
 Journal code: ISSN: 0749-2081.
 CY United States
 DT Journal Article (JOURNAL ARTICLE)
 (RESEARCH)
 General Ref:
 LA English
 FS Priority Journals
 EM 2001
 ED Entered STN 2001
 Last Update: 20 Mar 2001
 Entered Med 2001 Dec 2000

L11 ANSWER 129 MEDLINE on STN

Full Text

AN 2001 52135
 DN PubMed ID:
 TI Raloxifene
 AU Snyder K R; Malinowski J M
 CS Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA 18761, USA.
 SO American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, (2000 Sep 15) Vol. 57, No. 18, pp. 1675-8. Ref: 27
 Journal code: ISSN: 1079-2082.
 CY United States
 DT Journal Article (JOURNAL ARTICLE)
 General Ref:
 LA English
 FS Priority Journals
 EM 2001
 ED Entered STN 2001
 Last Update: 20 Mar 2001
 Entered Med 2001 Mar 2001

L11 ANSWER 130 MEDLINE on STN

Full Text

AN 2001 52134
 DN PubMed ID:
 TI A brief review of the current breast cancer prevention trials and protocols
 AU Campbell
 CS Department of Biostatistics, Statistics and Epidemiology, Imperial Cancer Research Fund, Lincoln's Inn Fields, WC2A 3PX, London, UK..
 SO European journal of cancer (Oxford, England : 1990), (2000 Jun) Vol. 36, No. 10, pp. 1111-1114.
 Journal code: ISSN: 0959-8049.
 CY ENGLAND; United Kingdom
 DT Journal Article (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 2001
 ED Entered STN 2001
 Last Update: 20 Mar 2001
 Entered Med 2001 Aug 2000

L11 ANSWER 131 MEDLINE on STN

AN	2000	79			
DN	PUBLICATION ID:	0819			
TI	Oral Efficacy of Tamoxifen in Postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.				
AU	Pandey J; Raulo T S; F; Flynn P J; Hynes H E; Rosenbluth R J; Kirshner J J; Pierce J L; Maguin V; Morrow G R				
CS	University of Rochester Cancer Center Community Clinical Oncology Program Research Building, Room 14642, USA.				
NC	CA37-06 (N)				
SO	Annals of Internal Medicine, (2000 May 16) Vol. 132, No. 10, pp. 788-93. Journal code: CMAJ. ISSN: 0003-4819.				
CY	United States				
DT	(CLINICAL TRIAL) Journal; Article (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL) (RESEARCH REPORT) U.S. GOV'T. P.H.S.)				
LA	English				
FS	Abstracted In Index Medicus Journals; Priority Journals				
EM	2000				
ED	Entered STM 25 Nov 2000 Last updated on Aug 2001 Entered online Jan 2001				

AN	2000 Jan-Feb	J Gynecol Invest
DN	PUBMED ID: 10732869	
TI	Serotonin Receptor Modulators (SERMs) in clinical practice.	
AU	Plummer J L	
CS	Elliott LJ and Co	US Medical Endocrine Division, Indianapolis, Indiana, USA
SO	Journal of the Society for Gynecologic Investigation, (2000 Jan-Feb) Vol. 7, Number Suppl., pp S34-46. Ref: 103	
	Journal code : 9 06. TSSN: 1071-5576.	
CY	United States	
DT	Journal Article (JOURNAL ARTICLE)	
	General Review; (WIFI)	
LA	English	
FS	Primary Journal	
EM	2000	
ED	Entered STM 5 May 2000	
	Last Modified on 5 May 2000	
	Endocrine Medicine Aug 2000	

AN	2000	17	
DN	PBM	071.	
TI	Surgery with mastectomy and tamoxifen treatment for breast cancer among Vietnamese women.		
AU	Lam T B; Nguyen D B; Nguyen V D; Havighurst T C		
CS	The University of Wisconsin Comprehensive Cancer Center, Madison, USA.		
NC	1999; 64(1)		
SO	Breast cancer prevention and treatment, (1999 Dec) Vol. 58, No. 3, pp. 2		
	J. Clin. Oncol. : 8. ISSN: 0167-6806.		
CY	National Cancer Institute		
DT	(National Cancer Institute)		
	Journal of Clinical Oncology (JCO) (NATIONAL CANCER INSTITUTE)		
	(NATIONAL CANCER INSTITUTE)		
	(NATIONAL CANCER INSTITUTE)		
LA	Evidence-based medicine (EBM)		
FS	Prevention of breast cancer		
EM	2000		
ED	Healthcare ST 21		
	Long-term follow-up study Apr 2000		
	Evidence-based medicine Apr 2000		

Full T

AN 2000 0687
 DN PubMed ID: 0687
 TI Chemopreventive effects of tamoxifen reported by healthy postmenopausal women receiving tamoxifen as placebo during osteoporosis prevention trial.
 AU Conner EA, Yeh J, et al.
 CS Lilly Research Laboratories, Indianapolis, IN 46285, USA..
 SO J Clin Oncol. 2000 Feb 1; 18(3):378-5122.
 CY Ireland
 DT (COMPARATIVE STUDY)
 LA English
 FS Pharmacology
 EM 200005
 ED Entered STN 12 May 2000
 Last Updated on 12 May 2000
 Entered Medline 12 May 2000

L11 ANSWER 335 F 18 MEDLINE on STN

Full Text

AN 2000 0687
 DN PubMed ID: 0687
 TI Chemopreventive effects of tamoxifen in the older patient.
 AU Montano J, et al.
 CS Department of Medicine, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA.
 SO J Clin Oncol. 2000 Feb 1; 18(3):378-5122.
 CY United States
 DT Journal Article (ORIGINAL ARTICLE)
 LA English
 FS Pharmacology
 EM 200005
 ED Entered STN 27 May 2000
 Last Updated on 27 May 2000
 Entered Medline 27 May 2000

L11 ANSWER 335 F 18 MEDLINE on STN

Full Text

AN 2000 0665
 DN PubMed ID: 0665
 TI Androgen deprivation therapy, sperms and beyond.
 AU Dearnaley D, et al.
 CS H. J. Cantor, La Jolla, CA 92037, USA.
 SO J Clin Oncol. 1999 Nov 1; 17(22):285-311. Ref: 247
 CY United States
 DT Journal Article (ORIGINAL ARTICLE)
 LA English
 FS Pharmacology
 EM 200005
 ED Entered STN 29 Feb 2000
 Last Updated on 29 Feb 2000
 Entered Medline 29 Feb 2000

L11 ANSWER 335 F 18 MEDLINE on STN

Full Text

AN 2000 0659
 DN PubMed ID: 0659
 TI Androgen deprivation therapy, sperms and beyond.
 AU Dearnaley D, et al.
 CS H. J. Cantor, La Jolla, CA 92037, USA.
 SO J Clin Oncol. 1999 Nov 1; 17(22):285-311. Ref: 247
 CY United States
 DT Journal Article (ORIGINAL ARTICLE)
 LA English
 FS Pharmacology
 EM 200005
 ED Entered STN 29 Feb 2000
 Last Updated on 29 Feb 2000
 Entered Medline 29 Feb 2000

L11 ANSWER OF 16 FROM F on STN

L11 A 100 100 OF 18 HEADLINE on STN

L11 A 1111 110 OF 18 MEDLINE on STN

89

EM 1999
ED E 11 Jan 2000
Last updated on TN: 17 Jan 2000
Entered on line: 17 Nov 1999

L11 ANSWER 1 OF 18 HEADLINE on STN

Full Text

AN 1999 10520 16
DN Pub Med 10520 16
TI [Abstract of international clinical trials with **raloxifene**].
Revue internationale des essais cliniques internationales du **raloxifene**.
AU Agnusdei Donato L; Liudskanov A; Andre-Ferrante B
CS Eli Lilly & Co., Florence, Italy.. agnusdeidonato@lilly.com
SO Annals of endocrinology (1999 Sep) Vol. 60, No. 3, pp. 242-6. Ref: 18
Journ code: 01 674 ISSN: 0003-4266.
CY French
DT (CONCEPTS) (JOURNAL ARTICLE)
Journ code: 01 674 ISSN: 0003-4266.
Gen review; REVIEW
LA French
FS Priority Journal
EM 1999
ED Entered on N: 11 Jan 2000
Last updated on TN: 17 Jan 2000
Entered on line: 23 Nov 1999

L11 ANSWER 2 OF 18 HEADLINE on STN

Full Text

AN 1999 10424 02
DN Pub Med 10424 02
TI Randomized trial of ethylstilbestrol vs. **tamoxifen** in postmenopausal women with metastatic breast cancer. An updated analysis.
AU Pruthi L; Suman V J; Hartmann L C; Loprinzi C L
CS Mayo Clinic and Foundation, Rochester MN, USA.
NC N01-10424 (NCI)
SO Breast cancer research and treatment, (1999 Mar) Vol. 54, No. 2, pp. 117-21.
Journ code: 81 1194 ISSN: 0167-6806.
CY Netherlands
DT (CLINICAL TRIAL) (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(PHASE III SUPPLEMENT, 1999 Mar, P.H.S.)
LA English
FS Priority Journal
EM 1999
ED Entered on N: 21 Sep 1999
Last updated on TN: 17 Jan 2000
Entered on line: 3 Nov 1999

L11 ANSWER 3 OF 18 HEADLINE on STN

Full Text

AN 1999 10402 75
DN Pub Med 10402 75
TI Late-onset acute estrogen deficiency and psychiatric syndromes in breast cancer patients.
AU Dufresne R; Greenberg D; Wenger J; Ferraro M G
CS Department of Psychiatry, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
SO Psychosomatics, (1999 Jul-Aug) Vol. 40, No. 4, pp. 304-8.
Journ code: 01 6576 ISSN: 0033-3182.
CY United States
DT Journal Article (JOURNAL ARTICLE)
LA English
FS Priority Journal
EM 1999
ED Entered on N: 27 Aug 1999
Last updated on TN: 17 Jan 2000
Entered on line: 17 Nov 1999

L11 ANSWER 4 OF 18 HEADLINE on STN

Full Text

L11 ANSWER : OF 10000000000 ON STN

AN 1999 9928.5
 DN PubM 9928.5
 TI Impact of different endocrine therapy strategies on quality of life in
 breast cancer survivors
 AU Ganz D; Rowland J H; Pritchard K E; Wertz H E; Desmond K A
 CS Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.
 NC R01 CA 628 (NCI)
 SO Recent results of clinical research. Fortschritte der Krebsforschung.
 Progress in breast cancer research. (1998) Vol. 152, pp. 396-411.
 JOURN Code: 0046-1536/98/0080-0015.
 CY GERMANY, Federal Republic of
 DT (COMPREHENSIVE STUDY)
 JOURN Article (GROUP ARTICLE)
 (RES. PROJ. SUPPORT, NON-U.S. GOVT)
 (RES. PROJ. SUPPORT, U.S. GOVT, P.H.S.)
 LA English
 FS Endocrine Journal
 EM 1999
 ED Entered on N: 26 Mar 1999
 Last updated on TN: 26 Mar 1999
 Entered on dline: 12 Mar 1999

L11 ANSWER 3 OF 18 MESSAGES on STN

Full Text

AN 1999 9881.1
 DN PubM 9881.1
 TI The effect of endocrine antiestrogens in a rat model for hot flush.
 AU Merchel I; Funderud T M; Carver J M; Lundeen S G; Ghosh K;
 Vonnahme C
 CS Wyeth Research, Morristown, Women's Health Research Institute,
 Wyeth Research, Wyeth, PA 19087, USA.. Merchel@war.wyeth.com
 SO J Clin Endocrinol (1999) Nov 16; 80, No. 3, pp. 307-16.
 JOURN Code: 7447-1424/99/0378-5122.
 CY Israel
 DT Journal Article (GROUP ARTICLE)
 LA English
 FS Endocrine Journal
 EM 1999
 ED Entered on N: 13 Apr 1999
 Last updated on TN: 13 Apr 1999
 Entered on dline: 26 Mar 1999

L11 ANSWER 3 OF 18 MESSAGES on STN

Full Text

AN 1999 9881.3
 DN PubM 9881.3
 TI Postmenopausal women and osteoporosis: available choices for maintenance
 of skeletal health.
 AU Sherman D; Wornat M
 CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
 46206-0029.
 SO J Clin Endocrinol (1999) Nov 16; 80, No. 3, pp. 241-5. Ref: 42
 JOURN Code: 7447-1424/99/0378-5122.
 CY Israel
 DT Journal Article (GROUP ARTICLE)
 (Clinical Review; Review)
 LA English
 FS Endocrine Journal
 EM 1999
 ED Entered on N: 13 Apr 1999
 Last updated on TN: 13 Apr 1999
 Entered on dline: 26 Mar 1999

L11 ANSWER 3 OF 18 MESSAGES on STN

Full Text

AN 1999 9861.3
 DN PubM 9861.3
 TI The role of tamoxifen in the treatment of breast cancer: revisiting the issues.
 AU Goss D M W; Sparano A J
 CS Department of Internal Medicine, University of California, Sacramento
 95833-0001.
 N 137 (NID) 3 (NID) 5

SO Journal of the American Pharmaceutical Association (Washington, D.C. :
1996 Nov-Dec; Vol. 1, No. 6, pp. 738-44; quiz 744-6. Ref: 51
Journal code: 981001. ISSN: 1036-5802.
CY United States
DT Journal Article (JOURN ARTICLE)
(RESTRICTED SUPPORT, S. 1001, P.H.S.)
General view; REVIEW
LA English
FS Periodical Journal
EM 1999
ED Entered on: 15 Jan 99
Last updated on: 15 Jan 1999
Entered on line: 6 Jan 1999

L11 ANSWER 1 OF 10 M 111 on STN

Full Text

AN 1999
DN PubMed ID: 981504
TI Phase II study of vorozole (P83842), a new aromatase inhibitor, in
postmenopausal women with advanced breast cancer in progression on
tamoxifen.
AU Cassinelli Clark M; Amadio G; Weizel H A; Wadden N A; Crump M; Walde D;
The International Cost; Brynnels J
CS Breast Group of the Toronto Hospital, Toronto, Ontario, Canada M5G 2C4.
SO Clinical Cancer Research: an official journal of the American Association
for Cancer Research. (1993 Mar) Vol. 1, No. 3, pp. 287-94.
Journal code: 982502. ISSN: 1078-0432.
CY United States
DT (CLINICAL TRIAL)
(CLINICAL TRIAL PHASE II)
Journal Article (JOURN ARTICLE)
(JOURNAL REVIEW)
(RESTRICTED SUPPORT, S. 1001, P.H.S.)
LA English
FS Periodical Journal
EM 1999
ED Entered on: 23 Feb 99
Last updated on: 23 Feb 1999
Entered on line: 2 Feb 99

L11 ANSWER 2 OF 10 M 111 on STN

Full Text

AN 1998
DN PubMed ID: 967800
TI Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or
placebo chemotherapy in healthy women: different compliance with
treatment.
AU Veronesi U; Pizzocchetti G; Ferlante M A; Zottar M; Magri M D; Crivellari
L; Fumagalli S
CS Division of Preventive Oncology, Centro di Riferimento Oncologico, Aviano,
Italy.
SO Tamoxifen. (1998 Mar-Apr) Vol. 4, No. 3, pp. 372-5.
Journal code: 071301. ISSN: 0300-8916.
CY Italy
DT (CLINICAL TRIAL)
Journal Article (JOURN ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Periodical Journal
EM 1999
ED Entered on: 20 Aug 99
Last updated on: 20 Aug 1999
Entered on line: 20 Aug 99

L11 ANSWER 3 OF 10 M 111 on STN

Full Text

AN 1999
DN PubMed ID: 961700
TI Phase II study of 199 in patients with advanced or recurrent
breast cancer: a dose finding study.
AU Zytka T; Tomlinson A
CS Department of Surgery, Centro di Riferimento Oncologico, Aviano Hospital.

SO Gan to kyojaku ryoku Cancer & chemotherapy, (1998 May) Vol. 25, No. 6, pp. 853-6.
 Journal code: 70 0041. ISSI: 0385-0684.
 CY Japan
 DT (CLINICAL TRIAL)
 (CLINICAL TRIAL, PHASE III)
 (ENGLISH ABSTRACT)
 Journal article (JOURNAL ARTICLE)
 (MULTI-PER STUDY)
 LA Japan
 FS Prior Journal
 EM 1998
 ED Entered: TN: 25 May 1999
 Last updated on: TN: 25 May 1999
 Entered deadline: 17 Jun 1998

L11 ANSWER 4 OF 10 MEDLINE on STN

Full Text

AN 1998 May 1 MEDLINE
 DN PubMed: 958074
 TI Toremifene and letrozole for advanced breast cancer.
 AU Ponder BA
 SO The British medical journal and therapeutics, (1998 Apr 10) Vol. 40, No. 9024, pp. 43-5.
 Journal code: 29 620R. ISSN: 0025-732X.
 CY United States
 DT Journal Article (JOURNAL ARTICLE)
 LA English
 FS Abstract Index Medicus Journals; Priority Journals
 EM 1998
 ED Entered: TN: 20 May 1998
 Last updated on: TN: 20 May 1998
 Entered deadline: 12 May 1998

L11 ANSWER 5 OF 18 MEDLINE on STN

Full Text

AN 1998 May 2 MEDLINE
 DN PubMed: 957632
 TI Effects of tamoxifen in premenopausal women treated for breast carcinoma: prevalence, severity, complications, management, and relation to quality of life.
 AU Corpe ED; J S; Pankow M A; Cordova M; Cunningham L; Studts J; McGrath E; Kohn D; Sloan J; Miller R
 CS Department of Biomedical Science, University of Kentucky, Lexington 40536-0055, USA.
 SO Cancer, 1998 May; Vol. 2, No. 9, pp. 1682-91.
 Journal code: 03 0045. ISSN: 0008-543X.
 CY United States
 DT Journal Article (JOURNAL ARTICLE)
 LA English
 FS Abstract Index Medicus Journals; Priority Journals
 EM 1998
 ED Entered: TN: 29 May 1998
 Last updated on: TN: 29 May 1998
 Entered deadline: 17 May 1998

L11 ANSWER 6 OF 18 MEDLINE on STN

Full Text

AN 1998 May 3 MEDLINE
 DN PubMed: 952297
 TI Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
 AU Pritchard alKhor
 CS School of Pharmacy, Marshall University, 6-9520, USA.
 SO American journal of system pharmacy : AJHP : official journal of the American Society of Health System Pharmacists, (1998 Mar 1) Vol. 55, No. 3, pp. 1679-2082.
 Journal code: 91 0003. ISSN: 1079-2082.
 CY United States
 DT Journal Article (JOURNAL ARTICLE)
 (SUBPOB-CON- GOV'T)

L11 ANSWER 7 OF 10 M. LINE on STN

Received deadline: 17 Apr 2008

Deadline: 2 year

Clinical Oncology 1998 Feb; 13(2): 372-183X.

CY Unit: Dates
DT JASPER OPTS
(CLINICAL TRIALS)
Journal Article (JOURN ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(ESSENTIAL SUPPORT NON-GOV'T)
(ESSENTIAL SUPPORT U.S. GOVT, P.H.S.)
LA English
FS Priority Journal
EM 199813
ED Entered STN: 12 Mar 1998
Last Modified on: 12 Mar 1998
Entered Medline: 2 Mar 1998

L11 ANSWER 2 OF 12 MEDLINE on STN

Full Text

AN 19980303
DN PubMed: 9335555
TI Effect of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
AU Delmas PD; Bjara M; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Drapkin CR
CS Hopital Rouquier, INSERM Research Unit 403, Lyons, France.
SO The American journal of medicine, (1997 Dec 4) Vol. 103, No. 6, pp. 1111-1117.
JOURN CODE: 0002-9273 (0: 9338-4793).

CY Unit: Dates
DT JASPER OPTS
(CLINICAL TRIALS)
(JOURNAL PER STN)
(RANDOMIZED CONTROLLED TRIAL)
(ESSENTIAL SUPPORT NON-GOV'T)

LA English
FS Abstract Index: Focus Journals; Priority Journals
EM 199707
ED Entered STN: 9 Oct 1998
Last Modified on: 3 Dec 2000
Entered Medline: 8 Dec 1997

L11 ANSWER 1 OF 12 MEDLINE on STN

Full Text

AN 19980303
DN PubMed: 9342118
TI Tamoxifen in the treatment of breast cancer. Efficacy, safety and cost.
AU Miettinen U; Alakisa S
CS Department of Obstetrics and Gynecology, University Hospital, Tampere, Finland.
SO Drug therapy, (1997 Oct) Vol. 11, No. 4, pp. 261-70. Ref: 53
JOURN CODE: 0001-4454 (0: 1170-229X).

CY New
DT Journal Article (JOURN ARTICLE)
General Review (REV)

LA English
FS Priority Journal
EM 199707
ED Entered STN: 9 Oct 1998
Last Modified on: 9 Oct 1998
Entered Medline: 8 Dec 1997

L11 ANSWER 2 OF 12 MEDLINE on STN

Full Text

AN 9741
DN PubMed: 9247777
TI A randomized trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute Cancer Clinical Trials Group (NCIC CTG) trial MA.1.
AU Sawhney R; Keshelley W; DeBoer G; Paterson AH; Meakin JW; et al
CS Cancer Therapy Evaluation Program, Cancer Centre, Ontario, Canada.
SO Breast international group treatment, (1997 Jul) Vol. 44, No. 3, pp.

211-7
 CY Journal Article (JOURN. ARTICLE)
 DT (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journal
 EM 1997
 ED Entered IN: 13 Jul 1997
 Last Updated on IN: 13 Jul 1997
 Entered on-line: 13 Jul 1997

L11 ANSWER TO QUESTION MACHINE ON STN

Full Text

AN 9736
 DN PubMed ID: 928007
 TI Altered levels of estrogen for the treatment of hot flashes.
 AU Lacey, J; McCall, W
 CS Department of Pharmacy Services, University of Massachusetts Medical Center, Worcester, MA 01655, USA.
 SO The Annals of pharmacotherapy, (1997 Jul-Aug) Vol. 31, No. 7-8, pp. 915-7.
 CY United States
 DT Journal Article (JOURN. ARTICLE)
 LA English
 FS Priority Journal
 EM 1997
 ED Entered IN: 3 Sep 2000
 Last Updated on IN: 3 Sep 2000
 Entered on-line: 3 Sep 2000

L11 ANSWER TO QUESTION MACHINE ON STN

Full Text

AN 9730
 DN PubMed ID: 9168
 TI Effects of tamoxifen on the pharmacokinetics of tamoxifen.
 AU Partridge, L
 CS University of Kentucky, College of Medicine, Lexington, Kentucky, USA.
 SO Cancer chemotherapy and biophysics, (1997 May) Vol. 11, No. 5 Suppl 4, pp. 1-2.
 CY United States
 DT Journal Article (JOURN. ARTICLE)
 (RESEARCH SUPPORT, NON-GRANT)
 LA English
 FS Priority Journal
 EM 1997
 ED Entered IN: 5 Aug 1997
 Last Updated on IN: 5 Aug 1997
 Entered on-line: 5 Jul 1997

L11 ANSWER TO QUESTION MACHINE ON STN

Full Text

AN 9730
 DN PubMed ID: 9168
 TI A comparison of the efficacy of fadrozole (fadrozole) versus tamoxifen in postmenopausal patients with metastatic breast cancer.
 AU Falson, P
 CS Department of Clinical Oncology, University of Pretoria, South Africa.
 SO Annals of the European Society for Medical Oncology, (1997 May) Vol. 7, No. 5, pp. 465-9.
 CY United States
 DT Journal Article (JOURN. ARTICLE)
 (RESEARCH SUPPORT, NON-GRANT)
 LA English
 FS Priority Journal
 EM 1997
 ED Entered IN: 5 Aug 1997
 Last Updated on IN: 5 Aug 1997
 Entered on-line: 5 Jul 1997

LA English
 FS Priority Journals
 EM 1996
 ED Entered: 28 Jun 1997
 Last Modified: 28 Jun 1997
 Entered: 28 Jun 1997

L11 ANSWER LINE on STN
Full Text
 AN 9636498
 DN PubMed
 TI A controlled trial of the effect of raloxifene (LY139481) HCl: impact on bone turnover and risk of fracture in healthy postmenopausal women.
 AU Draper L, Finkelstein D, Fenster W J; Neild J A; Harper K D; Arnaud C
 CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
 SO Journal of Bone and Mineral Research: the official journal of the American Society for Bone and Mineral Research, (1996 Jun) Vol. 11, No. 6, pp. 935-941.
 CY United States
 DT (CLINICAL TRIAL)
 (CLINICAL TRIAL - RCT)
 (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 1996
 ED Entered: 28 Jun 1997
 Last Modified: 28 Jun 2000
 Entered: 28 Jun 1996

L11 ANSWER LINE on STN
Full Text
 AN 9620498
 DN PubMed
 TI Factors associated with non-compliance in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment.
 AU Yeckel M, Frankowski R F; Weber D M; Bitsura J M; Vogt R
 CS University of Illinois at Chicago Health Science Center, School of Nursing, USA.
 SO Cancer Nursing, Vol. 76, No. 1, pp. 46-56.
 CY United States
 DT (JOURNAL ARTICLE)
 (REFERENCE SOURCE - NON-GOV'T)
 LA English
 FS Abridged Index of Journals; Priority Journals
 EM 1996
 ED Entered: 28 Jun 1997
 Last Modified: 15 Jul 1996
 Entered: 15 Jul 1996

L11 ANSWER LINE on STN
Full Text
 AN 961852
 DN PubMed
 TI Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: analysis of patients entered on four prospective clinical trials.
 AU Pritchard K I; Mailliard J A; Wieand H S
 CS Division of Cancer Therapy, Mayo Clinic and Foundation, Rochester, Minn.
 NC CA-1
 CA-2
 CA-3
 SO Cancer, Vol. 77, No. 4, pp. 683-90.
 CY United States
 DT (CLINICAL TRIAL)
 (RANDOMIZED CONTROLLED TRIAL)

Journal; (JOURNAL OF ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 (RESEARCH REPORT, U.S. GOV'T)
 (RESEARCH REPORT, U.S. GOV'T, P.H.S.)

LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 1996
 ED Entered 1996
 Last Modified 20 Jun 1996
 Entered 1996

L11 ANSWER 1 MEDLINE on STN

Full Text

AN 9617 980
 DN Published
 TI Therapeutic use of the aromatase inhibitor fadrozole hydrochloride in
 adjuvant breast cancer.
 AU Bonnerot C; Bowsett M; Trunet P F; Houston S J; da Luz R J;
 Rubinfeld S; Bowles T J
 CS Royal Marsden Hospital, Institute of Cancer Research, London, UK.
 SO British Medical Journal. (1996 Feb) Vol. 312, No. 4, pp. 539-42.
 JOURN: 0950-2688
 CY SCOTLAND
 DT (CLINICAL TRIAL)
 (COMPARATIVE)

Journal; (JOURNAL OF ARTICLE)
 (MULTICENTER TRIAL)
 (RANDOMIZED CONTROLLED TRIAL)

LA English
 FS Priority Journals
 EM 1996
 ED Entered 1996
 Last Modified 6 Feb 1996
 Entered 1996

L11 ANSWER 1 MEDLINE on STN

Full Text

AN 95075812
 DN Published
 TI High-dose tamoxifen for estrogen and progesterone receptor negative
 metastatic breast cancer: phase II trial of the Cancer and Leukemia
 Group B.
 AU Winer E B; Hayes D M; Duggan D B; Henderson I C
 CS University of North Carolina, Comprehensive Cancer Center of Wake Forest
 University, Winston-Salem, NC 27157-1082, USA.
 NC CA20
 CA20
 CA33

SO Breast International Group treatment, (1995) Vol. 36, No. 1, pp. 35-40.
 JOURN: 0950-2688
 CY Netherlands

DT (CLINICAL TRIAL)
 (CLINICAL TRIAL)
 (RANDOMIZED CONTROLLED TRIAL)
 (MULTICENTER TRIAL)
 (RESEARCH REPORT, U.S. GOV'T)
 (RESEARCH REPORT, U.S. GOV'T, P.H.S.)

LA English
 FS Priority Journals
 EM 1996
 ED Entered 1996
 Last Modified 24 Apr 1996
 Entered 1996

L11 ANSWER 1 MEDLINE on STN

Full Text

AN 9617 980
 DN Published
 TI Tamoxifen for the treatment of hot flashes in women with breast cancer.
 AU Winer E B; Hayes D M; Duggan D B; Henderson I C
 CS University of North Carolina, Comprehensive Cancer Center of Wake Forest
 University, Winston-Salem, NC 27157-1082, USA.

(RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority
 EM 1991 3
 ED Entered 1991
 Last Upd 3 1991
 Entered Mar 11

L11 ANSWER 1
 Full Text

AN 9029 385
 DN PubMed
 TI A randomized trial of medrogestrol acetate (MA) and medroxyprogesterone acetate in advanced breast cancer.
 AU Willemsen J; Sleijfer D T; Tjabbes T; van Veelen H
 CS Department of Medical Oncology, University Hospital Groningen, The Netherlands
 SO European Journal of Cancer (Oxford, England : 1990), (1990 Mar) Vol. 26, No. 3, p. 385-390.
 CY ENGLAND: Taylor & Francis Ltd
 DT (CLINICAL TRIAL)
 (COMPARATIVE)
 Journal; (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority
 EM 1990 7
 ED Entered 1991
 Last Upd 3 1991
 Entered Jun 1991

L11 ANSWER 1
 Full Text

AN 9031 400
 DN PubMed
 TI Chemotherapy and chemohormonal therapy in women with advanced breast cancer.
 AU Tjebbes T; Kluinman M; Olson J E; Cummings F J
 NE 04-0115
 04-0318
 SO Publication of the National Cancer Institute, (1986)
 CY United States
 DT (CLINICAL TRIAL)
 (COMPARATIVE)
 Journal; (RANDOMIZED CONTROLLED TRIAL)
 (CLINICAL TRIAL)
 J.S. GOV'T, P.H.S.)
 LA English
 FS Priority
 EM 1990 2
 ED Entered 1991
 Last Upd 3 1991
 Entered Dec 1991

L11 ANSWER 1
 Full Text

AN 87 384
 DN PubMed
 TI Tamoxifen-blind adjuvant trial in elderly women
 AU Tormey D C; Harris J E; Falkson G G
 NE 04-0115
 04-0318
 SO Publication of the National Cancer Institute, (1986)

CV No. 1, p. 1
D United States
Journal; (CLINICAL
Journal; (CLINICAL
(CRANIOFACIAL)
(RESEARCH)
LA English
FS Priority
EM 1986 2
ED Entered 1990
Last Upd 1990
Entered Dec 1986

```
=> data$tau      128 152 155 161 163 170 171
```

L1 ANSWER 1. TIME on STN
Full text
P: 1001 541 INE
T: Hot flashes ir management in breast cancer.
A: Corrate
SD: 1001 541
A3 J. NIV
flashes th cancer. DATA SOURCES: Published literature
of H f omer t breast cancer and in healthy women.
N NSI 107 hot flashes is influenced by several
leat c ver d factors. Hot flashes are a prevalent,

severe problems can negatively impact quality of life. Certain women are at high risk for hot flashes following breast cancer treatment. Little research supports the safety or effectiveness of treatments in women with breast cancer. IMPLICATIONS FOR NURSING PRACTICE: Implications include the need to improve patient education, perform comprehensive symptom assessment, and counsel women about various treatment alternatives.

TI Hot flashes and their management in breast cancer.
 AB OBJECTIVE: To review literature relevant to defining and managing hot flashes in women with breast cancer. DATA SOURCES: Published literature on hot flashes in women with breast cancer and in healthy women. CONCLUSIONS: The experience of hot flashes is influenced by several breast cancer treatment-related factors. Hot flashes are a prevalent, severe problem that can negatively impact quality of life. Certain women are at high risk for hot flashes following breast cancer treatment. Little research supports the safety or effectiveness of treatments in women with breast cancer. IMPLICATIONS FOR...

CT
 AE, adverse effects
 antineoplastic agents
 its use: TU, therapeutic use

* Breast
 Breast
 Breast
 * Hot Flash
 Hot Flash
 Hot Flash
 Hot Flash
 Hot Flash
 Tumors
 Middle
 Patient
 Quality
 Life Factor
 * Tamoxifen: Adverse effects
 Tamoxifen: Therapeutic use

RN 1.511-29- (1st Edition)

L11 ANSWER 12 OF 12 HEADLINE on STN

Full

AN 1994; 417: 1-5
 TI Tamoxifen at breast surgery for breast cancer and tamoxifen or placebo in healthy women: different compliance with treatment
 AU Agresti M A; Werlante M A; Zottar M; Magri M D; Crivellari
 SO Tamoxifen, (un) Vol. 84, No. 3, pp. 372-5.
 AB Aim: The study was to investigate whether tamoxifen toxicity and treatment-related side effects differed in the adjuvant versus chemoprevention setting. METHODS: At our Institutions 119 postmenopausal breast cancer patients were randomized from August 1987 to March 1995 to receive tamoxifen 20 mg bid in the adjuvant setting (International Breast Cancer Study Group) and 202 healthy hysterectomized women aged 50-69 years were randomized from November 1993 to May 1995 in a double-blind, placebo-controlled chemoprevention study (Prevention Study). The tamoxifen dose was 20 mg bid in both studies. Median age was 66 years (54-85) in the adjuvant study and 55 years (37-69) in the chemoprevention study. Duration was 238 and 120 weeks, respectively. RESULTS: In both adjuvant studies experienced more hot flashes, vaginal bleeding, and/or bleeding, bone marrow depression and weight gain than in the chemoprevention study, consistent with the fact that a placebo was given in the latter study were receiving placebo. Permanent discontinuation occurred in 2.5% of patients in the adjuvant study and 15.1% in the chemoprevention study (difference not significant). Permanent discontinuation was more frequent in the chemoprevention study than in the adjuvant ones (26.7% vs 15.1%--P<0.05). In summary, our data show that, although the toxicity profile was similar in the two settings, a larger proportion of women in the chemoprevention study discontinued treatment spontaneously. In the chemoprevention study, the impact of tamoxifen on compliance in the chemopreventive setting was not studied.

TI Tamoxifen or placebo after surgery for breast cancer and tamoxifen or placebo in healthy women: different compliance with treatment?

AB AIM: The study was to investigate whether tamoxifen toxicity and treatment side effects differed in the adjuvant versus chemoprevention setting. METHODS: At our Institutions 119 postmenopausal breast cancer patients were randomized from August 1987 to March 1995 to tamoxifen or placebo in adjuvant studies (International Breast Cancer Study Group, VI and VII) and 202 healthy hysterectomized women aged 35-70 years were randomized from November 1993 to May 1996 in a multicenter, double-blind, placebo-controlled chemoprevention study (Italian Chemoprevention Study). The tamoxifen dose was 20 mg/day for 5 years in both studies. Median age was 66 years (54-85) in the adjuvant study and 55 years (35-70) in the chemoprevention study. Median treatment duration was 100 weeks, respectively. RESULTS: Patients treated with tamoxifen experienced more hot flashes, vaginal discharge, bleeding, bone marrow depression and weight gain than those treated with placebo. The incidence of these side effects was higher in the chemoprevention study, consistent with the... (26.7% vs 15.1%--P< 0.05). CONCLUSIONS: In chemoprevention, although the toxicity of tamoxifen is lower than in the adjuvant setting, a larger proportion of women treated with tamoxifen experienced side effects spontaneously. Due to the double-blind design of the chemoprevention study, the impact of the toxicity of tamoxifen on compliance in the chemopreventive setting cannot be assessed.

CT
therapy

* Breast Cancer PC, prevention & control
* Lung Cancer SU, lung cancer
* Chemotherapy
* Humans
* Middle-aged
* Patient
* Prognosis
* Tamoxifen
* Tamoxifen
* Tamoxifen

RN 1051-29 (T. En)

L11 ANSWER 1 OF 1 DI LINE on STN

Full Text

AN 1051-29 (T. En)

TI Hot flashes in breast cancer: prevalence, correlates, management, and relation to quality of life.

AU Corrao S, Cella D, Wolkstein M, Cordova M, Cunningham L, Studts J, McGrath P, Bradburn N, Vickers A, No. 9, pp. 1682-91.

SO J Clin Oncol 1998; 16: 3894-3900. 008-543X.

AB BACKGROUND: Hot flashes (HFs) after the diagnosis and treatment of breast cancer (BC) is scarce. To our knowledge, this research project is the second study of HF prevalence and severity in women with BC. The study of 1) correlates of HF prevalence and severity, 2) HF management strategies, and 3) the relation between HFs and quality of life (QOL) among women with BC. METHODS: Eligible women (n=111) were interviewed in structured telephone interviews. RESULTS: Of the 111 women interviewed, 65% reported HFs, with 59% of whom the symptom was severe. Multivariate analysis showed that HFs were most common in women with a high school education and who were younger at diagnosis and 2) HFs were more common in women with a higher body mass index, those who were younger at diagnosis, and those who were taking tamoxifen. Among women with HFs, 37% reported interest in HF management strategies and 63% expressed interest in a management strategy. HFs marginally were related to QOL using the SF-12 Health Survey (P < 0.05). CONCLUSIONS: The results of the current study significantly support the hypothesis of the relation between HFs in women with BC and support the hypothesis of the relation between HFs and QOL. The results of the current study significantly support the hypothesis of the relation between HFs in women with BC and support the hypothesis of the relation between HFs and QOL.

TI Hot flashes in breast cancer: prevalence, correlates, management, and relation to quality of life.

AB BACKGROUND: Hot flashes (HFs) after the diagnosis and

treatment 3 ca. (BC) is scarce. To our knowledge, this
research on the setting. . . . were most severe in women with a
higher b. . . . those who were younger at diagnosis, and those
in certain a. . . . women with HF, 37% were not using any HF
in some s. . . . expressed interest in learning more

CT
Adjuvant
Age 7, 8
*Breast pl. II, medically induced
Breast pl. EP, epidemiology
Breast pl. TH, therapy
*Not Fla s: omplications
Not Fla s: oidology
Not Fla s: her
Humans
Middle i
Multiva te sis
*Postmen: us ph: idology
Preval: I
Quality I

L11 ANSWER 1 OF
Full T
AN 1998 019 INE
TI Toremife in breast cancer. Efficacy, safety and cost.
AU Toremife
SO Toremife & 11, No. 4, pp. 261-70. Ref: 53
AB Toremife. Toremife is a toremifene analogue that is indicated for
the treat- et: opus l hormone-dependent breast cancer. It
completes th- for estrogen receptors and has growth-inhibitory
effects MC- at breast cells. At concentrations < 10(-6) mol/L,
this gro- i- can be reversed by estradiol, but at higher
concentr- or- it is cytotoxic. In dimethylbenzanthracene
(400-1000) ce- try author in rats, toremifene has been shown to
decrease e- of few tumours and to inhibit the growth of existing
tumours. or- the growth inhibition by suppressing mitosis and
inducing op- T- mechanism by which these events occur may involve
the indu- or- g- growth factor-beta 1 and inhibition of
insulin- e- (mecasermin). Toremifene is primarily an
anti-tr- a- estrogen agonist properties in
postend- e- the latter are reflected by the fall in luteinising
hormone e- stimulating hormone levels and the rise in sex
hormone- di- levels that are associated with its use in most
women. er- gen-priming, toremifene 68mg administered orally has
been fou- to- a similar antiestrogenic effect on the vaginal
epitheli- ir- endousl women as tamoxifen 60mg. The half-life of
toremife in- a i 5 days, and the drug is > 99% bound to plasma
pot ins- Th- me- bolites of toremifene are N-demethyl-
toremife ar- ino- toremifene. Altered liver, but not
liver, ot- led- the pharmacokinetics of toremifene.
Toremife. 60- y- as effective as tamoxifen 20mg daily in the
treatment f- op- hormone-dependent breast cancer, producing a
response e- patients. Soft tissue and visceral metastases
spread e- re- more than bone metastases. Most of the adverse
effects e- e- related to its activity at estrogen receptors
adjuvant l- y- vaginal discharge and nausea. Although
toremife de- a- albumin III levels slightly, the incidence of
toremife li- e- is low. Thus far, no carcinogenic effects
have been ot- preclinical data are mostly reassuring.
Toremife ha- e- effects on serum lipids, and thus has
potential n- a- primary heart disease. Although toremifene is
somewhat re- e- than tamoxifen, toremifene is an
effective ac- e- alternative to tamoxifen in the treatment
of post- pa- hormone-dependent breast cancer. No formal
parallel co- e- of toremifene and tamoxifen have yet been
parallel co- e- potentially safer than tamoxifen in relation
to cardi- e- effects on serum lipids.
TI Toremife in breast cancer. Efficacy, safety and cost.
AB Toremife in breast cancer. Efficacy, safety and cost.

CT

* J. Kenneth T
For wife: T
For wife: T
For wife: T
For wife: T
* For wife: T

L11 ANSWER 17 OF INCIDENT on STN

AN 9 5 65

AU I A H - M - 1997 7 8 915-7.
SO The ana of 1997 Jul-Aug Vol. 31, No. 7-8, pp. 915-7.
 C l e : 060-0280.

107

effects. ec ... lack of literature supporting their clinical use, options h ... E and ginseng need to be approached cautiously. Exercise s ... alleviating some of the complications associated with menopausal a heart disease and osteoporosis, but its effect on neurotransmitti and hormone concentrations, and how this relates to the treatment of hot flashes have not been characterized. Patients should be told t ... activity, a balanced diet, avoidance of alcohol c ... stress reduction may be of additional help in decreasing va ...

TI Alternat s ... for the treatment of hot flashes.

AB Postmeno sa ... experiencing hot flashes in whom estrogen replacement i ... have alternatives available to them; however, er ... defined treatment modality. The. . . opt to use st ... be told in advance that the effects will not be t ... if tamoxifen is used concomitantly. Confin no ... one may constitute potential alternatives, but it s ... to tolerate the adverse. . . heart disease and to re ... or neurotransmitters and hormone concentr or ... relates to the treatment of hot flashes have not en ... Patients should be told that regular physical ti ... diet, avoidance of alcohol and caffeine, . .

L11 ANSWER 1 OF 1 QUESTION ON STN

Full Text

AN 9500012

TI High dose or ... estrogen and progesterone receptor negative metastatic br ... Phase II trial of the Cancer and Leukemia Group B.

AU For J Be ... B; Hayes D M; Duggan D B; Henderson I C
SO Breast c ... and treatment, (1995) Vol. 36, No. 1, pp. 35-40.
Journal e: ... 894: 6167-6806.

AB High-dose ic ... clinical studies, high doses (> or = 200 mg/day) th ... ethylene derivative toremifene showed activity in ER-negative and ER-unknown metastatic breast cancer after pr ... and a mechanism of action independent of hormone re ... The CALGB conducted a Phase II trial (C ... efficacy of high dose toremifene in a population of hormone receptor-negative, metastatic breast c ... for chemotherapy exposure, good performance and ... Twenty eligible patients received toremifene at 400 mg/day orally for 8 weeks. Toxicity was ... by 20% of the patients, lightheadedness by 20%, hot flashes by 15%. There was no grade 3 or 4 ... responses were observed, and 5 of 6 patients with ... developed progressive disease at 11 to 33 weeks. Toremifene (400 mg/day) is well-tolerated but imparts ... one receptor-negative, metastatic breast cancer.

TI High dose or ... estrogen and progesterone receptor negative metastatic br ... Phase II trial of the Cancer and Leukemia Group B.

AB High-dose ic ... clinical studies, high doses (> or = 200 mg/day) th ... ethylene derivative toremifene showed activity in ER-negative and ER-unknown metastatic breast cancer after pr ... and a mechanism of action independent of hormone re ... The CALGB conducted a Phase II trial (C ... efficacy of high dose toremifene in a population of hormone receptor-negative, metastatic breast c ... for chemotherapy exposure, good performance and ... Twenty eligible patients received toremifene at 400 mg/day orally for 8 weeks. Toxicity was ... by 20% of the patients, lightheadedness by 20%, hot flashes by 15%. There was no grade 3 or 4 ... responses were observed, and 5 of 6 patients with ... developed progressive disease at 11 to 33 weeks. Toremifene (400 mg/day) is well-tolerated but imparts ... one receptor-negative, metastatic breast cancer.

CT

Breast

... drug

LUNGS
 HIGH LE d
 JEC PLAS et
 *LECOTO E
 *LECOTO F
 FORMIFIL: ts
 *FORMIFIL: ts
 PRETIME Out
 RN 89778-26 (T)

L11 ANSWER 17 OF 17 ON STN

Full 17

AN 8955015
 TI 8955015 er symptoms in women with breast cancer.
 AU 8955015
 SO 8955015 re J. Clin. Oncol., (1995 Feb) Vol. 91, No. 2, pp. 54-6.
 8955015 es: 043-3284.
 AB 8955015 at woman with breast cancer presents the
 8955015 it. with respect to hormone replacement
 8955015 T). Published meta-analyses have been consistent in
 8955015 t. increased risk of developing breast
 8955015 ho. postmenopausal estrogens for greater than
 8955015 10 year. been no published placebo-controlled
 8955015 ia. of HRT in women with a history of breast
 8955015 al. be balanced against the theoretical risk of
 8955015 th. of osteoporotic and cardiac risk factors
 8955015 in. family history, hyperlipidemia) should
 8955015 he. alternatives to estrogen replacement
 8955015 -c. such as Biphosphonates or vitamin E for hot
 8955015 d. calcium, anabolic steroids, and calcitonin
 8955015 rc.
 AB 8955015 pc. should influence the decision. Valid
 8955015 s. alternatives include low-dose progestones such
 8955015 l. hot flashes, and biphosphonates,
 8955015 at. and calcitonin for osteoporosis.
 CT 8955015 pl.
 8955015 c.
 8955015 ex.
 8955015 d.
 8955015 us.
 8955015 r.
 8955015 T.
 RN 8955015 (T)

=> file	FILE	SINCE FILE	TOTAL
COST	ENTRY	ENTRY	SESSION
FULL	61.88	61.88	91.04

FILE ON 22 MAR 2007
 CA IN AMERICAN CHEMICAL SOCIETY (ACS)
 FILE 30 MAR 2007
 CA IN AMERICAN CHEMICAL SOCIETY (ACS)

=> d
 YOU H? - CONTINUE? (Y)/N:y

'HSI' CS 'DT' AI D. 'MPD' NE'

The f

The d

ABS -
 ALL - CM, CN, DT, LA, FS, NCT, OS,
 BIB -- CN, CN
 CY, LA, FS, NCT, OS, EM, ED

CBIB ---- CM, CY, DT, LA, FS, NCT, OS, EM, ED
 DALL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IABS ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IALL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IBIB ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IND ---- CM, DT, LA, FS, NCT, OS, EM, ED
 TRIAL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 (SAM, DT, LA, FS, NCT, OS, EM, ED)
 HIT ---- CM, DT, LA, FS, NCT, OS, EM, ED
 HITIND ---- CM, DT, LA, FS, NCT, OS, EM, ED
 KWIC ---- CM, DT, LA, FS, NCT, OS, EM, ED
 OCC ---- CM, DT, LA, FS, NCT, OS, EM, ED

Hit terms will be displayed in all available fields except CM and PM.

To display a particular field, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an appropriate prompt. The following formats include: 'BIB'; 'AB'; 'ST'; 'Y'. You may specify the format fields in any order, and the fields will be displayed in the same order as the format specified.

The same format codes (HITIND, KWIC, and OCC) may be used with the special codes to display the record for a specific field. For example, to display the record for a specific field, enter the following commands:

ENTER D. [field code] [format code]

ENTER I. [field code] [format code]

ENTER P. [field code] [format code]

The following are the default formats:

The default format is:

ABS ---- CM, CY, DT, LA, FS, NCT, OS, EM, ED
 ALL ---- CM, CY, DT, LA, FS, NCT, OS, EM, ED
 BIB ---- CM, CY, DT, LA, FS, NCT, OS, EM, ED
 CBIB ---- CM, CY, DT, LA, FS, NCT, OS, EM, ED
 DALL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IABS ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IALL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IBIB ---- CM, DT, LA, FS, NCT, OS, EM, ED
 IND ---- CM, DT, LA, FS, NCT, OS, EM, ED
 TRIAL ---- CM, DT, LA, FS, NCT, OS, EM, ED
 (SAM, DT, LA, FS, NCT, OS, EM, ED)
 HIT ---- CM, DT, LA, FS, NCT, OS, EM, ED
 HITIND ---- CM, DT, LA, FS, NCT, OS, EM, ED
 KWIC ---- CM, DT, LA, FS, NCT, OS, EM, ED
 OCC ---- CM, DT, LA, FS, NCT, OS, EM, ED

Hit terms will be displayed in all available fields except CM and PM.

To display a particular field, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an appropriate prompt. The following formats include: 'BIB'; 'AB'; 'ST'; 'Y'. You may specify the format fields in any order, and the fields will be displayed in the same order as the format specified.

The same format codes (HITIND, KWIC, and OCC) may be used with the special codes to display the record for a specific field. For example, to display the record for a specific field, enter the following commands:

ENTER D. [field code] [format code]

ENTER I. [field code] [format code]

ENTER P. [field code] [format code]

The following are the default formats:

The default format is:

A ----

AVL ---- CM, CY, DT, LA, FS, NCT, OS,
 B.B ---- CN, GEN
 C.B ---- CY, DT, LA, FS, NCT, OS, EM, ED
 D.L ---- CY, DT, LA, FS, NCT, OS, EM, ED
 I.H.S ---- processing
 I.H.L ----
 I.B ----
 I.D ----
 TRIAL ----
 (SAM, T))
 H.T ---- terms
 H.TIND ----
 K.W.I.C ---- on either side
 O.C ---- maining hit terms

Hit terms in be available fields except CM and
 F.

To display the fields, enter the display field
 codes. If you enter codes, enter 'HELP DFIELDS'
 at an arrow prompt. The list of formats include: 'BIB';
 'B'; 'S'; 'T'. You can specify the format fields in any order,
 and the fields will be displayed in the same order as the
 format specified.

The same format (H.TIND, KWIC, and OCC) may be
 used with the same format to display the record for a
 specific record.

= file			
COUNT		SINCE FILE	TOTAL
		ENTRY	SESSION
FILE	AT	2.94	97.25

FILE BUS ON 30 MAR 2007
 C. INDE RE AMERICAN CHEMICAL SOCIETY (ACS)
 FILE BUS ON 30 MAR 2007
 C. INDE RE AMERICAN CHEMICAL SOCIETY (ACS)

= d file

(31 MAR 2007) ON 30 MAR 2007)

FILE 16:57 CN 30 MAR 2007
 L S
 L S
 L S
 L S
 L S
 L S

FILE 13:34 CN 30 MAR 2007
 L S SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
 L S
 L S
 L S
 L S
 L S
 L S

FILE 13:12:20 ON 30 MAR 2007

FILE 13:20 ON 30 MAR 2007

FILE 13:12:46 ON 30 MAR 2007

FILE 13:12:52 ON 30 MAR 2007

```

=> s (tamoxifen or toremifene or triphenylethylene)
L12 4 (TAMOXIFEN OR TOREMIFENE OR TRIPHENYLETHYLENE)

=> s (tamoxifen or toremifene or triphenylethylene)/clm
L13 133 (TAMOXIFEN OR TOREMIFENE OR TRIPHENYLETHYLENE)/CLM

=> s (antiestrogen receptor modul? or serm)
L14 8 ANTIESTROGEN RECEPTOR MODUL? OR SERM)

=> s (antiestrogen receptor modul? or serm)/clm
L15 3 ANTIESTROGEN RECEPTOR MODUL? OR SERM)/CLM

=> s hot f1a
L16 2 HC

=> s hot f1a c
L17 2 HC

=> s l12 or
L18 1 1.

=> s l16 and
MCSIN 1 1
The search process contains terms or
nested terms at 11 by a logical operator.

=> s l16 3 16
L19 3 16

=> s l13 15 11
L20 15 11

=> s l17 1 1
L21 1 1

=> d 1-2

L22 7 1 1
F111111
A 1 9
T 1 9
I 1 9
P 1 9
F 1 9
A 1 9
P 1 9
D 1 9
F 1 9
L1.CNT 1 9
I 1 9
N 1 9
I 1 9

L23 1 1
F111111
A 1 9
T 1 9
I 1 9
P 1 9
F 1 9
A 1 9
P 1 9
D 1 9
F 1 9
L1.CNT 1 9
I 1 9
N 1 9
I 1 9

L24 1 1
F111111
A 1 9
T 1 9
I 1 9
P 1 9
F 1 9
A 1 9
P 1 9
D 1 9
F 1 9
L1.CNT 1 9
I 1 9
N 1 9
I 1 9

```


[illegible]

A	U	000	0	0	721	10)
D	U	000	0	0		
F	A	000	0	0		
L	E	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		
C	I	000	0	0		
L	I	000	0	0		
F	A	000	0	0		
A	U	000	0	0		
T	U	000	0	0		
I	I	000	0	0		
P	U	000	0	0		
A	U	000	0	0		
F	I	000	0	0		
D	U	000	0	0		
F	A	000	0	0		
L	I	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		
C	I	000	0	0		
L	I	000	0	0		
F	A	000	0	0		
A	U	000	0	0		
T	U	000	0	0		
I	I	000	0	0		
P	U	000	0	0		
A	U	000	0	0		
R	U	000	0	0		
F	I	000	0	0		
D	U	000	0	0		
F	A	000	0	0		
L	I	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		
C	I	000	0	0		
L	I	000	0	0		
F	A	000	0	0		
A	U	000	0	0		
T	U	000	0	0		
I	I	000	0	0		
P	U	000	0	0		
A	U	000	0	0		
R	U	000	0	0		
F	I	000	0	0		
D	U	000	0	0		
F	A	000	0	0		
L	I	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		
C	I	000	0	0		
L	I	000	0	0		
F	A	000	0	0		
A	U	000	0	0		
T	U	000	0	0		
I	I	000	0	0		
P	U	000	0	0		
A	U	000	0	0		
R	U	000	0	0		
F	I	000	0	0		
D	U	000	0	0		
F	A	000	0	0		
L	I	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		
C	I	000	0	0		
L	I	000	0	0		
F	A	000	0	0		
A	U	000	0	0		
T	U	000	0	0		
I	I	000	0	0		
P	U	000	0	0		
A	U	000	0	0		
R	U	000	0	0		
F	I	000	0	0		
D	U	000	0	0		
F	A	000	0	0		
L	I	000	0	0		
I	I	000	0	0		
N	M	000	0	0		
I	I	000	0	0		
C	I	000	0	0		

[illegible]

AN 2 396 I FU
 T M for tr ng
 I S Mitch S
 R R chara S
 V r Kaia
 P U 4892
 A U 7833
 R C tion-
 2 2003-747691, filed on 30 Dec 2003,
 2 2003-609684, filed on 1 Jul
 2 2002-305363, filed on
 P U 33373
 L U
 F A ION
 I 14/65
 I 14/65
 I 1K03
 I 1K00
 I 1K00 1K001-138 [I,A]
 C I DE G AVAIL
 L INS OF 20
 I 149 U FU
 T for tr ng
 I Mitch S
 R chara S
 V r Kaia
 P U 3841
 A U 4762
 R C tion-
 2 2003-609684, filed on 1 Jul 2003,
 2 2002-305363, filed on 27 Nov
 P U 33373
 L U
 F A ION
 I 14/45
 I 14/45
 I 14/45
 I 14/45
 I 1K03
 I 1K00
 I 1K00 09-20 [ICS,7]
 I 1K00 1K001-138 [I,A]
 C I DE G AVAIL
 I INS OF 20
 P 27 I FU
 T D e for latr flashes
 I W Owen S
 R Timot S
 P U 2733
 A U 7363
 S511
 D
 F A ION
 I 14/33
 I 14/4
 I 14/33
 I 14/4
 I 1K0
 I 1K0
 I 1K0 31-31 [ICS,7]
 I 1K0 1-38 [I,A]; A61K0031-452 [I,C*];
 I 1K0 1-565 [I,C*]; A61K0031-565 [I,A]

FS APPLICATION
LN.CNT 2854
INCL INCLM: 514/177.000
INCLS: 514/178.000
NCL NCLM: 514/177.000
NCLS: 514/178.000
IC [7]
ICM A61K031-56
IPCI A61K0031-56 [ICM,7]
IPCR A61K0031-35 [I,C*]; A61K0031-35 [I,A]; A61K0031-565 [I,C*];
A61K0031-565 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 17 OF 20 USPATFULL on STN

Full Text

AN 2003:29916 USPATFULL
TI Soy formulations and their use for promoting health
IN Tabor, Aaron, Winston-Salem, NC, UNITED STATES
PI US 2003021859 A1 20030130
AI US 2002-260993 A1 20020930 (10)
RLI Division of Ser. No. US 1999-356167, filed on 16 Jul 1999, GRANTED, Pat.
No. US 6482448
PRAI US 1998-92985P 19980716 (60)
US 1998-105797P 19981027 (60)
DT Utility
FS APPLICATION
LN.CNT 1339
INCL INCLM: 424/757.000
INCLS: 514/027.000; 514/456.000
NCL NCLM: 424/757.000
NCLS: 514/027.000; 514/456.000
IC [7]
ICM A61K035-78
ICS A61K031-7048; A61K031-353
IPCI A61K0035-78 [ICM,7]; A61K0031-7048 [ICS,7]; A61K0031-7042
[ICS,7,C*]; A61K0031-353 [ICS,7]; A61K0031-352 [ICS,7,C*]
IPCR A23L0001-20 [I,C*]; A23L0001-20 [I,A]; A23L0001-29 [I,C*];
A23L0001-29 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-35 [I,C*];
A61K0031-35 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A];
A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-7042 [I,C*];
A61K0031-7048 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 18 OF 20 USPATFULL on STN

Full Text

AN 2002:192152 USPATFULL
TI SOY FORMULATIONS AND THEIR USE FOR PROMOTING HEALTH
IN TABOR, AARON, WINSTON-SALEM, NC, UNITED STATES
PI US 2002103223 A1 20020801
US 6482448 B2 20021119
AI US 1999-356167 A1 19990716 (9)
PRAI US 1998-92985P 19980716 (60)
US 1998-105797P 19981027 (60)
DT Utility
FS APPLICATION
LN.CNT 1339
INCL INCLM: 514/310.000
NCL NCLM: 424/757.000; 514/310.000
NCLS: 426/629.000; 514/027.000; 514/028.000
IC [7]
ICM A61K031-47
ICS A01N043-42
IPCI A61K0031-47 [ICM,7]; A01N0043-42 [ICS,7]; A01N0043-34 [ICS,7,C*]
IPCI-2 A61K0031-70 [ICM,7]; A61K0033-00 [ICS,7]; A23L0001-36 [ICS,7]
IPCR A23L0001-20 [I,C*]; A23L0001-20 [I,A]; A23L0001-29 [I,C*];
A23L0001-29 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-35 [I,C*];
A61K0031-35 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A];
A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-7042 [I,C*];
A61K0031-7048 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 19 OF 20 USPATFULL on STN

Full Text

AN 2002:27435 USPATFULL
TI Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
IN Guttuso, Thomas J., JR., Rochester, NY, UNITED STATES
PI US 2002016283 A1 20020207
AI US 2001-879390 A1 20010612 (9)
PRAI US 2000-211116P 20000612 (60)
DT Utility
FS APPLICATION
LN.CNT 590
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM A61K031-00
IPCI A61K0031-00 [ICM,7]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-395 [I,C*]; A61K0031-395 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-401 [I,C*]; A61K0031-401 [I,A]; A61K0031-403 [I,C*]; A61K0031-403 [I,A]; A61K0031-404 [I,A]; A61K0031-405 [I,A]; A61K0031-445 [I,C*]; A61K0031-445 [I,A]; A61K0031-451 [I,C*]; A61K0031-451 [I,A]; A61K0031-4523 [I,C*]; A61K0031-454 [I,A]; A61K0031-4545 [I,A]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 20 OF 20 USPATFULL on STN

Full Text

AN 2001:191165 USPATFULL
TI Method of treating symptoms of hormonal variation, including hot flashes
IN Guttuso, Jr., Thomas J., Rochester, NY, United States
PA University of Rochester, Rochester, NY, United States (U.S. corporation)
PI US 6310098 B1 20011030
AI US 2000-620979 20000721 (9)
PRAI US 1999-145061P 19990722 (60)
DT Utility
FS GRANTED
LN.CNT 625
INCL INCLM: 514/567.000
NCL NCLM: 514/567.000
IC [7]
ICM A61K031-195
IPCI A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-195 [I,A]

EXF 514/567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti pi kwic 1-20

L21 ANSWER 1 OF 20 USPATFULL on STN

Full Text

AN 2007:62819 USPATFULL
TI Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts
PI US 2007054964 A1 20070308
CLM What is claimed is:
12. The method of claim 11, wherein the subject suffering from vasomotor symptoms experiences **hot flashes**.

13. The method of claim 12, wherein administering the composition to the subject comprises applying a therapeutically effective amount of the composition to one or more skin surface areas of the subject's body experiencing **hot flashes**.

17. The method of claim 16, wherein the breast cancer treatment comprises administration of **tamoxifen**.

L21 ANSWER 2 OF 20 USPATFULL on STN

Full Text

AN 2007:61834 USPATFULL

TI Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts

PI US 2007053968 A1 20070308

CLM What is claimed is:

20. The method of claim 19, wherein the subject suffering from vasomotor symptoms experiences **hot flashes**.

24. The method of claim 23, wherein the breast cancer treatment comprises administration of **tamoxifen**.

L21 ANSWER 3 OF 20 USPATFULL on STN

Full Text

AN 2007:48218 USPATFULL

TI Methods and compositions using gonadotropin hormone releasing hormone

PI US 2007042040 A1 20070222

CLM What is claimed is:

1. A composition consisting of: a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of releasing . . . of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the **hot flashes** that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient, . . .

. . . estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, **tamoxifen**, **toremifene**, **raloxifene**, lasofoxifene and mixtures thereof.

. . . of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the **hot flashes** that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient.

. . . estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, **tamoxifen**, **toremifene**, **raloxifene**, lasofoxifene and mixtures thereof.

. . . of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the **hot flashes** that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient, . . .

. . . estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, **tamoxifen**, **toremifene**, **raloxifene**, lasofoxifene and mixtures thereof.

L21 ANSWER 4 OF 20 USPATFULL on STN

Full Text

AN 2006:160082 USPATFULL

TI Anthranilic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

PI US 2006135619 A1 20060622

CLM What is claimed is:

15. The pharmaceutical composition of claim 14, wherein said anti-cancer or cytotoxic agent is selected from **tamoxifen**, **toremifene**, **raloxifene**, **droloxifene**, **iodoxifene**, **megestrol acetate**, **anastrozole**, **letrozole**, **borazole**, **exemestane**, **flutamide**, **nilutamide**, **bicalutamide**, **cyproterone acetate**, **gosereline acetate**, **leuprolide**, **finasteride**, **metalloproteinase inhibitors**, **inhibitors**.

18. The pharmaceutical composition of claim 17, wherein said anti-cancer or cytotoxic agent is selected from **tamoxifen**, **toremifene**,

raloxifene, droloxifene, idoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, metalloproteinase inhibitors, inhibitors.

. . . of testosterone levels in men, cancers containing at least one estrogen receptor, breast cancer, ovarian cancer, uterine cancer, endometrial cancer, **hot flashes**, vaginal dryness, menopause, amenorrhea, dysmennorrhea, contraception, pregnancy termination, cancers containing at least one progesterone receptor, cyclesynchrony, meningioma, fibroids, labor induction, . . .

24. The method of claim 23, wherein said anti-cancer or cytotoxic agent is selected from **tamoxifen**, **toremifene**, **raloxifene**, droloxifene, idoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, metalloproteinase inhibitors, inhibitors. . .

L21 ANSWER 5 OF 20 USPATFULL on STN

Full Text

AN 2006:22155 USPATFULL

TI Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

PI US 2006019989 A1 20060126

CLM What is claimed is:

1. A composition comprising a 5-alpha reductase inhibitor and a **selective estrogen receptor modulator (SERM)** compound represented by the structure of formula I, its N-oxide, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof: ##STR3##.

2. The composition according to claim 1, wherein said **selective estrogen receptor modulator** compound is an analog, isomer, metabolite, derivative, pharmaceutically acceptable salt, pharmaceutical product, N-oxide, hydrate or any combination thereof of said. . .

3. The composition according to claim 1, wherein said selective androgen receptor modulator is **triphenylethylene**, **toremifene**, or a combination thereof.

4. The composition according to claim 1, wherein said **selective estrogen receptor modulator** compound is at a concentration of between about 5 to about 80 milligrams.

50. A method of suppressing, inhibiting, reducing the risk of developing, preventing or treating a subject with **hot flashes**, comprising the step of administering to said subject the composition of claim 1, in an amount effective to suppress, inhibit, reduce the risk of developing, prevent or treat **hot flashes** in said subject.

L21 ANSWER 6 OF 20 USPATFULL on STN

Full Text

AN 2005:221473 USPATFULL

TI Compositions and methods for treating diseases

PI US 2005192210 A1 20050901

CLM What is claimed is:

. . . dysfunctions, vaginal lubrication, vaginal engorgement, pain during intercourse (e.g., dyspareunia or vulvadynia), urogenital infections, estrogen depletion conditions, menopause and post-menopause, **hot flashes**, preeclampsia, vulvodynia, cataract, intraocular pressure, dry eye, and diabetic retinopathy, aging, necrotizing fascitis, decubitus ulcers, anal fissures, scleroderma, Raynaud's phenomenon, . . .

. . . the group consisting of pilocarpine, timolol maleate, betataxolol HCl, epinephrine, dipivefrin, demecarium bromide, echothiophate iodide, A3 subtype adenosine receptor antagonist, **antiestrogen**, and calmodulin antagonist.

L21 ANSWER 7 OF 20 USPATFULL on STN

Full Text

AN 2005:93464 USPATFULL

TI Treatment of androgen-deprivation induced osteoporosis

PI US 2005080143 A1 20050414

CLM What is claimed is:

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

2. The method according to claim 1, wherein said **toremifene** is **toremifene** citrate.

3. The method according to claim 1, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

8. The method according to claim 7, wherein said **toremifene** is **toremifene** citrate.

9. The method according to claim 7, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

14. The method according to claim 13, wherein said **toremifene** is **toremifene** citrate.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

17. The method according to claim 16, wherein said **toremifene** is **toremifene** citrate.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject A **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

20. The method according to claim 19, wherein said **toremifene** is **toremifene** citrate.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof

23. The method according to claim 22, wherein said **toremifene** is **toremifene** citrate.

. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

26. The method according to claim 25, wherein said **toremifene** is **toremifene** citrate.

. . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

29. The method according to claim 28, wherein said **toremifene** is **toremifene** citrate.

31. A method of treating an androgen-deprivation induced **hot flash** in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

32. The method according to claim 31, wherein said **toremifene** is **toremifene** citrate.

33. The method according to claim 31, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

37. A method of reducing the incidence of androgen-deprivation induced **hot flashes** in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

38. The method according to claim 37, wherein said **toremifene** is **toremifene** citrate.

39. The method according to claim 37, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

43. A method of suppressing or inhibiting an androgen-deprivation induced **hot flash** in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

44. The method according to claim 43, wherein said **toremifene** is **toremifene** citrate.

45. The method according to claim 43, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

. . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

50. The method according to claim 49, wherein said **toremifene** is **toremifene** citrate.

51. The method according to claim 49, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically.

. . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically

acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

56. The method according to claim 55, wherein said **toremifene** is **toremifene** citrate.

57. The method according to claim 55, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

62. The method according to claim 61, wherein said **toremifene** is **toremifene** citrate.

63. The method according to claim 61, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

68. The method according to claim 67, wherein said **toremifene** is **toremifene** citrate.

69. The method according to claim 67, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

74. The method according to claim 73, wherein said **toremifene** is **toremifene** citrate.

75. The method according to claim 73, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
. . . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

80. The method according to claim 79, wherein said **toremifene** is **toremifene** citrate.

81. The method according to claim 79, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .

L21 ANSWER 8 OF 20 USPATFULL on STN

Full Text

AN 2005:75165 USPATFULL

TI Methods, compositions, and kits for predicting the effect of compounds

PI
CLM

on hot flash symptoms
US 2005064462 A1 20050324

What is claimed is:

1. A method for determining the effect of a candidate compound on **hot-flash** symptoms, comprising: a) contacting a first cell that expresses an estrogen receptor or estrogen related receptor with said candidate compound;. . . b) determining the effect of said candidate compound on said first cell's expression of a panel of genes associated with **hot flash** symptoms.

. . of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with **hot flash** symptoms with a reference expression profile of said panel of genes associated with **hot flash** symptoms.

. . of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, **raloxifene**, and **tamoxifen**.

. . of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with **hot flash** symptoms with a second cell's expression of said panel of genes associated with **hot flash** symptoms following contact with a compound that has a known effect on **hot flash** symptoms.

5. The method of claim 4, wherein said compound that has a known effect on **hot flash** symptoms is selected from the group that consists of estradiol, tibolone, **raloxifene**, and **tamoxifen**.

6. The method of claim 2 or 4, wherein said method comprises determining that said compound decreases the incidence of **hot flash** symptoms.

12. The method of claim 1, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by determining the presence and amount of mRNA expressed from said panel of genes.

13. The method of claim 12 wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, . . .

14. The method of claim 13, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a multiplexed array mRNA assay.

15. The method of claim 1, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by determining the presence and amount of protein expressed from said panel of genes.

16. The method of claim 15, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a technique selected from the group of a western blot assay, an ELISA assay, a cytokine. . .

23. A method for rapidly determining the effects of a plurality of compounds on **hot-flash** symptoms, comprising: a) separately contacting a sample of cells that express an estrogen receptor or estrogen related receptor with each. . . of said plurality of compounds on each of said samples of cells' expression of a panel of genes associated with **hot flash** symptoms, thereby predicting the effect of each of said compounds on **hot-flash** symptoms.

. . The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with **hot flash** symptoms by said samples of cells with a reference expression profile of said panel of genes associated with **hot flash** symptoms.

25. The method of claim 24, wherein said reference expression profile of said panel of genes is the expression profile. . . of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, **raloxifene**, and **tamoxifen**.

. . . The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with **hot flash** symptoms by said samples of cells with the expression of said panel of genes associated with **hot flash** symptoms by a sample of cells following contact with a compound that has a known effect on **hot flash** symptoms.

27. The method of claim 26, wherein said compound that has a known effect on **hot flash** symptoms is selected from the group that consists of estradiol, tibolone, **raloxifene**, and **tamoxifen**.

28. The method of claim 24 or 26, wherein said method comprises determining that said compound decreases the incidence of **hot flash** symptoms.

34. The method of claim 23, wherein said expression of said panel of genes associated with **hot flash** symptoms by said sample of cells is quantified by determining the presence and amount of mRNA expressed from said panel.

35. The method of claim 34, wherein said expression of said panel of genes associated with **hot flash** symptoms by said sample of cells is quantified by a technique selected from the group of reverse transcription real time.

36. The method of claim 35, wherein said expression of said panel of genes associated with **hot flash** symptoms by said sample of cells is quantified by a multiplexed array mRNA assay.

37. The method of claim 23, wherein said expression of said panel of genes associated with **hot flash** symptoms by said sample of cells is quantified by determining the presence and amount of protein expressed from said panel.

38. The method of claim 37, wherein said expression of said panel of genes associated with **hot flash** symptoms by said sample of cells is quantified by a technique selected from the group of a western blot assay.

. . . surface, wherein at least one of said oligonucleotides is specific for a member of a panel of genes associated with **hot flash** symptoms, and wherein each of said different oligonucleotides is connected with said surface in a different predetermined region of said.

. . . at least one of said oligonucleotides hybridizes under stringent conditions to a member of a panel of genes associated with **hot flash** symptoms.

L21 ANSWER 9 OF 20 USPATFULL on STN

Full Text

AN 2004:292777 USPATFULL

TI Method of lowering body temperature with (S)-2,3-benzodiazepines

PI US 2004229866 A1 20041118

CLM What is claimed is:

13. The method according to claim 9 wherein the disorder comprises **hot flashes**.

14. The method according to claim 13 wherein said **hot flashes** occur during menopause.

15. The method according to claim 13 wherein said **hot flashes** occur during perimenopause.

16. The method of claim 13 wherein said **hot flashes** are side effects of drug therapy.

17. The method of claim 13 wherein said **hot flashes** occur subsequent to the removal of estrogen-producing tissue.

18. The method of claim 13 wherein said **hot flashes** occur subsequent to organ failure of estrogen-producing organs.

22. A method of lowering body temperature of an individual suffering from **hot flashes** associated with menopause, comprising administering to said individual an effective amount of (a) at least one compound according to Formula. . . a compound; and (b) one or more additional therapeutic agents selected from the group consisting of estrogen

agonists, progesterone agonists, **selective estrogen receptor modulators**, bisphosphonates, selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.

26. The method according to claim 22, wherein the **selective estrogen receptor modulator** agonist is selected from the group consisting of **raloxifene** and **bazedoxifene**.

. . . a compound; and (b) at least one additional therapeutic agent selected from the group consisting of estrogen agonists, progesterone agonists, **selective estrogen receptor modulators**, bisphosphonates; selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.

L21 ANSWER 10 OF 20 USPATFULL on STN

Full Text

AN 2004:286775 USPATFULL

TI Method of lowering body temperature with (R) - 2,3-benzodiazepines

PI US 2004224943 A1 20041111

CLM What is claimed is:

13. The method according to claim 9 wherein the disorder comprises **hot flashes**.

14. The method according to claim 13 wherein said **hot flashes** occur during menopause.

15. The method according to claim 13 wherein said **hot flashes** occur during perimenopause.

16. The method of claim 13 wherein said **hot flashes** are side effects of drug therapy.

17. The method of claim 13 wherein said **hot flashes** occur subsequent to the removal of estrogen-producing tissue.

21. A method of lowering body temperature of an individual suffering from **hot flashes** associated with menopause, comprising administering to said individual an effective amount of (a) at least one compound according to Formula. . . . a compound; and (b) one or more additional therapeutic agents selected from the group consisting of estrogen agonists, progesterone agonists, **selective estrogen receptor modulators**, bisphosphonates, selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.

25. The method according to claim 21, wherein the **selective estrogen receptor modulator** agonist is selected from the group consisting of **raloxifene** and **bazedoxifene**.

. . . a compound; and (b) at least one additional therapeutic agent selected from the group consisting of estrogen agonists, progesterone agonists, **selective estrogen receptor modulators**, bisphosphonates; selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.

L21 ANSWER 11 OF 20 USPATFULL on STN

Full Text

AN 2004:274396 USPATFULL

TI Methods for treating hot flashes

PI US 2004214898 A1 20041028

CLM What is claimed is:

1. A method of treating a subject with **hot flashes**, said method comprising the step of administering to said subject a **selective estrogen receptor modulator (SERM)** and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

2. The method according to claim 1, wherein said **SERM** is **Toremifene**.

5. The method according to claim 1, wherein said **SERM** is administered

at a dosage of about 20 mg per day.

6. The method according to claim 1, wherein said **SERM** is administered at a dosage of about 40 mg per day.

7. The method according to claim 1, wherein said **SERM** is administered at a dosage of about 60 mg per day.

8. The method according to claim 1, wherein said **SERM** is administered at a dosage of 80 mg per day.

9. A method of suppressing, inhibiting or reducing the risk of **hot flashes**, said method comprising the step of administering to said subject a **SERM** and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

10. The method according to claim 9, wherein the **SERM** is **Toremifene**.

13. The method according to claim 9, wherein said **SERM** is administered at a dosage of about 20 mg per day.

14. The method according to claim 9, wherein said **SERM** is administered at a dosage of about 40 mg per day.

15. The method according to claim 9, wherein said **SERM** is administered at a dosage of about 60 mg per day.

16. The method according to claim 9, wherein said **SERM** is administered at a dosage of 80 mg per day.

L21 ANSWER 12 OF 20 USPATFULL on STN

Full Text

AN 2004:273349 USPATFULL

TI Methods for treating hot flashes and gynecomastia

PI US 2004213841 A1 20041028

CLM What is claimed is:

1. A method of treating a subject with **hot flashes**, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, .

2. The method according to claim 1, wherein said anti-estrogen is a **selective estrogen receptor modulator (SERM)**.

3. The method according to claim 1, wherein said anti-estrogen is a **triphenylethylene**.

4. The method according to claim 1, wherein said anti-estrogen is **Toremifene**.

7. The method according to claim 1, wherein said **antiestrogen** is administered at a dosage of about 20 mg per day.

8. The method according to claim 1, wherein said **antiestrogen** is administered at a dosage of about 40 mg per day.

9. The method according to claim 1, wherein said **antiestrogen** is administered at a dosage of about 60 mg per day.

10. The method according to claim 1, wherein said **antiestrogen** is administered at a dosage of 80 mg per day.

11. A method of suppressing, inhibiting or reducing the risk of **hot flashes**, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, .

12. The method according to claim 11, wherein the anti-estrogen is a **selective estrogen receptor modulator (SERM)**.

13. The method according to claim 11, wherein the anti-estrogen is a **triphenylethylene**.

14. The method according to claim 11, wherein the anti-estrogen is **Toremifene**.
17. The method according to claim 11, wherein said **antiestrogen** is administered at a dosage of about 20 mg per day.
18. The method according to claim 11, wherein said **antiestrogen** is administered at a dosage of about 40 mg per day.
19. The method according to claim 11, wherein said **antiestrogen** is administered at a dosage of about 60 mg per day..
20. The method according to claim 11, wherein said **antiestrogen** is administered at a dosage of 80 mg per day.
22. The method according to claim 21, wherein said anti-estrogen is a **selective estrogen receptor modulator (SERM)**.
23. The method according to claim 21, wherein said anti-estrogen is a **triphenylethylene**.
24. The method according to claim 21, wherein said anti-estrogen is **Toremifene**.
27. The method according to claim 21, wherein said **antiestrogen** is administered at a dosage of about 20 mg per day.
28. The method according to claim 21, wherein said **antiestrogen** is administered at a dosage of about 40 mg per day.
29. The method according to claim 21, wherein said **antiestrogen** is administered at a dosage of about 60 mg per day.
30. The method according to claim 21, wherein said **antiestrogen** is administered at a dosage of 80 mg per day.
32. The method according to claim 31, wherein the anti-estrogen is a **selective estrogen receptor modulator (SERM)**.
33. The method according to claim 31, wherein the anti-estrogen is a **triphenylethylene**.
34. The method according to claim 31, wherein the anti-estrogen is **Toremifene**.
37. The method according to claim 31, wherein said **antiestrogen** is administered at a dosage of about 20 mg per day.
38. The method according to claim 31, wherein said **antiestrogen** is administered at a dosage of about 40 mg per day.
39. The method according to claim 31, wherein said **antiestrogen** is administered at a dosage of about 60 mg per day.
40. The method according to claim 31, wherein said **antiestrogen** is administered at a dosage of 80 mg per day.

L21 ANSWER 13 OF 20 USPATFULL on STN

Full Text

AN 2004:197427 USPATFULL

TI Duloxetine for treatment of hot flashes

PI US 2004152733 A1 20040805

CLM What is claimed is:

1. A method of treating **hot flashes** in a mammal comprising administering to a mammal in need thereof an effective amount of duloxetine.

5. Duloxetine for use in the treatment of **hot flashes**.

6. A pharmaceutical formulation containing, as an active ingredient, duloxetine adapted for use in the treatment of **hot flashes**.

7. The use of duloxetine for the manufacture of a medicament for the treatment of **hot flashes**.
8. A method of treating **hot flashes** in a human undergoing **raloxifene** administration comprising administering an effective amount of duloxetine to a human in need thereof.
9. The method according to claim 7 where the **raloxifene** is **raloxifene** hydrochloride.
10. The method according to claim 7 where the administration of duloxetine and **raloxifene** is concurrent.
11. The method according to claim 9 where the administration of duloxetine and **raloxifene** is simultaneous.
12. The use of duloxetine for the manufacture of a medicament for treating **hot flashes** in a human female undergoing **raloxifene** administration.
13. A pharmaceutical formulation adopted for treatment of **hot flashes** in humans comprising duloxetine and **raloxifene**.
14. A method of treating **hot flashes** in a human undergoing estrogen replacement therapy comprising administering an effective amount of duloxetine to a human in need thereof.
17. The use of duloxetine for the manufacture of a medicament for treatment of **hot flashes** in a human female undergoing estrogen replacement therapy.
18. A pharmaceutical formulation adopted for treatment of **hot flashes** in humans comprising duloxetine and estrogen replacement therapy.
19. A method of treating **hot flashes** in a human female comprising administering to a woman in need thereof an effective amount of duloxetine estrogen replacement therapy.
20. The use of duloxetine for the manufacture of a medicament for treatment **hot flashes** in a human female where estrogen replacement therapy is contraindicated.

L21 ANSWER 14 OF 20 USPATFULL on STN

Full Text

- AN 2003:335359 USPATFULL
- TI Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
- PI US 2003236237 A1 20031225
- CLM What is claimed is:
1. A method of treating **hot flashes** in a patient comprising: providing a tachykinin receptor antagonist selected from the group of NK₂ receptor antagonists and NK₃ receptor antagonist; and administering the tachykinin receptor antagonist to a patient experiencing **hot flashes** under conditions effective to treat the **hot flashes**.
13. The method according to claim 12, wherein the drug is an **antiestrogen** compound.
14. The method according to claim 13, wherein the anti-estrogen compound is **tamoxifen**.
16. The method according to claim 15, wherein the male patient experiences drug induced **hot flashes**.

L21 ANSWER 15 OF 20 USPATFULL on STN

Full Text

- AN 2003:93647 USPATFULL
- TI Selective estrogen receptor modulators in combination with estrogens

What is claimed is:

1. A method of treating or reducing the risk of acquiring a condition selected from the group consisting of osteoporosis, . . . amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen receptor modulator** or prodrug thereof, said modulator having the following formula: ##STR12## wherein R_1 and R_2 are independently hydrogen, hydroxyl or a . . .

. . . amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen receptor modulator** or prodrug thereof, said modulator being a different compound from said estrogen and being a different compound from a benzothiophene. . .

. . . amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen receptor modulator** or prodrug thereof, said modulator being a different compound from said estrogen, further comprising the step of administering, as part. . .

5. The method of claim 4, wherein the **selective estrogen receptor modulator** has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms, . . .

7. The method of claim 5, wherein the **selective estrogen receptor modulator** is selected from the group consisting of a **triphenylethylene** derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

8. The method of claim 5, wherein the **selective estrogen receptor modulator** is a **triphenylethylene** or diphenylhydronaphthalene derivative compound of the following formula: ##STR15## wherein D is --OCH₂CH₂N(R₃)R₄, --OCH₂CH₂OH, or --CH₂dbd.CH--COOH (R₃ and R₄ either. . .

9. The method of claim 1, wherein **selective estrogen receptor modulator** is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.

10. The method of claim 5, wherein the **selective estrogen receptor modulator** is a centchroman derivative compound of the following formula: ##STR16## wherein R_1 and R_2 are independently selected from the group. . .

12. The method of claim 5, wherein the **selective estrogen receptor modulator** has the following formula: ##STR17## wherein R_1 and R_2 are independently hydrogen, hydroxyl or a moiety which is converted to. . .

16. The method of claim 14, wherein said **selective estrogen receptor modulator** is selected from the group consisting of: ##STR21## wherein all of the foregoing molecular structures whose stereochemistry is indicated are. . .

19. The method claim 1, wherein said **selective estrogen receptor modulator** is: ##STR22## and is optically active due to a majority of its stereoisomers being of 2S configuration; and wherein the. . .

21. The method of claim 1, wherein the **selective estrogen receptor modulator** has no estrogenic activity in breast or endometrium tissues.

24. The method of claim 1, wherein menopausal symptoms are selected from the group consisting of **hot flashes**, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.

26. The method of claim 2, wherein the **selective estrogen receptor modulator** has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms, . . .

28. The method of claim 26, wherein the **selective estrogen receptor modulator** is selected from the group consisting of a **triphenylethylene** derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

29. The method of claim 26, wherein the **selective estrogen receptor modulator** is a **triphenylethylene** or diphenylhydronaphthalene derivative compound of the following formula: ##STR24## wherein D is --OCH₂CH₂N(R₃)R₄, --OCH₂CH₂OH, or --CH₂dbd.CH--COOH (R₃ and R₄ either.

30. The method of claim 2, wherein **selective estrogen receptor modulator** is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.

31. The method of claim 26, wherein the **selective estrogen receptor modulator** is a centchroman derivative compound of the following formula: ##STR25## wherein R_1 and R_2 are independently selected from the group.

33. The method of claim 26, wherein the **selective estrogen receptor modulator** has the following formula: ##STR26## wherein R_1 and R_2 are independently hydrogen, hydroxyl or a moiety which is converted to.

37. The method of claim 35, wherein said **selective estrogen receptor modulator** is selected from the group consisting of: ##STR29## wherein all of the foregoing molecular structures whose stereochemistry is indicated are.

40. The method claim 2, wherein said **selective estrogen receptor modulator** is: ##STR30## and is optically active due to a majority of its stereoisomers being of 2S configuration; and wherein the.

42. The method of claim 2, wherein the **selective estrogen receptor modulator** has no estrogenic activity in breast or endometrium tissues.

45. The method of claim 2, wherein menopausal symptoms are selected from the group consisting of **hot flashes**, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.

47. The method of claim 1, wherein said condition is hyperlipidemia, said **selective estrogen receptor modulator** is EM-652.HCl and said estrogen is 17 β -estradiol.

48. The method of claim 4, wherein said condition is hyperlipidemia, said **selective estrogen receptor modulator** is EM-652.HCl, said estrogen is 17 β -estradiol and said additional agent is dehydroepiandrosterone.

L21 ANSWER 16 OF 20 USPATFULL on STN

Full Text

AN 2003:57944 USPATFULL

TI Selective estrogen receptor modulators in combination with estrogens

PI US 2003040510 A1 20030227

CLM What is claimed is:

. amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen receptor modulator** or prodrug thereof, said modulator being a different compound from said estrogen and not being a benzothiophene or a phenylindole.

. amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen receptor modulator** or prodrug thereof, said modulator being a different compound from said estrogen and not being a phenylindole derivative, further comprising.

4. The method of claim 1, wherein the **selective estrogen receptor modulator** has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms,.

6. The method of claim 4, wherein the **selective estrogen receptor modulator** is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

7. The method of claim 8, wherein the **selective estrogen receptor modulator** is a benzothiophene derivative compound of the following formula: ##STR13## wherein R_1 and R_2 are independently selected from the group.

8. The method of claim 7, wherein the **selective estrogen receptor modulator** is selected from the group consisting of Raloxifene, LY 353381 and LY 335563.

9. The method of claim 4, wherein the **selective estrogen receptor modulator** is a triphenylethylene or diphenylhydronaphthalene

derivative compound of the following formula: ##STR14## wherein D is

--OCH₂CH₂N(R₃)R₄, --OCH₂CH₂OH, or

--CH₂CH₂COOH (R₃ and R₄ either.

10. The method of claim 1, wherein **selective estrogen receptor modulator** is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.

11. The method of claim 4, wherein the **selective estrogen receptor modulator** is a centchroman derivative compound of the following formula: ##STR15## wherein R₁ and R₂ are independently selected from the group.

13. The method of claim 4 wherein the **selective estrogen receptor modulator** has the following formula: ##STR16## wherein R₁ and R₂ are independently hydrogen, hydroxyl or a moiety which is converted to.

17. The method of claim 15, wherein said **selective estrogen receptor modulator** is selected from the group consisting of: ##STR19## wherein all of the foregoing molecular structures whose stereochemistry is indicated are.

20. The method claim 1, wherein said **selective estrogen receptor modulator** is: ##STR20## and is optically active due to a majority of its stereoisomers being of 2S configuration; and wherein the.

22. The method of claim 1, wherein the **selective estrogen receptor modulator** has no estrogenic activity in breast or endometrium tissues.

25. The method of claim 1, wherein menopausal symptoms are selected from the group consisting of **hot flashes**, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.

L21 ANSWER 17 OF 20 USPATFULL on STN

Full Text

AN 2003:29916 USPATFULL

TI Soy formulations and their use for promoting health

PI US 2003021859 A1 20030130

CLM What is claimed is:

33. The pharmacological composition of claim 32 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

36. The pharmacological composition of claim 35 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

39. The pharmacological composition of claim 38 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

50. The method of claim 49 wherein the menopausal like symptoms comprise **hot flashes**, vaginal itching, vaginal dryness, irritability, insomnia, night sweats, headaches and/or mood swings.

L21 ANSWER 18 OF 20 USPATFULL on STN

Full Text

AN 2002:192152 USPATFULL

TI SOY FORMULATIONS AND THEIR USE FOR PROMOTING HEALTH

PI US 2002103223 A1 20020801

US 6482448 B2 20021119

CLM What is claimed is:

33. The pharmacological composition of claim 32 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

36. The pharmacological composition of claim 35 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

39. The pharmacological composition of claim 38 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an **SERM**.

50. The method of claim 49 wherein the menopausal like symptoms comprise **hot flashes**, vaginal itching, vaginal dryness, irritability, insomnia, night sweats, headaches and/or mood swings.

L21 ANSWER 19 OF 20 USPATFULL on STN

Full Text

AN 2002:27435 USPATFULL

TI Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist

PI US 2002016283 A1 20020207

CLM What is claimed is:

1. A method of treating **hot flashes** in a patient comprising: providing a tachykinin receptor antagonist and administering the tachykinin receptor antagonist to a patient experiencing **hot flashes** under conditions effective to treat the **hot flashes**.

15. The method according to claim 14, wherein the anti-estrogen compound is **tamoxifen**.

17. The method according to claim 16, wherein the male patient experiences drug induced **hot flashes**.

L21 ANSWER 20 OF 20 USPATFULL on STN

Full Text

AN 2001:191165 USPATFULL

TI Method of treating symptoms of hormonal variation, including hot flashes

PI US 6310098 B1 20011030

CLM What is claimed is:

1. A method of treating **hot flashes** in a patient comprising: providing a compound which binds an $\alpha_2\delta$ subunit of a voltage-gated calcium channel and administering the compound to a patient experiencing **hot flashes** under conditions effective to treat the **hot flashes**.

11. The method according to claim 10, wherein the anti-estrogen compound is **tamoxifen**.

13. The method according to claim 12, wherein the male patient experiences drug induced **hot flashes**.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

60.58

157.83

STN INTERNATIONAL LOGOFF AT 23:30:45 ON 30 MAR 2007

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox